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Abstract 
This body of research is focused on developing calixarene conjugates targeting i-motif 
structures and integrin receptors. In Chapter 1, a general background of DNA secondary 
structures and i-motifs was described, mainly focused on the biological relevance, the 
experimental techniques and known interacting ligands in i-motif studies. 
In Chapter 2, a high-throughput i-motif ligand screen method was established, based on 
fluorescent intercalator displacement. Thiazole orange was used as the fluorescent 
intercalator in the screen against human telomeric i-motif. Its binding was studied using 
several spectroscopic techniques. A compound library was used to evaluate the newly 
developed high-throughput screen method using a plate reader and tobramycin was 
found as the most valuable hit compound in this screen.  
In Chapter 3, a family of water soluble, DNA-targeting calixarene conjugates were 
synthesis and characterised. They were functionalised with and DNA-binding moiety 
on the lower rim. It was found that two of the calixarene conjugates, 28 and 54, were 
able to condense G-quadruplex and i-motif forming sequences from human telomere 
and c-MYC promoter. The calixarene induced condensation was stable under acidic pH, 
but behave reversible by heating at neutral pH. 
Chapter 4 discussed the possibility to develop a calixarene based tumour recognising 
ligand. In order to achieve tumour targeting, a novel cyclic RGD peptide bearing alkyne 
was made and tested in the ‘click’ reaction. Later on, a route to conjugate the novel 
cyclic RGD peptide with a calixarene tethered with a fluorescent tag was established. It 
was found that a linker between calixarene and peptide moiety or the copper (I) catalyst 
was crucial in making this calixarene-peptide conjugate.  
Chapter 5 described the experimental procedures used in Chapter 2, 3 and 4. 
Chapter 6 summarised the key findings in Chapter 2, 3 and 4, as well as proposing the 
future work for all three chapters.  
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1.1  Oligonucleotides and DNA secondary structures 
Parents pass their heritable genetic information to their offspring through DNA. 
This biopolymer, along with its ribonucleic acid analogue is crucial to all living 
cellular organisms. They distinguish life from other chemical or physical processes. 
On a cellular level, they serve as a ‘guide book’ to cells for the synthesis of proteins, 
orchestrating the process of cell cycle and reproduction.1 In 1869, Friedrich 
Miescher first discovered and isolated a mysterious phosphorous-rich material, 
later called nuclein, from the nuclei of white blood cells; this marked the beginning 
of oligonucleotide chemistry.2, 3 In the late 1940s, structures of basic monomer 
nucleosides and their corresponding nucleobases in DNA & RNA (adenine, guanine, 
thymine, uracil and cytosine) were discovered.1 In the year 1953, two Cambridge 
scientists, Francis Crick and James D. Waston, presented a milestone paper 
proposing the secondary structure of B-form DNA based on Rosalind Franklin’s X-
ray diffraction images.4 This model showed two complementary DNA strands 
parallel paired via classical ‘Watson-Crick’ hydrogen bonding (adenine to thymine 
and cytosine to guanine, Figure 1.1 a) resulting in the iconic right-handed B-form 
DNA ‘double helix’ (Figure 1.1 b). 5 
 
Figure 1.1  a) Watson & Crick base paring (Adenine to Thymine & Guanine 
 to Cytosine) and b) The structure of B-DNA (X- ray diffraction, 
 PDB ID: 1BNA 6) 
Chapter 1 General Introduction 
3 
 
However, the subsequent 60 years of research has revealed that the conventional 
duplex is not the only form of DNA structure. Depending on the sequences, non-
Watson Crick base pairing, surrounding conditions and other factors, non-B DNA 
secondary structures are also possible as well.7 Known DNA secondary structures 
include B-, A-and Z-form duplex, triplex, G-quadruplexes, i-motif, A-motif, 
cruciform and Holliday junctions (Figure 1.2).  
 
Figure 1.2  Examples of some alternative DNA secondary structures 
During DNA transcription, recombination and replication, several alternative DNA 
secondary structures have been discovered with specific biological functions.7 
Evidence has also shown that genomic instability induced by non-canonical DNA 
structure formation not only contributes to the predisposition to disease,8,9 but to 
rapid evolutionary changes.10 Since scientists are interested in their molecular 
mechanisms in cells, non-canonical DNA secondary structures have been 
extensively studied. Moreover, scientists have found that these non-canonical DNA 
structures are ideal materials for applications in bio-related nanotechnology or drug 
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vectors due to their safety and robustness in physiological conditions.11, 12 Thus the 
study of DNA secondary structures has become a popular branch of chemical 
biology, driving more and more researchers and resources into this field. 
1.2  G-quadruplexes 
G-quadruplexes are a family of well-characterized oligonucleotide secondary 
structures which have been intensively investigated over the past twenty five 
years.13 G-quadruplexes arise from guanine-rich nucleic acid sequences, in both 
DNA and RNA，and have a 3D structure composed of at least two or three planar 
arrangements called G-tetrads. The first published example of a G-tetrad had 4 
guanine bases joined via eight Hoogsteen hydrogen bonds in a clockwise or anti-
clockwise orientation (N1-H to N7 & N2-H to O6 atoms, Figure 1.3 a).14 Two or 
more tandem layers of G-tetrads can be assembled as a G-quadruplex structure 
stabilised by monovalent cations (Figure 1.3 b & c).13 Thus the strong negative-
charged electrostatics at the centre of the G-tetrad created by the lone pair of O6 
atoms of each guanine is partially neutralized, further enhancing the rigidity of the 
structure. As a result, G-quadruplexes formed from some sequences possess higher 
stability when compared to their conventional Watson-Crick double helical 
counterparts under physiological conditions.13  
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Figure 1.3  a) Planar G-tetrad held together by Hoogsteen hydrogen bonds. 
 b) A top view of human telomeric G-quadruplex stabilised by K+ 
 (X-ray diffraction, PDB ID: 3T5E). c) A side view of human 
 telomeric G-quadruplex stabilised by K+ (X-ray diffraction, PDB 
 ID: 3T5E 15). 
How relevant are G-quadruplexes to living organisms? Although G-quadruplexes 
were first shown in the 1960s,14 they did not receive a lot attention until the 1990s 
after some G-quadruplexes were discovered in living prokaryotic organisms.13 In 
the context of the human genome, over 360,000 estimated G-quadruplex forming 
sequences have been discovered in silico,16 and some of them are located at critical 
regions of the genome. G-quadruplexes have been found not only to exist in human 
cells,17,18 but also participate in key biological processes, including telomere 
maintenance, transcription and replication.19-23 In 2016, with the help of high-
throughput DNA sequencing methodology and a G-quadruplex targeting antibody, 
about 10,560 G-quadruplex structures were found in human chromatin, mostly in 
regulatory, nucleosome-depleted regions.24 When considering gene promoter 
regions, G-quadruplex interacting ligands have been shown to interfere with 
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transcription of the respective gene.25,26 These reports all indicate undiscovered 
transcriptional functions of G-quadruplexes in living organisms. Thus G-
quadruplexes can be utilised as a potential druggable target for cancer diagnosis 
and intervention. Apart from anti-cancer therapeutics, G-quadruplexes have also 
been found in other gene sequences associated with viral infections such as human 
papilloma virus, HIV and even diabetes.27-29 
1.3  i-Motifs 
G-quadruplexes arise from guanine-rich sequences, however, in the context of the 
human genome, what will happen to the complementary cytosine-rich sequences? 
These sequences may form a secondary structure called the intercalated motif, or i-
motif. i-Motifs are quite different from G-quadruplexes, especially in terms of their 
structural arrangement as they are the only known nucleic acid secondary structure 
held together by systematic base intercalation. Two parallel-stranded 
hemiprotonated C≡C+ base pairs intercalate and lock themselves in an antiparallel 
manner with the help of Hoogsteen hydrogen bonds, forming a compact structure 
stable under slightly acidic conditions (Figure 1.4 a).30 It was not until 1993 that i-
motif structures were first resolved by Gehring et al. in studying an four stranded 
d(TCCCC) oligomer structure which possess the intercalated base-pairing. 31,32 As 
shown in Figure 1.4 b, i-motifs possess two major and two minor grooves, the 
distance between two paired cytosines is usually only a few Å.33  
 
 
Chapter 1 General Introduction 
7 
 
 
Figure 1.4  a) C≡C+ base pairing b) A side view of dimeric i-motif structure 
 from centromeric alpha-satellite DNA (solution NMR, PDB ID: 
 2MRZ 34) 
For i-motifs, the slightly acidic conditions which favour folding have paved their 
way to be employed extensively as pH-sensitive switches in various DNA 
nanotechnologies35-38 but this has also provoked scepticism in their potential to play 
physiological roles in cells. However, this is changing, i-motif forming sequences 
that can fold at near neutral pH conditions have been found.39 Accumulating 
evidence in recent years has indicated that the i-motif may exist in the cell as well.40 
Thus, the potential biological roles of i-motifs are beginning to attract people’s 
attention. 
1.3.1 Polymorphism and stability of i-motifs 
Like the G-quadruplex, the i-motif can also form intermolecular species such as 
dimers and tetramers where multiple strands are involved in the structure. The first 
known i-motif structure was a tetramer (Figure 1.5a). In 1994, Gehring, Leroy and 
Guron resolved the first tetramer i-motif structure arising from four d(TC5)-strands 
via NMR and gel filtration chromatography.30 As shown in Figure 1.5 b, when two 
cytosine-rich hairpins are intercalated, a dimer i-motif is formed. This case was 
seen with a cytosine-rich dodeca satellite strand in an endogenous Drosophila 
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centromere (Figure 1.4 a).34 Other putative biologically relevant cytosine-rich 
sequences exist in other biologically relevant regions, such as in the human 
telomeric repeat region and sequences within the promoter regions of HIF-1α,39 c-
MYC,41 and Bcl-2.42 These are able to form intramolecular i-motif structures via 
folding a single strand with four cytosine stretches back upon itself (Figure 1.5 c).40  
Figure 1.5  Schematic of different types of i-motif a) Tetramer b) Dimer c)  
    Intramolecular  
Originally it was suggested that intramolecular i-motifs can be categorized into two 
classes based on their loop size. Smaller loop-sized (2 to 4 nucleobases on the loops) 
were denoted ‘Class I’ and larger loop-sized (over 4 nucleobases on the loops) i- 
classified as ‘Class II’.43 Initially, it was considered that ‘Class II’ i-motifs were 
more stable than their ‘Class I’ counterparts, since they had a higher chance to gain 
extra stability via interactions between bases in the loops.43 However, recent years 
have given rise to a debate on whether stability is in fact related to loop length.44,45 
For example, in the case of the human telomeric repeat region, bases in the loop 
(TAA) not only form extra A-T base paring, but they stack back on the i-motif’s 
main cytosine core as well however these are classified as ‘Class I’ i-motifs. This, 
coupled with the debate in the literature, suggests the classification of i-motif 
structures based on the loops was premature.  
In addition to loop length, other factors, such as the number of cytosine bases, the 
presence of cations, buffer conditions, and functionalites conjugated to 
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oligonucleotides, can influence the stability of i-motifs.40 More C≡C+ base pairs 
present in i-motifs provide more hydrogen bonding, thus enhancing the stability of 
i-motif structures.40 In terms of cations, it is clearly shown that presence of Li+ 
destabilises human telomeric i-motif.46 The size of Li+ is believed to be the reason. 
Lithium cations possess a radius around 0.7 Å, which facilitate themselves fitting 
into the pockets in C≡C+ base paring,46 but Li+ does not have the ability to mimic 
the quantum mechanical effects of a proton on the hydrogen bonding. So the 
original packed i-motif structure is disrupted. Previous studies in the Waller group 
have shown that Ag+ is able to fold the human telomeric i-motif forming sequence 
into an i-motif even at pH 7.4, and that this Ag+ induced i-motif formation is 
reversible with the addition of cysteine, a chelating agent for silver cations.47 The 
mechanism of this interaction is believed to be an insertion of Ag+ into the C≡C+ 
base pair where it mediates the mismatch in hydrogen-bonding.48 Another study 
centred around cations showed recently that Cu2+ is able to convert human 
telomeric i-motif into a hairpin structure, even in acidic conditions.49  
Unlike G-quadruplexes, where RNA analogues are always more stable than the 
same sequence in DNA, intramolecular i-motifs formed using RNA sequences are 
not as stable.50 This is due to the 2ʹ-OH group on the ribose which sits in the narrow 
groove of the i-motif, resulting in structural expansion and destabilisation. However, 
some examples of DNA/RNA hybridised oligonucleotides are able to form i-motifs, 
but their structural rigidity is not comparable with intramolecular i-motifs formed 
purely by DNA.32,51  
1.3.2 Biological relevance of i-motifs 
The existence of G-quadruplexes and i-motifs in vivo has been constantly 
questioned ever since their discovery. As estimated from in silico experiments,52 
43% of gene promoters and 69% of oncogene promoters contain guanine/cytosine-
rich sequences, capable of forming DNA secondary structures including promoters 
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of genes involved in cell proliferation, including c-MYC,41,53,54 PDGF-A,39,43 
pRb,55 Bcl-2,42,56-58 K-ras43,59 and VEGF.40,52 In 2013, Balasubramanian and co-
workers published the first report of imaging G-quadruplex structures in cells via 
immunofluorescence technology.17  
In contrast, so far there is no direct evidence showing the existence of i-motif in 
cells. Nevertheless, there is data that supports the existence of i-motifs in biology. 
Negative supercoiling is a phenomenon introduced by unwinding the DNA double 
helix during transcription. This phenomenon creates negative superhelical stress on 
double-stranded DNA which is believed to be relieved by formation of i-motif and 
G-quadruplex structures.60 Hurley’s group investigated the effect of negative 
superhelicity via incorporating the G/C-rich sequences from c-MYC promoter, 
which can form i-motif and G-quadruplex, into a supercoiled plasmid. When the 
plasmid is transcribed, artificial negative superhelicity is created. The result 
indicated that c-MYC i-motif forms under neutral pH, alongside G-quadruplex 
formation.60 Apart from negative supercoiling, molecular crowding conditions are 
another supporting factor for the formation of i-motif under physiological 
conditions.61 By simulating intracellular conditions utilising high molecular weight 
polyethylene glycol polymers, such as 20% PEG as a cosolute, it was shown that 
the formation of G-quadruplexes and i-motif was more favoured over duplex or 
single stranded DNA.62,63 Under these conditions, modestly stable i-motif 
structures (Tm ≈ 20℃) were observed even at neutral pH as a result of the increased 
pKa of the C≡C+ base pairs.64   
Telomeres  
The telomere regions of chromosomes are one of the most intensively studied 
regions in the human genome, featuring several hundreds to thousands of tandem 
repeat sequences at each end of a eukaryotic chromatid.65 Telomeres are utilised by 
eukaryotes in maintaining genome integrity and avoiding loss of genetic 
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information. A telomere consists of 3 to 15 kilobases of tandem 5ʹ-d(TTAGGG)n-
3ʹ-repeats (or 5ʹ-d(AATCCC)n-3ʹ on the cytosine-rich sequences), with a 20- to 150-
base-long single-stranded 3ʹ-overhang at the terminus, and associated capping 
proteins.66 Telomeres are truncated as cells divide to a senescent stage when 
apoptosis is triggered following shortening of telomeric repeats, serving as an 
indicator of cell age.  
Telomeric repeats can be replenished via telomerase, an enzyme found only in stem 
cells, activated lymphocytes and cancer cells.67 Telomerase immortalises cells and 
it has been found that about 85% of cancer cells over-express this critical 
enzyme.68,69 Thus, reducing the length or otherwise interfering with the synthesis 
of the telomeric repeats can promote cell apoptosis, with potential applications as 
an anti-cancer intervention. It has already been shown that G-quadruplex 
interacting compounds inhibit telomerase activity with a high efficacy.70,71 
Stabilising the i-motif forming sequence in the human telomere using carboxyl-
modified single-walled carbon nanotubes (SWNTs) has been shown to inhibit 
telomerase, followed by telomere uncapping and cell apoptosis.72 Proteins that bind 
the telomeric i-motif forming sequences have also been found,73,74 but whether they 
bind i-motif structure specifically or just single-stranded DNA is a question that 
needs further exploration.  
Oncogenic Promoters  
In addition to the telomeres, non-canonical DNA structures are prevalent in 
oncogene promoter regions. Several oncogenes whci contain i-motif forming 
sequences have been studied, including c-MYC,75,76 Bcl-2,42,56 VEGF77 and c-
kit.78,79  
About 90% of c-MYC transcription is controlled by a highly conserved sequence in 
the P1 promoter called nuclease hypersensitive element (NHE) III1. This consists 
of a 27 base-pair sequence which is able to form both G-quadruplex and i-motif.75,76 
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In in vitro experiments, c-MYC i-motif possesses a transitional pH of 6.6 43 (pHT; 
a pH value where 50% of the DNA population is folded into an i-motif structure), 
which is relatively close to neutral conditions, It adopts a 5:5:5 loop topology with 
8 hemi-protonated base pairs.76 However, as mentioned in Section 1.2, with the 
help of artificially induced negative supercoiling to mimic conditions within a 
cellular context, Laurence Hurley’s group showed that c-MYC promoter is able to 
form a different i-motif structure at neutral pH with a 6:2:6 loop topology.53,60 Later 
studies identified two proteins that bind to the C-rich single strand of c-MYC NHE 
III1, named heterogeneous ribonucleoprotein K(hnRNP K) and human 
nonmetastatic 23 isoform 2(NM23-H2).53 
GC-rich sequences can also be found close to the Bcl-2 P1 promoter, the C-rich 
sequence is able to form an i-motif structure with a high transitional pH (pHT 6.6).42 
The Bcl-2 i-motif adopts a ‘Class II’ loop topology (8:5:7) with a highly dynamic 
equilibrium towards a hairpin structure.42,56 Hurley’s group found two specific 
ligands, NSC 1398948 and NSC 59276 (Figure 1.6), that are able to interact with 
this i-motif forming sequence.56 NSC 1398948 binds the i-motif structure while 
NSC 59276 binds a hairpin structure which exists in equilibrium with the i-motif. 
Further experiments showed that the Bcl-2 mRNA expression level was up-
regulated by the stabilization of i-motif structure and down-regulated by converting 
the i-motif structure into a hairpin.56 This is direct evidence that, like G-
quadruplexes, ligands that target the i-motif may also have the ability to regulate 
gene expression.  
 
Figure 1.6  Ligands interacting with the i-motif forming sequence from Bcl-2 
    promoter 
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A follow-up study carried out by Hurley’s group found the protein responsible for 
converting Bcl-2 i-motif into its hairpin form, hnRNP LL, an analogue of hnRNP 
K that binds to c-MYC G-quadruplexes (Section 1.2).57 The dissociation constant 
of hnRNP LL towards Bcl-2 i-motif was determined at pH 6.5 via surface plasmon 
resonance.The Kd for i-motif was found to be 19.4 pM whilst the Kd for the single 
stranded DNA was 69.8 pM.57 Futher studies showed that the RRM1 and RRM2 
domains of hnRNP LL contribute to the binding and unfolding of i-motif.58 As a 
result, the current working hypothesis is that transcription will increase as the 
consequence of i-motif unfolding.57 
1.3.3 Methods for characterising i-motif structures 
A wide range of biophysical methods are employed to characterise and investigate 
non-canonical secondary DNA structure. The examples presented below are 
commonly used for i-motif research.  
Förster resonance energy transfer (FRET) DNA-melting 
A FRET DNA-melting assay is a routine primary screen to study the structure and 
the effects of ligands on the stability of G-quadruplexes and i-motifs.80 The 
experiment is carried out with artificially-synthesised nucleic acids tagged with two 
fluorescent substituents on either end of the oligonucleotide. For example, 6-
carboxyfluorescein (6-FAM or FAM) can be conjugated to the 5ʹ- end and 6-
carboxytetramethyl-rhodamine (6-TAMRA or TAMRA) to the 3ʹ- end (Figure 
1.7).81 
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Figure 1.7  Chemical Structure of FAM & TAMRA 
In this case the FAM fluorophore behaves as a donor while TAMRA serves as an 
acceptor (quencher). When the DNA is unfolded, there is no interaction between 
FAM and TAMRA due to a large distance between them. Exciting the FAM group 
at 495 nm gives rise to an emission from FAM at 517 nm. Once the DNA structure 
is folded, FAM can be designed to be proximal to the TAMRA group. In this case, 
exciting FAM at 495 nm results in the emission of FAM at 517 nm being quenched 
and replaced by the emission of TAMRA at 580 nm, known as the FRET 
phenomenon.80 During the process, the energy received by the donor is transferred 
to TAMRA via a non-radiative dipole-dipole interaction if the distance between the 
donor and acceptor is within the range of 15 to 60 Å. The FRET efficiency (EFRET) 
can be described mathematically as the distance between the two fluorophores 
(Equation 1.1) or the change in fluorescence of the donor (Equation 1.2).82 
Equation 1.1:     𝐸FRET =
𝑅0
6
𝑅6+𝑅0
6 
Equation 1.2:     𝐸FRET = 1 −
𝐹𝐼𝑑
𝐹𝐼𝑑
0 
Where EFRET is the FRET efficiency, R is the distance between FAM and TAMRA, 
R0 is the Förster distance, where the energy transfer between fluorophores is 50%, 
FId is the fluorescence of FAM in the presence of TAMRA, FId0 is the fluorescence 
of FAM in the absence of TAMRA. 
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By selectively filtering and measuring the emission intensity of FAM at 517 nm, an 
indication of how much of the DNA population is folded or unfolded can be 
determined by the changes in fluorescence (Figure 1.8).  
 
Figure 1.8  A diagram illustrating how Förster resonance energy transfer can 
 monitor folding of DNA 
Disassociation of oligonucleotides can be achieved by changing their environment 
or temperature. Thus, thermal stability of a particular oligonucleotide structure can 
be assessed by measuring and comparing the melting point (Tm) of DNA, the 
temperature at which 50% of the secondary structure population has unfolded into 
single strands.80 Additionally, FRET can also be applied at a static temperature to 
investigate the folding or unfolding patterns of i-motif on changing the conditions 
or adding a ligand. 
UV-Vis Spectroscopy 
Oligonucleotides contain purine and pyrimidine bases. Both of which absorb light 
around 260 nm as a characteristic property of their aromaticity. However, this 
property is altered when oligonucleotides are folded due to π-π stacking interactions 
between nucleobases. This phenomenon can also be employed to identify and 
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investigate DNA conformational changes.39,83 In the study of i-motifs, UV-
absorption is normally recorded from 220 to 330 nm.76 When i-motif forming 
sequences become folded into an i-motif, this results in an increase in absorbance 
at 240 nm and a decrease in absorbance at 295 nm.83,84 Just like FRET, UV-Vis 
spectroscopy can also be used to investigate thermal stability or folding patterns of 
oligonucleotides. However, results from UV-Vis spectroscopy may be complicated 
by ligand absorptions which commonly occur in the same region as DNA. 39  
Circular Dichroism (CD) 
Circular dichroism is a low-resolution but highly-sensitive experimental technique 
using circularly polarised electromagnetic rays to detect macro-biological 
molecules such as peptides and nucleotides. Oligonucleotides are chiral 
macromolecules that possess different glycosidic bond angles. These glycosidic 
torsion angles absorb right- and left-handed polarized light differently, which can 
be measured and quantified empirically as ellipticity.85,86 
For an intramolecular i-motif, the characteristic CD spectrum gives a large positive 
peak at 288 nm and a strong negative peak at 255 nm. In contrast, a CD spectrum 
for a single-stranded DNA molecule has a weaker positive peak at 275 nm and a 
negative peak at 250 nm.87 CD can be employed as a diagnostic and dynamic 
method to monitor the conformational changes induced by altered environment or 
ligand interactions.  
Nuclear Magnetic Resonance (NMR) spectroscopy 
NMR spectroscopy is a high-resolution experimental technique for the study of 
oligonucleotide secondary structure, providing detailed dynamic information, 
stability, atomic resolution structures and intermolecular interactions in vitro.88 In 
a C≡C+ base pair, the imino proton gives a resonance between 15 to 16 ppm and 
the two amino protons give resonances from 8 to 10.5 ppm, which can be 
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considered the characteristic signals for i-motif structures.89 In a Hoogsteen base 
pairing, the characteristic peak assigned as imino proton is at 15 to 16 ppm90,91 
while in a Waston-Crick base pairing, this characteristic peak is normally found 
from 12 to 13 ppm.56  
Surface Plasmon Resonance (SPR) spectroscopy 
SPR spectroscopy is an optical-based, real-time and highly sensitive detecting 
method for binding affinity and kinetic studies.92 Its mechanism is based on the 
changes in refractive index near a sensor surface (metal) induced by ligand binding 
or dissociation. In an SPR experiment, biotin-tagged oligonucleotides capable of 
forming i-motif structures are non-covalently attached to streptavidin coated 
sensor.93 The side immobilised with oligonucleotides is washed continuously with 
running buffer and laser light is cast onto the other side of gold plate with the correct 
angle to create resonant plasmons. The reflected light contains a resulting 
detectable interference band as an SPR signal. By adding ligands into the running 
buffer, the interaction between ligands and i-motif will be recorded as changes in 
the interference band.92,93 By measuring and analysing variations of refractive index 
on the interference band detailed ligand binding, information such as binding 
constants and stoichiometry, can be determined.  
1.3.4 i-Motif binding ligands 
Compared to the large library of G-quadruplex interacting compounds,94 the 
number of i-motif binding ligands is quite limited. Only a handful of compounds 
have been reported to interact with i-motifs (Figure 1.9). Apart from the Bcl-2 i-
motif interacting compound mentioned in Section 1.3.2 (NSC 1398948), one of the 
most prominent ligands is the carboxyl modified single-walled carbon nanotube 
(SWNT). This reagent is able to specifically stablise human telomeric i-motif even 
in slightly alkaline conditions (pH = 8) without any interaction with G-quadruplex 
and duplex DNA.95 A proposed mechanism for this stablisation is that the nanotube 
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Figure 1.9 Reported and group in-house ligands which have been found to 
interact with i-motifs. 
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binds to the 5ʹ-end major groove of i-motif while the carboxyl acids attached to the 
nanotube interact with the C≡C+ base pairs via electrostatics. Later experiments 
showed that this nanotube can also inhibit telomerase.72 The cationic porphyrin 
TMPyP4 is another ligand that binds to i-motifs with a dissociation constant of 45 
μM. Unfortunately, it also binds to duplex DNA (1.2 μM) and G-quadruplexes (0.5 
μM), so TMPyPy lacks selectivity and binds i-motif nuch weaker than other types 
of DNA structure.96 Crystal violet has been reported to bind i-motif formed from 
a poly-cytidine sequence. But its binding against other more complicated i-motif 
structures are not documented.97 BisA is another i-motif binding ligand based on 
an acridine structure that has been studied before. It was found that this compound 
stabilises human telomeric i-motif at pH 6.8.98 Other ligands, such as 
phenanthroline derivatives99 and terbium complexes100, showed very weak i-motif 
binding affinities. In our group, several i-motif binding ligands were identified via 
FRET melting and SPR binding studies.101 These compounds include 
mitoxantrone, tilorone, tyrothyrcin and tamoxifen. Among them, mitoxatrone 
was the most effective i-motif binder, possessing the lowest micromolar Kd towards 
human telomeric i-motif (Kd = 11 μM).101,102 meanwhile, tilorone was found to bind 
with a far weaker affinity (Kd = 158 μM).101  
Given the scant literature reporting i-motif interacting ligands, and bearing in mind 
the potential biological implications of being able to target them, more work needs 
to be done to discover new compounds which can bind and stabilize i-motif. 
1.4  Thermodynamics of oligonucleotides 
Oligonucleotides tends to self-assemble into higher order structures, driven by the 
local thermodynamic and mechanical properties of the molecules. The study of 
thermodynamics includes binding energies (thermodynamics), transition-state 
enerties, mechanisms and transformational rates (kinetics), yielding macroscopic 
data of DNA self-assembly or DNA-ligand interactions.  
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1.4.1 DNA self-assembly 
Single-stranded DNA molecules are not stable in aqueous solution due to the 
presence of hydrophobic nucleic base. These molecules can self-assemble into 
higher order structures either between two molecules or on their own. The whole 
process can be explamed via the classical Gibbs free energy equation and a diagram 
shown below. 
 
Figure 1.10 DNA folding process pushing the water molecules aside, human 
telomeric i-motif structure as an example. 
Equation 1.3     𝐷𝑁𝐴𝑢𝑛𝑓𝑜𝑙𝑑
𝐾
⇔𝐷𝑁𝐴𝑓𝑜𝑙𝑑 
Equation 1.4     ∆𝐺 =  ∆𝐻 − 𝑇∆𝑆 = −𝑅𝑇ln 𝐾 
In Equation 1.4, the sign and value of ΔG determines the spontaneity of the reaction. 
The ∆H is generally attributed to changes in covalent and hydrogen bonds and salt 
bridges. In the process of DNA self assembly, enthalpy changes are generally 
negative in duplex DNA, G-quadruplex and i-motif formation due to the energy 
output in hydrogen bond formation. 103-105 The ∆S attributes to the order of system, 
which is also generally negative due to the changes from a less ordered structure to 
an ordered system. However, to the whole environment (including the DNA 
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molecules and buffer), the entropic changes is increased.  
Whether the higher-order DNA structures are present or not is determined by the 
competitation between entropic (TΔS) and enthalpic (ΔH) components. By 
changing the temperature of the environment, the ΔG can reach 0, where 
oligonucleotides exist in a transit state between folding and unfolding. 105  
1.4.2 DNA-ligand binding.  
Intercalation 106 and the minor groove binder 107 are the two principle mode in 
DNA-ligand binding. 107 In the case of intercalation, flat and aromatic molecules 
interacts with nucleobase by π-π stacking, which results in a negative enthalpic 
change while the hydrophobicity of the molecule contributes to a positive entropic 
change. 107 However, for minor groove binders, such as Hoechst 33258, positive 
changes in entropy alone contributes to the majority of the Gibbs free energy. 107 
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2.1  Introduction 
Despite the fact that research in the field of i-motif is growing rapidly, there are still 
only a limited number of i-motif interacting compounds recorded in the literature.40 
Additionally, compounds identified to interact with i-motifs often possess higher 
affinity towards duplex or G-quadruplex structures.40 Thus, to search for 
compounds which specifically interact with i-motifs has became increasingly 
important in the research of i-motifs.  
As described in Section 1.3.3, FRET melting based DNA experiments are widely 
used as a screening method for DNA binding ligands. However, this method still 
has some limitations. First, oligonucleotide samples used in FRET assays are all 
modified on both ends of the sequences with fluorophores, such as FAM and 
TAMRA. These two bulky, planar and aromatic substituents may affect DNA 
conformations, especially if short sequences are used.80 Futhermore, the addition 
of fluorophores to the DNA is more expensive than using non-labelled 
oligonucleotides. Apart from their price, FRET-labelled oligonucleotides may also 
possess altered binding affinities towards various DNA binding ligands.80 
Additionally, melting experiments require heating the sample to break down 
hydrogen bonding interactions between the C≡C+ base pairing, which is very 
different from physiological process observed in the cell and also prevents the use 
of traditional plate readers for screening different types of ligands. 
In this chapter, a screening method based on fluorescent intercalator displacement 
was developed to identify DNA interacting ligands, and tested in human telomeric 
i-motif.   
2.1.1 Fluorescent Intercalator displacement (FID) 
Fluorescent intercalator displacement, also known as fluorescent intercalator 
replacement, is a simple, cost-effective, nondestructive and high-throughput 
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method to study DNA sequence selectivity and binding affinity. This assay was first 
described by Boger, Fink and Hedrick,108 where DNA was treated with a 
fluorescent intercalator (Figure 2.1a), such as ethidium bromide,108 thiazole orange 
(TO),109  and Hoechst 33258 (Figure 2.1b),110 resulting in significant fluorescence 
enhancement due to DNA intercalation. When a non-fluorescent DNA binding 
agent was added and replaced the bound fluorescent intercalator, the fluorescence 
of the DNA-intercalator complex decreased as the result of competitive 
displacement (Figure 2.1a).108,109 By calculating the decreasing percentage in 
fluorescence, relative DNA binding affinities can be calculated. In the same way, 
when subsequent quantitative titration is applied, accurate absolute binding 
constants may be obtained by calculation of the changes in fluorescence. By 
altering the DNA sequence, even more detailed insights such as the size of the 
binding site on nucleic acids can be investigated.108 DNA intercalators, such as 
ethidium bromide and thiazole orange, insert into the gaps between adjacent base, 
exhibiting drastic changes in their respective fluorescent properties. However, non-
fluorescent Hoechst 33258 does not bind DNA in the same way, instead 
intercalating into the minor-grove and binding specifically to adenine and 
thymidine base pairs, but still exhibits enhanced fluorescence in a similar manner 
to thiazole orange and ethidium bromide.  
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Figure 2.1  a) Example of fluorescent intercalator displacement on B-DNA 
 structure. b) common fluorescent probes for FID assay 
FID assays were first established on double-stranded and hairpin structures111 and 
later on applied to G-quadruplexes.112,113 In terms of executing an FID assay, 
thiazole orange (TO), an asymmetric cyanine, offers many advantages over 
ethidium bromide.The fluorescence quantum yield (ΦF) of thiazole orange is very 
low (ΦF = 2 × 10-4) in the absence of DNA, however, when bound to G-
quadruplexes and double-helical DNA, the quantum yield increases 100 to 1000 
times.111 For comparison, fluorescence enhancement caused by ethidium bromide 
is only 20-fold.109 Apart from that, G-quaduplex-bound thiazole orange possesses 
a large Stokes shift. It is excited by light at 485 nm but emits fluorescent radiation 
at 550 nm. This property minimises the possibility of fluorescence self-quenching. 
In a series of fluorometric studies carried out by Teulade-Fichou’s group, thiazole 
orange was observed to bind intramolecular human telomeric G-quadruplexes 
(22AG, 5ʹ-AG3(T2AG3)3-3ʹ) in an anti-parallel conformation with reasonably high 
affinity (Ka = 2.1 to 3.4 × 106 M-1) and an unambiguous 1:1 stoichiometry (Figure 
2.2) in both K+ and Na+ buffers.114 Once thiazole orange was bound to 22AG, it can 
be excited at 501 nm and its corresponding fluorescent emission peaked at 539 
nm.112 In contrast intermolecular G-quadruplex composed of four oligonucleotides 
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([TG3T]4) has two available binding sites for thiazole orange and a similar binding 
affinity (Ka = 1.5 × 106 M-1, for each of the binding sites).114 The only difference 
between these two G-quadruplex structures is the loop region. Thus thiazole orange 
locates in the loop-free end of human telomeric G-quadruplex, exerting external π-
π stacking on G-tetards.114 Thiazole orange binds to double-helical DNA with 
similar affinity (Ka = 2 to 3 × 106 M-1).115 The stoichiometry of thiazole orange 
binding to G-quadruplexes was further studied with ESI-MS experiments. 115 In 
these experiments, the result suggested a different binding stoichiometry. The major 
observation of thiazole orange binding falls in the 1:1 stoichiometry, with a 
marginal sub-population of 2:1 TO:DNA complex. This might result from a second 
binding site for thiazole orange which possesses a very weak fluorescence quantum 
yield.115 
 
Figure 2.2  Example of fluorescent intercalator displacement on human 
 telomeric G-quadruplex structure 
After confirming the binding mode between thiazole orange and human telomeric 
G-quadruplex, Teulade-Fichou et al. carried out a series of fluorescent intercalator 
displacement experiments with different G-quadruplex forming sequences and 
various G-quadruplex binding ligands.115-117 These G-quadruplex forming 
sequences were not restricted to human telomeric repeats but also included other 
proto-oncogenic sequences, such as VEGF, c-kit, c-MYC and K-ras G-quadruplex 
forming sequences, indicating that a wide range of G-quaduplexes are suitable for 
FID assay. Additionally, the ligand to oligonucleotide ratio was set as 2:1 to mimic 
the two plausible binding sites on G-quadruplexes.115 Further development led to a 
high-throughput screening method for G-quadruplex ligands allowing for quick 
Chapte 2 Development of a High-throughput Fluorescent Intercalator Displacement Assay for Human Telomeric i-motif 
27 
 
determination of ligand-G-quadruplex interactions.117 
2.1.2 Fluorescent probes interacting with i-motifs  
Given the success of using FID for DNA binding compounds and the lack of known 
i-motif binding ligands, we decided to explore the potential of using FID assays to 
identify ligands for i-motif structures. Thus, the first step for the development of an 
i-motif-FID assay is to find the ideal fluorescent probes for i-motif structures. 
Crystal violet  
Crystal violet, a triphenylmethane dye (Figure 2.3), is widely used as a biological 
stain and probe in biochemical research.  
 
 
Figure 2.3  Chemical structure of crystal violet  
Examples of crystal violet binding to i-motif structures have been reported.97,118 
Oligonucleotide C29 (5ʹ-(C5T3)3C5-3ʹ) was shown to be a stable i-motif with 5 layers 
of intercalated C≡C+ base pairs at pH 5.0. Crystal violet binds to this rigid i-motif 
structure with a similar affinity (Ka = 1.2×106 M-1 1:1 stoichiometry)97 as seen for 
G-quadruplexes.119 In the UV absorption titration experiment and a drastic 
enhancement of the fluorescent emission at 580 nm was observed when crystal 
violet solution was titrated with C29 oligomer at pH 5.0.97 Crystal violet’s binding 
to a tetramolecular i-motif (5ʹ-(AC3T)4-3ʹ) was studied via molecule docking. The 
in silico calculation results suggested two capping sites on either end of the i-motif 
(-38.44 and -31.57 kcal·mol-1 as binding energy, respectively).97 The insertion of 
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crystal violet into this tetramolecular i-motif seems, however, not to be a 
spontaneous event (23 kcal·mol-1 as binding energy). Crystal violet also shows 
great ‘light-on’ i-motif selectivity over double-helix and single-stranded 
structures.97 In addition, crystal violet was used as a selective electrochemical probe 
for i-motif structure to achieve pH-driven electrochemical switch.118 
Thiazole orange 
Thiazole orange (TO) has been shown to interact with i-motifs as well (Figure 
2.4).118,120-122  
 
Figure 2.4  Chemical structure of thiazole orange 
In 2014, Shao’s group reported a pH-gated exciplex using modified i-motif forming 
sequences. Thiazole orange was covalently conjugated to the human telomeric i-
motif, replacing a thymine substituent (T16) on the loop. (Figure 2.6a) Later the 
exciplex was shown to possess a strong fluorescent emission at 580 nm and a Stokes 
shift of 90 nm at pH 5.5. The fluorescence quantum yield of this exciplex is 
comparable to that of thiazole orange intercalated into the double-helix DNA (ΦF 
= 4 × 10-2).120 The fluorescence life-time of this exciplex was significantly 
prolonged (τ = 2.49 ns), which is even higher than thiazole orange in duplex (τ = 
1.83 ns). This study suggested that TO can be used as a fluorescent probe if it binds 
to human telomeric i-motif.120 
In 2016, a study on i-motif unfolding pathways was carried out using human 
telomeric i-motifs tethered with thiazole orange as a fluorescent reporter. In this 
study, single thiazole orange molecules replace multiple nucleic bases on the human 
telomeric sequences, such as at the 5ʹ-end, loop I, loop II, loop III and the 3ʹ-end 
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position.122 All TO-modified nucleic acids adopted i-motif structures at pH 5.0 in 
sodium cacodylate buffer and were excited at 490 nm in the same condition. When 
thiazole orange was at the 5ʹ -end, the 3ʹ-end and loop II, fluorescent emission was 
observed at 535 nm and when thiazole orange was at the loop II and loop I and loop 
III, fluorescent emission was observed at 580 nm.122 By monitoring the change of 
fluorescence for four TO-modified i-motifs individualy when changing the 
temperature, it was concluded that the disassociation of intermolecular human 
telomeric i-motif starts with unzipping C≡C+ base pairs initiated from the 3ʹ- to 
form a triplex-like intermediate first.122  
Pei et. al. questioned whether thiazole orange can be directly used as fluorescent 
light-up probe for human telomeric i-motif in 2015.121 In their research, they 
focused on applying H+ or Ag+ to achieve ‘OR’ logical gate with TO-i-motif 
complex.121 Thiazole orange was previously incubated with human telomeric i-
motif in PB buffer at pH 6.0. A fluorescent emission at 535 nm was observed when 
TO bound to pre-formed human telomeric i-motif and excited at 488 nm.121  
Pyrene 
The interaction of pyrene and i-motif structures has also been reported (Figure 2.5). 
 
Figure 2.5 Chemical structure of pyrene 
In 2011, Kim et. al. described an oligonucleotide-based nanostructure close to that 
observed for thiazole orange with a shorter oligonucleotide (5ʹ-(TA2C4)2T-3ʹ).123 
Two adenosines on each of the loop region were modified with pyrene. In acidic 
buffer, four pyrene motifs on the loop were able to cap both ends of the bimolecular 
i-motif formed (Figure 2.6b). This capping effect dramatically increased the 
melting temperature of modified oligonucleotides (ΔTm = 23.5℃ ) and the 
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formation of pyrene-capped i-motif in turn enhanced pyrene’s fluorescence 4–fold 
(Figure 2.6b).123 Pyrene has also been conjugated to i-motif forming sequences 
closer to human telomeric repeats. In 2013, Majima’s group reported an i-motif-
based, pH-gated electronic device in which pyrene-appended uridine replaced one 
thymidine on a TTA loop and successfully achieved photoinduced electron transfer 
with an anthraquinone substituent conjugated to the other end of human telomeric 
i-motif.124  
 
Figure 2.6 Exciplex formed from thiazole orange (a) or pyrene conjugated human 
telomeric i-motif (b)Pyrene-appended bimoleculear i-motif 
2.2  Aims 
Although G-quadruplexes-FID assays have been established for over 8 years, there 
are no reports of i-motif-FID assays. In light of the successful development of FID 
assays that use thiazole orange as the DNA intercalator and the lack of i-motif 
binding compounds, it was proposed that a similar assay could be established for 
screening ligands against i-motif DNA. (Scheme 2.1) 
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Scheme 2.1  Proposed FID assay on human telomeric i-motif  
The aims of this project are: 
1) To investigate the potential suitability of different i-motif binding compounds 
for use as FID fluorescent probes. 
2) To characterise the binding properties of the selected fluorescent probes with 
human telomeric i-motif, to evaluate binding stoichiometry, stabilization of i-
motif, binding affinity and the plausible structural alteration of the i-motif.  
3) To apply the selected fluorescent probe in an FID assay with some known i-
motif binding compounds, to determine methods to screen for possible i-motif 
binding compounds 
4) To estabish a high-throughput ligand screening method for human telomeric i-
motif using a compound library. 
2.3  Results and discussion 
2.3.1 Screening of fluorescent probes suitable for i-motif-FID assay  
Ideally a fluorescent probe needs to have a drastic change in fluorescent emission 
upon binding oligonucleotides. At the beginning of the screening, several G-
quadruplex and i-motif fluorescent probes were considered, including acridine 
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orange, ethidium bromide, crystal violet and 1-pyrenemethanol (Figure 2.7). 
Acridine orange and ethidium bromide are both used as nuclear stains. Ethidium 
bromide has been used as a fluorescent probe replacement for thiazole orange in an 
FID assay previously.125,126 In the early study of fluorescent intercalator 
displacement on double helical DNA, acridine orange was reported as an 
ineffective dye.127 However, due to the structural differences between double helix 
and i-motif, acridine orange was still considered as one of the candidate probes.  
 
Figure 2.7 Fluorescent probes screened in finding the intercalator for FID assay 
The compounds were assessed by monitoring the change in fluorescence after 
addition of human telomeric i-motif forming DNA (hTeloC, 5ʹ-
TAACCCTAACCCTAACCCTAACCC-3ʹ), at pH 5.5, conditions where most i-
motif structures are stable. The aim was to observe any changes in fluorescence, 
such as fluorescence intensity, excitation and emission wavelength, after the probes 
binds to hTeloC. The result showed that thiazole orange has a dramatic fluorescent 
enhancement (125-fold) after binding to i-motif with 1:1 concentration ratio 
(Figure 2.8a). However, the excitation band peaks at 430 nm and gives a narrow 
Stoke shift of only 21 nm, which is very different from reported i-motif induced 
fluorescence.121,122 This might be a result of the fact that thiazole orange in our 
experiments is not closely stacking on either end of the i-motif. 
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Figure 2.8 Fluorescence emission of TO-i-motif complex in 10 mM sodium  
   cacodylate buffer. The sample was excited at 430 nm. Thiazole orange 
   is 5 μM. a) pH = 5.5, b) pH 7.4 
Binding of thiazole orange to hTelo i-motif in pH 7.4 buffer was also studied but 
no significant fluorescence was observed compared to that in pH 5.5 buffer (Figure 
2.8b). This can be explained by the lack of π-π stacking since the human telomeric 
i-motif forming sequence is mostly in the unfolded conformation at pH 7.4. It is 
unsurprising that when the pH value was at 5.5 the hTeloC i-motif was rigid enough 
to provide strong a π-π stacking effect, and thus enhanced the fluorescence of 
thiazole orange. An additional small shoulder on the emission spectra was observed 
at 535 nm with an intensity of only 1/3 of the highest emission peak at 451 nm. 
Thus the emission peak at 451 nm should be selected as the target for fluorescence 
screening. 
In contrast, attempts to use other probes were rather unsuccessful. Although crystal 
violet had been demonstrated to interact with poly-cytidine DNA, we observed no 
useful changes in fluorescence on addition of hTeloC (Figure 2.9).  
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Figure 2.9 Fluoresent emission of probe-i-motif complex in pH 5.5 10 mM 
sodium cacodylate buffer. a) [ethidium bromide]= 5 μM, excited at 
490 nm; b) [acridine orange]=5μM, excited at 490 nm; c) [1-
pyrenemethanol] = 5 μM, excited at 440 nm; d) [crystal violet] = 5 
μM, excited at 580 nm.  
The fluorescence of ethidium bromide and acridine orange only increased by 25 to 
70 % upon binding to human telomeric i-motif (1:1 binding), which is not sufficient 
for a potential FID assay (Figure 2.9a and Figure 2.9b). For 1-pyrenemethanol, its 
fluorescence decreased by 70% after titration with human telomeric i-motif (Figure 
2.9c), indicating a fluorescent quenching on DNA binding. A plausible explaination 
for this phenomenon is i-motif condensation in the buffer after pyrene binds to 
human telomeric i-motif. The same phenomenon occurred with ethidium bromide 
as well. For crystal violet, only a very weak fluorescent emission was detected 
when the sample was excited at 580 nm (Figure 2.9d). Thus, the other fluorescent 
probes tested failed to exhibit equal ‘light-up’fluorescence properties as thiazole 
orange. A summary of the fluorescence properties of the tested probes can be found 
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in Table 2.1. Due to these observed characteristics, thiazole orange was selected as 
the fluorescent probe for further studies. 
Compound 
Excitation 
(nm) 
Emission 
(nm) 
Fluorescent Emission 
enhancement (%) 
Acridine orange  490 520 23 
Crystal violet 580 625 70 
Ethidum bromide  490 620 -12 
Thiazole orange 430 450 11860 
1-pyrenemethanol 440 470 -74 
Table 2.1 Fluorescence probe screening upon binding to hTeloC (1 equivlent). 
[hTeloC] = 5 μM, [probe] = 5 μM. Buffer: pH 5.5, 10 mM sodium 
cacodylate.  
Fluorescence enhancement of thiazole orange upon i-motif binding 
Fluorescent enhancement experiments were performed in collaboration with 
Tasnim Mahound, a project student previously working in our lab. In order to study 
the enhancement of fluorescence upon binding to human telomeric i-motif, aliquots 
of preformed human telomeric i-motif were titrated into a solution of thiazole 
orange at pH 5.5, resulting in a steady increase in fluorescence emission. This result 
suggested a concentration-dependant binding event between thiazole orange and 
hTeloC (Figure 2.10). With 1 equivalent of added DNA, the fluorescence 
enhancement was found to be 4.52 × 106 (A. U.), 2 equivalence gave 6.14 × 106 (A. 
U.) and the enhancement started to plateau at 3 equivalence.  
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Figure 2.10 Fluorescence emission of thiazole orange titrated with hTeloC at pH 
5.5 in 10 mM sodium cacodylate buffer. [TO]= 5μM. [hTeloC] = 0 - 
20 μM. Samples were excited at 430 nm.  
Additionally, the interaction of thiazole orange and the i-motif forming sequence 
from the c-MYC promoter (c-MYCC,41 5ʹ-TCCCCACCTTCCCCACCCTCCCCA 
CCCTCCCCA-3ʹ) was also examined by analogous titration experiments. The 
results also showed a concentration-dependant fluorescence enhancement similar 
to that observed for hTeloC (Figure 2.11). This suggested that the FID assay 
developed on thiazole orange with human telomeric i-motif can be applied to other 
i-motif structures in the future.  
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Figure 2.11 Fluorescence emission of thiazole orange titrated with c-MYCC at pH 
5.5 in 10 mM sodium cacodylate buffer. [TO]= 5μM. [hTeloC] = 0 ~ 
20μM. Samples were excited at 430 nm. 
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2.3.2 Determining the binding stoichiometry and affinity of thiazole orange 
After confirming the potential of thiazole orange as the fluorescent probe in i-motif-
FID assays, the binding properties of thiazole orange towards hTelo i-motif needed 
to be determined. Two UV-based methods were used to characterise the interaction 
between TO and i-motif. These experiments were performed in collaboration with 
Joe Neaveason, a project student under my supervision throughout his research in 
the lab.  
Continuous Variation Binding analysis 
Using the method of continuous variation binding analysis (also known as a Job 
plot) with UV spectroscopy we were able to determine the stoichiometry of thiazole 
orange binding to hTeloC i-motif.115,128 In these experiments, the total 
concentration of thiazole orange and hTeloC was kept constant, but the ratio of 
TO:hTeloC varied. Using maximum concentrations of 20 µM of each component 
in 50 mM sodium cacodylate buffer at pH 5.5, the samples were measured using 
UV spectroscopy. In Figure 2.9, the peak at 505 nm increased as more thiazole 
orange was titrated with the hTeloC, however this absorption peak plateaued when 
the concentration ratio of thiazole orange to hTeloC was around 6:4 to 7:3. The 
resulting Job plot indicated a 2:1 binding ratio of TO:hTeloC (Figure 2.12). This 
result may suggest an end-stacking binding mode between human telomeric i-motif 
and thiazole orange. 
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Figure 2.12 a) UV-vis spectra of hTeloC and thiazole orange at pH 5.5 in 50 mM 
sodium cacodylate buffer; b) UV Job Plot for thiazole orange;hTeloC 
titration, indicating 2:1 stoichiometry 
UV titration and curve fitting 
The binding affinity between thiazole orange and hTeloC was determined using UV 
titrations. Starting with 5 µM of hTeloC in 50 mM sodium cacodylate at pH 5.5, 
small aliquots of thiazole orange were titrated in and the resulting UV spectrum 
taken. Using the least squares method,129,130 a hyperbolic binding curve of fraction 
bound versus TO concentration was generated. Given the known stoichiometry, the 
data was fitted with an independent two-site binding model (Equation 2.2) to give 
two dissociation constants (Kd1 = 3.61 µM and Kd2 = 75.6 µM, Figure 2.13). Fitting 
to a 1:1 binding model (Equation 2.1) was also attempted (Figure 2.13) but did not 
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give a good fit to the data.  
Equation 2.1     
Where θ is the fraction of binding measured, K1 = the equilibrium association 
constant for the binding sites. Kd = 1/K1. n = 1 due to the set-up of the model.131,132 
Equation 2.2     
Where θ is the fraction of binding measured; K1 = the equilibrium association 
constant for the first binding site; and K2 = the equilibrium association constants 
for second binding site. Kd1 can be determined by the reciprocal of the binding 
constant (ie. Kd1 = 1/K1). The results from the binding studies support the model 
that two thiazole orange molecules bind to one i-motif.130-132  
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Figure 2.13 UV-vis spectroscopy titration of thiazole orange with hTeloC at pH 
5.5 in 50 mM sodium cacodylate buffer. UV absorbance was 
measured at 505 nm. [hTeloC] = 10μM 
𝜃 =
𝑛𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
       𝑛
= 1 
𝜃 =
𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑] + 2𝐾1𝐾2[𝐿𝑖𝑔𝑎𝑛𝑑]
2
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑] + 𝐾1𝐾2[𝐿𝑖𝑔𝑎𝑛𝑑]2
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The experiments were also conducted in an opposite manner, by titrating hTeloC 
into 5 µM TO and monitoring the fluorescence enhancement. The resulting binding 
constants were found to be the same within error. These results reveal that thiazole 
orange binds in a weaker affinity to i-motif compared to G-quadruplex and duplex 
DNA (which demonstrate Kd between 0.3 and 0.67 µM).114,115 However, this is 
important, because if thiazole orange were to bind i-motif DNA too tightly, it would 
be more difficult for a ligand being tested to displace it from the DNA. Since 
previous assays with other DNA secondary structures have been shown to work 
with TO binding with similar affinities, these results demonstrate that TO can bind 
i-motif DNA strongly enough to observe good fluorescence, but weakly enough to 
be displaced by a ligand.  
2.3.3 Effect on i-motif conformation and stability of thiazole orange binding 
Experiments in Section 2.3.3 were performed in collaboration with Joe Neaveason, 
a project student under my supervision throughout his research in the lab. 
Given i-motif forming sequence can exist in equilibrium with hairpin structure,49,57 
experiments to determine the nature of the bound complex are required. Circular 
dichroism (CD)87 is a technique capable of distinguishing between hairpin and i-
motif secondary structures. It was therefore used to investigate the effects of adding 
thiaozle orange to hTeloC under different pH conditions to determine whether the 
ligand is able to alter or influence the conformation of the i-motif.  
At and below the transitional pH (pH 6 and pH 5.5) intense positive signals are 
observed around 288 nm accompanied by negative signals around 258 nm for 
hTeloC, both characteristic of i-motif formation.87 These signals are less intense at 
pH 6 compared to pH 5.5, indicating the proportion of i-motif present is higher at 
pH 5.5. At pH 7.4 the signal at 288 nm is absent, indicating hTeloC is no longer 
folded into an i-motif. At this pH the equilibrium is shifted towards a mixture of 
random coil and possible hairpin structures.87 Thiazole orange was titrated into 
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hTeloC at different pHs to investigate whether it could alter the conformation of 
DNA. At pH 5.5, significant changes in the CD spectrum were observed, with a 
shift in the negative signal from 258 to 270 nm and a decrease in the positive signal 
at 288 nm (Figure 2.14a). A decrease in the positive signal at 288 nm rather than a 
shift in the positive signal from 288 nm to 275 nm indicates the changes observed 
are not consistent with i-motif unfolding or converting to a hairpin structure. The 
smooth CD spectra obtained when 10 equivalents of thiazole orange were titrated 
with human telomeric i-motif indicated the signal-to-noise ratio was not affected 
and unlikely to be the result of precipitation. The signals could be due to an induced 
CD signal (ICD), which occurs on TO-i-motif binding. A similar ICD effect was 
also observed at pH 6 (Figure 2.14b). However, at pH 7.4 (Figure 2.14c), a 
reduction in signal intensity appeared at 10 µM and 50 µM of thiazole orange, 
coupled with a change to poor signal-to-noise in the spectrum. Additionally, a 
positive absorbance was also observed at 300-320 nm, indicating a scattering effect 
Together these features indicate precipitation at pH 7.4. This shows that at higher 
pH and higher concentrations of thiazole orange the DNA condenses and scatters 
light. It also reveals that the i-motif is less susceptible to condensation in acidic 
conditions than the same sequence at physiological pH.  
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Figure 2.14a: Circular dichroism titration of hTeloC (10 μM)with thiazole 
orange (0 – 100 μM) at pH 5.5 10mM sodium cacodylate buffer.  
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Figure 2.14b: Circular dichroism titration of hTeloC (10 μM)with thiazole 
orange (0 – 50 μM) at pH 6.0 10mM sodium cacodylate buffer. 
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Figure 2.14c Circular dichroism titration of hTeloC (10 μM) with thiazole 
orange (0 - 50 μM) at pH 7.4 10mM sodium cacodylate buffer.  
These experiments highlighted some potential limitations of the conditions possible 
for use in an FID-type assay; to counter this, acidic pH and lower molar equivalents 
of thiazole orange were therefore selected. Nevertheless, the results from the CD 
indicate that the addition of thiazole orange does not alter the conformation of the 
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hTeloC i-motif within 10 micromolar concentration, so is suitable for use in a FID 
assay under these conditions.  
To determine whether thiazole orange can stabilise i-motif DNA at different pHs, 
DNA melting experiments were conducted using FRET-melting experiments.  
In addition to hTeloC and c-MYCC41 which are i-motifs that are stable at slightly 
acidic pH, HIF-1αC39 (5ʹ-CGCGCTCCCGCCCCCTCTCCCCTCCCCGCGC-3ʹ) 
was also examined as it is relatively stable at near-physiological pH (Figure 2.12a). 
For comparison, G-quadruplex (hTeloG, 5ʹ-GGGTTAGGGTTAGGGTTA GGG-3ʹ) 
and double helical DNA (ds, 5ʹ-TATAGCTATA-HEG(18)a-TATAG CTATA-3ʹ) 
were also studied (Figure 2.15). For the i-motif forming sequences, melting 
experiments were performed at the transitional pH (where 50% of the i-motif is 
folded) and also at pH 5.5. All experiments showed that thiazole orange has a 
stabilising effect on i-motif DNA, regardless of sequence or pH. For example, 
adding 12.5 μM of TO to hTeloC at pH 5.5 resulted in an increase in Tm of 13°C.  
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Figure 2.15 ΔTm vs concentration on different i-motif forming sequences with 
TO in 50 mM sodium cacodylate buffer at pH 5.5, TO 
concentration ranges from 0 to 25 μM. Fluorescent emission was 
measured at 533 nm. 
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The effect of adding thiazole orange is even more noticeable at the transitional pH 
(Figure 2.16). For example, a large increase in melting temperature of HIF-1αC 
(∆Tm = 12.5°C) was observed even with addition of just 3.1 μM TO. In general, 
with addition of 6.25 μM TO, the thermal stability of three i-motif forming 
sequences at their transitional pH was increased by 12-18°C (Figure 2.16). The 
differences in ∆Tm between the different i-motif forming sequences were minimal, 
suggesting that TO binds a region in the structure which is common to all of these 
different i-motif sub-types, ie. it does not bind the loop-region, where these i-motif 
forming sequences vary. 
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Figure 2.16 ∆Tm vs concentration on different i-motif forming sequences with 
TO in 50 mM sodium cacodylate buffer at transitional pH , TO 
concentration ranges from 0 to 25 μM. Fluorescent emission was 
measured at 533 nm. 
Results from the experiments carried out on hTeloG and double helical DNA 
sequences at pH 7.4 also show some degree of stabilistion, as consistent with 
previous disclosures.113,133,134 In general, duplex DNA structure was more prone to 
be stabilised by addition of TO (Figure 2.17). After adding 3.1 μM of TO, the ∆Tm 
was shown to be above 6°C. In contrast, induced thermal stabilisation of human 
telomeric G-quadruplex by TO was not that significant, for example a ∆Tm of only 
5°C was observed even when 12.5 μM TO was added.  
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Figure 2.17 FRET melting experiment on double-stranded DNA and G-
quadruplex forming sequences with TO at pH 7.4 in 50 mM 
sodium cacodylate buffer. TO concentration ranges from 0 to 25 
μM. Fluorescent emission was measured at 533 nm. 
 
2.3.4 Development of an i-motif FID titration assay 
After confirming the binding and stabilising effects of TO on human telomeric i-
motif, the next step was to develop an assay to explore whether pre-bound TO can 
be replaced by candidate i-motif binding ligands (Scheme 2.1).  
Using the information obtained from the preliminary experiments, 1 μM of pre-
annealed hTeloC i-motif in 10 mM sodium cacodylate at pH 5.5 was incubated with 
thiazole orange. The equivalence between hTeloC and thiazole orange was set as 
2:1, consistent with the 2:1 binding mode determined in Section 2.3.2. After an 
equilibration period of 5 minutes, the samples were excited at 430 nm and the 
fluorescence spectra of the samples were recorded using a fluorimeter.  
Initial studies were performed using the known i-motif binding ligand 
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mitoxatrone.101,102 On addition of mitoxatrone, a significant loss in fluorescence 
emission at 450 nm was observed (Figure 2.18), indicative of displacement of TO 
from the DNA. Displacement at different ligand concentrations was calculated 
using Equation 2.3 (Figure 2.18).  
Equation 2.3    𝐷𝑥 = 1 −
𝐹𝑥
𝐹0
= 1 −
𝐹𝑟𝑒𝑎𝑑−𝐹𝑐0
𝐹𝑟𝑒𝑓𝑒𝑟𝑒𝑒𝑛𝑐𝑒−𝐹𝑐0
        
Where Dx is TO displacement resulting from competitive substitution of ligand; F0 
= the fluorescence intensity of the TO-i-motif complex at 450nm in the absence of 
any ligands; Fx = the fluorescence intensity at 450 nm after titration with the 
candidate ligand.  
By varying the concentration of ligand added, the ligand concentration where 50% 
of the TO was displaced by competitive ligand (DC50), can be calculated from a 
plot of Dx against [ligand] (Table 2.2). The results show that i-motifDC50 for 
mitoxantrone was 1.92 ± 0.15 μM. Additionally, other ligands previously found to 
bind i-motif in the Waller group: tilorone, tamoxifen and tyrothyrcin, were also 
used in the assessment (Figure 2.19). Tilorone exhibits an i-motifDC50 of 2.47 ± 0.44 
μM, which is slightly weaker than that of mitoxatrone. The other two compounds 
have i-motifDC50 higher than 5 μM, suggesting far weaker binding properties 
compared to mitoxatrone and tilorone. This suggests that the TO FID assay might 
be able to adequately act as a threshold to eliminate weaker i-motif binders. 
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Figure 2.18 Fluorescent intercalator displacement assay carried out using 
hTelo i-motif forming sequences and mitoxatrone at pH 5.5 in 10 
mM sodium cacodylate buffer. [hTeloC] = 1 μM, [TO] = 2 μM, 
[mitoxatrone]= 0 – 5 μM. The sample was excited at 430 nm.  
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Figure 2.19 TO displacement calculation based on hTelo i-motif FID assay on 
mitoxatrone, tilorone, tamoxifen and tyrothrycin at pH 5.5 in 10 
mM sodium cacodylate buffer. [hTeloC] = 1 μM, [TO] = 2 μM, 
[ligand]= 0 – 5 μM. The sample was excited at 430 nm and the 
fluorescence emission was measured at 450 nm.  
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Compound i-motifDC50 (µM) 
TMPyP4 1.15±0.15 
Mitoxatrone 1.92±0.15 
Tilorone 2.47±0.44 
Tamoxifen N/A 
Tyrothrycin N/A 
Table 2.2 TO displacement calculation based on hTelo i-motif FID assay on 
mitoxatrone, tilorone, tamoxifen and tyrothrycin at pH 5.5 in 10 
mM sodium cacodylate buffer. [hTeloC] = 1 μM, [TO] = 2 μM, 
[ligand]= 0 – 5 μM. The sample was excited at 430 nm and the 
fluorescence emission was measured at 450 nm. 
Additionally, TMPyP4, another model compound which binds to the hTelo i-
motif,135 was also studied. Although it showed very good binding affinity in the 
FID assay (Figure 2.20) with a i-motifDC50 of 1.15 ± 0.15 μM. Further investigation 
indicated that the drop of fluorescence was caused by the UV absorption of 
TMPyP4 instead of thiazole orange displacement (Figure 2.21). This case indicated 
that UV absorption of the ligand itself can be a source of a false positive hit due to 
a ‘self-quenching’ event. Thus checking the UV absorption of ligand hits would be 
necessary for the FID assay to be reliable. 
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Figute 2.20 Fluorescent intercalator displacement assay carried out using 
hTelo i-motif forming sequences and TMPyP4 at pH 5.5 in 10 mM 
sodium cacodylate buffer. [hTeloC] = 1μM, [TO] = 2μM, 
[TmPyP4]= 0 - 5μM. The sample was excited at 430nm and 
fluorescence signal dropped as more TmPyP4 was titrated. 
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Figure 2.21  UV-vis spectrum on TmPyP4 at pH 5.5 in 10 mM sodium  
    cacodylate buffer 
In conclusion, non-fluorescent thiazole orange was found to become fluorescent 
when titrated with pre-formed i-motif structures at acidic pH. The fluorescent 
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emission was detected at 450 nm when the sample was excited at 430 nm. Although 
the Stoke’s shift in i-motif assay is very narrow when compared to G-quadruplexes 
(a Stoke’s shift of 20 nm compared to 38 nm from the original G-quadruplex-FID 
assay112), it is still possible to conduct FID on i-motif with thiazole orange. Four 
previously identified i-motif compounds were tested in a trial i-motif FID assay. 
Their relative binding affinity towards human telomeric i-motif can be quantified 
by calculating their i-motifDC50 and the results from i-motif FID assay were 
consistent with studies carried out previously.101 
2.3.5 Development of a high-throughput screen based on FID i-motif assay 
(HT-IM-FID) 
After confirming the result from the i-motif-FID assay using a fluorimeter, the next 
stage was to develop TO as a fluorescent indicator in a high-throughput screening 
FID assay in a microplate format. To establish a low-cost and viable screening 
method using FID aganist human telomeric i-motif, a microplate and plate-reader 
were used. A 384-well PCR black microplate was chosen due to its relatively small 
well volume to reduce the amount of material consumed. The Gen-Plus compound 
library, was obtained from Microsource Discovery Systems Inc (a gift from Prof. 
Rob Field, John Innes Center) and contains 960 ligands, including the previously 
identified mitoxatrone, tilorone, tyrothrycin and tamoxifen. In the screening, 0.5 
μM (1 equivalents) pre-folded hTelo i-motif was mixed with 1.0 μM (2 equivalents) 
TO in the sodium cacodylate buffer in the well and the sample was made to 40 μL. 
Then 2.5 μM (5 equivalents) ligand from the compound library was added into the 
well to screen. The microplate was excited at 430 nm and the read of the signal was 
defined as the intergration of fluorescent intensity from 460 to 480 nm. The value 
of TO displacement (Dx) was calculated via Equation 2.3 shown before. Then the 
compounds were ranked according to their Dx (Table 2.3) to identify the strong i-
motif binders. The result from the primary FID assay was then compared with a 
FRET-melting based ligand screening perform in the group before101 and futher 
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additional experiments performed using SPR. 
Position  Compound name  Structure TO displacement (%) 
P9H8 
Mitroxatrone 
hydrochloride 
 
85.8 
P9C11 
Alexidine 
hydrochloride  
82.5 
P11H11 Tilorone 
 
70.1 
P2B6 Tobramycin 
 
48.6 
P1A3 Chlorhexidine 
 
42.3 
P3C9 
Phenazopyridine 
hydrochloride 
 
30.5 
P7B10 
Amodiaquine 
dihydrochloride 
 
29.7 
P1A11 
harmalol 
hydrochloride  
26.7 
P4A8 Quinalizarin 
 
22.2 
P5B11 
Minocycline 
hydrochloride 
 
21.0 
P3A4 tyrothrycin  18.6 
P2H4 Cadmium acetate  16.7 
Table 2.3 FID screening result on NIC library (960 compounds). [hTeloC] = 0.5 μM, 
[TO] =1.0 μM, [ligand] = 2.5μM. Buffer: pH 5.5, 10 mM sodium cacodylate. 
Excitation range: 415 to 430 nm, emission recorded: 445 to 495 nm. The 
data was recorded as the integration of emission curve from 445 to 495 nm.  
In the FID screening of 960 ligands (see Table 2.3), mitoxantrone and tilorone 
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were confirmed as top hits with FID displacement of over 80%, followed by 
chlorhexidine and alexidine hydrochloride (83% and 42%, respectively). However, 
the later are known nucleotide condensing reagents,101 so they were omitted from 
further studies. Tyrothricin and tamoxifen were both found to displace TO under 
the conditions of the experiment but did not meet the 50% disppacement criteria 
set for hits. This is consistent with their low-affinity towards human telomeric i-
motif described in Section 2.2.4.  
Other DNA alkylating reagents (such as cisplatin and carboplatin) present in the 
library previously gave rise to false positive hits in FRET-melting experiments;101 
however, they did not show any activity in the FID assay. This is because the two 
screens are measuring different DNA interaction properties. In the FRET-melting 
experiments, pre-annealed i-motif is heated to 95°C in order to melt the DNA and 
the change in melting temperature on addition of ligands is used as a measure of 
interaction. In this case, DNA alkylating reagents can hold the DNA conformation 
by cross-linking the structure. However, in the FID assay the mechanism is based 
on competitive binding with pre-bound thiazole orange. This will only give a result 
if the molecule of interest interacts in the same way. This means, alkylating reagents 
will not give a postitive result in these experiments. However, it does mean that if 
the tested ligand binds elsewhere on the structure, ie a place not occupied by TO, 
this may result in a false negative. 
Interestingly, tobramycin was found to be a hit using the FID screening method, 
but not in the previously used FRET assay.101 This might indicate that if DNA 
FRET-melting and FID screening were performed side by side, different properties 
could be revealed on a large scale with ease. Further studies to characterise 
tobramycin are discussed in Section 2.3.8. 
2.3.6 Assessing the high-throughput screening with Zʹ factor 
The quality of the TO-based FID high-throughput screening can be quantified using 
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the Zʹ factor (Equation 2.4) as demonstrated below.136,137 Zʹ factor gives an 
indication of the statistical effect size, ie whether a type of response in an assay is 
large enough to be called a “hit” or worth repeating. 
Equation 2.4     𝑍ʹ = 1 −  
3 ×(𝜎𝑝+𝜎𝑛)
|𝜇𝑝−𝜇𝑛|
      
Here, σp = the standard deviation of positive control; σn = the standard deviation of 
negative control; μp = the mean value of positive control; and μn = the mean value 
negative control  
When the Zʹ value is between 0.5 and 1.0, this gives a strong indication that the 
positive responses from the assay are more likely to be actual hits.137 A Zʹ value 
lower than 0 indicates that the signal from the positive and negative controls 
overlap and will not provide enough distinction to identify hits; Zʹ values between 
0 and 0.5 are marginal. In this assay, as we already know tobramycin and 
mitoxatrone were an effective hit in FID screening, it was possible to use them as 
a positive control; the wells with only TO and hTeloC were then set as a negative 
control. The calculated values of Zʹ in this assay were found to be 0.66 for 
mitoxantone and 0.97 for tobramycin, which are both within the range from 0.5 to 
1.0, indicative that the result of the screen is a true hit worth following up with 
further experiments.137  
2.3.7 Assessing the hit compounds with SPR  
In collaboration with Dr. Clare Stevenson at the John Innes Center, the hit 
compounds were studied using SPR at a single concentration. A moderately high 
concentration (50 μM) was used to give an indication for a wide range of 
compounds with different binding capabilities. In this situation, high affinity 
ligands would be expected to provide a very high response on association with the 
target oligonucleotides immobilised on the sensor chip; in contrast, low affinity 
compounds would give a poor response. Also, a concertation higher than 50 μM 
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would be reaching the solubility limit for some of these compounds.  
In this experiment, 50 μM of the ‘hit’ ligands in buffer were measured using a 
streptavidin coated chip with immobilised biotinylated duplex DNA, hTeloC and 
c-MYC i-motifs at pH 5.5. The responses were recorded at equlibrirum and 
compared to the predicted binding response (Rmax) calculated with a 1:1 binding 
stoichiometry (Table 2.4, Equation 2.5). 
Equation 2.5    𝑅𝑚𝑎𝑥 =  
𝑀𝑊𝑙𝑖𝑔𝑎𝑛𝑑
𝑀𝑊𝑜𝑙𝑖𝑔𝑜
×𝑅𝑈𝑜𝑙𝑖𝑔𝑜×𝑖.  
Where: MWligand = the molecular weight of tested ligands; MWoligo = molecular 
weight of the immobilised oligonucleotides on the chip. RUoligo = the average 
response in the SPR experiments in the absence of ligand. i = stoichiometry of 
binding.  
As shown in Table 2.4, the percentage of predicted maximium response (%Rmax) is 
an indicator for binding affinity. Of all the compounds tested, mitoxatrone has the 
highest %Rmax (2125% for hTeloC, 2534 % for c-MYCC and 4894% for double 
helical DNA), followed by tobramycin (325% for hTeloC, 419 % for c-MYC and 
810% for double helical DNA). Tilorone was found to bind to all three DNA types 
as well, but not as strongly as tobramycin and mitoxatrone (116% for hTeloC, 121% 
for c-MYC and 233% for double helical DNA). The fact that tilorone possesss 
higher affinity towards double helical DNA rather than c-MYCC and hTeloC i-
motifs was consistent with previous studies using SPR (hTeloCKd = 158 μM vs duplexKd 
= 14.7μM).101 Other ligands such as amlodiaquine, harmalol, minocycline and 
tyrothrycin failed to exert similar affinity towards the i-motifs compared to 
mitoxatrone and tobramycin. This is consistent with the fluorescent intercalator 
screening in Section 2.2.5, providing some validation to the procedure and 
technique used. 
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Ligands %Rmax (%) 
hTelo i-motif c-MYC i-motif Duplex DNA 
mitoxantrone 2125 2534 4894 
tobramycin 325 420 810 
tilorone 116 121 233 
phenazopyridine 37 70 136 
minocycline 29 49 95 
amodiaquine 14 31 59 
tyrothrycin 6 14 26 
quinalizarin -0.37 36 69 
harmalol -27 64 123 
Table 2.4 SPR screening on the hit compounds from the FID screen against 
hTelo i-motif, c-MYC i-motif and duplex DNA. [ligands] = 50 μM 
Running buffer: [sodium cacodylate] = 10mM, [NaCl] = 100 mM, 
0.05% tween, pH 5.5 
Tobramycin was subjected to further SPR binding experiments across a wider 
concentration range and the dissociation constants were found to be 23 ± 3.7 µM, 
22 ± 6.9 µM and 13 ± 3.4 µM for hTeloC, c-MYCC and duplex DNA respectively 
(Figure 2.22), calculated using a 1:1 binding model (Equation 2.6).132  
Equation 2.6     
Where: θ = the fraction of binding; Req = the response at equilibrium from the 
sensorgram; Rmax = response at saturation.132   
𝜃 =  
𝑅𝑒𝑞
𝑅𝑚𝑎𝑥
=
𝑛𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
       𝑛
= 1 
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Figure 2.22  SPR titration of tobramycin against hTeloC, c-MYCC and duplex 
    DNA at pH 5.5 Running buffer; pH 5.5, [sodium cacodylate]=  
    10mM, [sodium chloride] = 100mM, 0.05% tweet 20, 5% DMSO 
    tweet 20, 5% DMSO 
The Kd for tobramycin binding to the human telomeric i-motif (23 ± 3.7 µM) was 
the same order of magnitude as mitoxatrone (Kd = 12 ± 3.0 μM).102 However, 
although tobramycin binds i-motif structures well, it also binds duplex DNA with 
almost 2-fold higher affinity. A plausible explaination is that the multiple amino 
groups on the tobramycin will be protonated in acidic conditions, providing 
multiple positive charges which can then interact with oligonucleotide sugar 
phosphate backbones indiscriminately. 
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2.3.8 Further studies on tobramycin 
In the studies above, it was confirmed that tobramycin was the effective hit in the 
high-throughput screening. Tobramycin is an aminoglycoside used to treat airway 
infection caused by Pseudomonas aeruginosa.138 To provide another supportive 
technique, tobramycin binding to the hTeloC i-motif was measured using circular 
dichroism as well (Figure 2.23). Aliquots of tobramycin were titrated into 10 µM 
pre-formed human telomric i-motif at pH 5.5. Since tobramycin is a chrial molecule, 
the molar ellipticity signal of tobramycin was measured and then subtracted from 
the subsequent spectra. As shown in Figure 2.16, the positive peak at 289 nm and 
the negative peak at 255 nm indicates intramolecular human telomeric i-motif 
structure.86  
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Figure 2.23  Circular dichroism titration of hTeloC DNA sequences with 
 tobramycin at pH 5.5 10mM sodium cacodylate buffer 
 (tobramycin signal subtracted). The molar ellipticity signal 
 was recorded from 500 nm to 230 nm. 
On addition of tobramycin, the signal is observed to shift towards longer 
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wavelengths by 20 nm. This is consistent with tobramycin binding i-motif. The 
changes in the spectrum are not consistent with conformational changes on the i-
motif structure, or conversion to a hairpin or unfolded species.49,56 The increased 
signal between 300 and 500 nm is unusual, but may arise from the chiral nature of 
the ligand. Despite substracting control spectra containing equivalent proportions 
of ligand, these signals remain, indicating perphaps a form of induced signal which 
arises on binding.  
In a previous study of tobramycin-DNA interaction, DNA forms columnar close-
packed hexagonal DNA complexes in the presence of tobramycin.139 Tobramycin 
is electrostatically bound in these tobramycin-DNA complexes due to its 
multivalent catonic charges at pH 7.0.139 Thus as a negatively-charged 
polyelectrolytes in a packed formation, human telomeric i-motif may also binds to 
tobramycin and the i-motif structures may be unfolded into other formations due to 
the presence of tobramycin as well. 
2.4  Conclusions 
In this chapter, a fluorescent intercalator displacement assay against human 
telomeric i-motif was developed. In the development of the assay, several DNA-
binding fluorescent probes were screened with the C-rich sequence from the human 
telomere, hTeloC. It was found that thiazole orange exhibited the ideal fluorescent 
‘light-up’ property when bound to hTeloC at pH 5.5. Subsequently, thiazole orange 
binding to the hTeloC i-motif was studied intensively using UV-vis spectroscopy, 
Job’s analysis, FRET-melting and circular dichoism experiments. These revealed 
thiazole orange binds to hTeloC at acidic pH with a 2:1 stoichiometry, with a high-
affinity binding site and a weaker secondary site (Kd1 = 3.61 µM and Kd2 = 75.6 
µM). CD experiments indicated the conformation of human telomeric i-motif was 
not altered when bound to thiazole orange under the conditions used in the FID 
assay. FRET-melting experiments showed the thermal stability of several i-motif 
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structures increased upon addition of thiazole orange indicating that TO is able to 
stabilize multiple i-motif structure types. Fluorescent intercalator displacement 
experiments were developed using some known i-motif binding ligands previously 
discovered in the Waller group as positive controls.101 Finally, a high-throughput i-
motif ligand screening method based on fluorescent intercalator displacement was 
established. A library of 960 known biologically active compounds were tested and 
the screening result was verified via SPR. The TO displacement assay offers an 
alternative to using FRET-based DNA melting experiments for discovery of i-motif 
binding ligands.  
Tobramycin was found to be an effective i-motif binding ligand in the high-
throughput screening. It binds to human telomeric i-motif with a Kd of a similar 
magnitude to that of known i-motif binding compound mitoxatrone.  
The FID assay as a primary ligand screening method has its own advantages as well 
as some flaws. In principle, the FRET-bsed DNA melting assay is focused on 
measuring the the stabilising effect of the tested compound while FID assay was 
designed to measure ligand binding. Both the FID titration and high-throughput 
screening experiments are carried out under room temperature, which remove the 
possibility of ligand degradation caused by heating in DNA-melting based assay. It 
is much more cost-effective compared to the FRET-melting assay, because there is 
no requirement for specialised DNA synthesis, furthermore FID experiments use 
unmodified DNA, and are therefore not affected by the prescence of fluorophores 
on the DNA. Unfortunately, like all other screening methods, FID has limitations 
as well. Firstly, FID is not able to distinguish nucleic acid condensing reagents from 
hit binding compounds but may also be used as a tool to assess nucleic acid 
condensing reagents. Additionally, its accuracy can be easily affected by 
compounds which either have UV-absorption or fluorescent emission within the 
range of 420 to 490 nm. There is also the possibility that tested ligands may have a 
higher affinity for the thiazole orange itself rather than the i-motif structure, thus 
Chapte 2 Development of a High-throughput Fluorescent Intercalator Displacement Assay for Human Telomeric i-motif 
60 
 
causing false hits. Also if the tested ligand binds i-motif in a region where TO does 
not, these will not be picked up. Neverthless, every method has its advantages and 
disadvantages and FID can be a screening and analysis method to support existing 
i-motif characterization methods, such as circular dichroism and FRET melting 
experiments. 
In the context of tobramycin, it was the first time that an aminoglycoside was shown 
to be an i-motif binding ligand. However, it was also shown that tobramycin was 
not able to distinguish duplex DNA with i-motif structures. Thus, tobramycin 
would not be a suitable ligands for use in i-motif binding studies. However, it is 
possible to use medicinal chemistry approaches to develop a tobramycin based 
ligand to target i-motifs with improved selectivity. 
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3.1  Introduction 
Very few molecules have been documented in the literature to interact with i-
motif.40 However, it is widely known that calixarene derivatives have multiple 
applications in medicinal chemistry and biology.140 Herein, an attempt to use 
calixarene derivatives to interact with DNA secondary structrures is described.  
3.1.1 Calix[4]arenes 
Calixarenes are a family of macrocyclic oligomers arising from the by-product of 
phenol-aldehyde resin synthesis.141,142 The word ‘calixarene’ (calix: Greek for cup) 
was coined by Gutsche, indicating a bowl-shaped supramolecular macrocycle with 
aryl groups in the cyclic array.143 The number of aromatic rings can be any number 
above 3 and their structural flexibility increases with increasing ring number.144 But 
commonly-used calixarenes usually contain 4 to 8 aromatic rings. The number of 
rings is given as [n] between ‘calix-’ and ‘-arene’.  
In the 1940’s, an efficient base-induced reaction of p-alkyl phenols with 
formaldehyde yielding p-tert-calix[4]arene was discovered by Zinke and Ziegler, 
marking the beginning of calixarene chemistry.142 A calix[4]arene scaffold has four 
phenol rings linked by four methylene bridges, resembling a cup-shaped molecule 
bearing a higher rim (wider edge) and a lower rim (narrower edge); both these 
aspects can also be functionalised. Phenol member rings can be replaced by other 
substituted phenols145, polycyclic or even heteroaromatic rings, while methylene 
bridges can also be replaced by ethers, thiolethers, or tertiary amines according to 
the different needs. The central cavity inside a calix[4]arene is a hydrophobic space 
suitable for transporting lipophilic reagents.146,147  
Calix[4]arenes can adopt four distinct conformers: cone, partial cone, 1,3-alternate 
and 1,2-alternate; this is due to the free rotation of the carbon bonds on the 
methylene bridges (Figure 3.1).148,149 A fixed conformation of calix[4]arene can be 
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achieved via metal templating, followed by alkylating the phenol group to create 
steric hindrance.150 
Figure 3.1  p-tert calix[4]arene and its conformer.  
Compared to other macrocycles, calix[4]arene platforms, especially the water-
soluble versions, have indispensable advantages; including synthetic availability, 
low toxicity, negligible immunogenicity and efficient regioselective synthesis.151 
Calixarenes also have various biological applications, including being used as 
antineoplastic, antiviral, antibacterial and antifungal therapeutics,152 and also in 
DNA chips153,154 and biosensing technology.152,155,156 
Due to the many applications of calix[4]arene derivatives in pharmaceutical studies, 
these will be described separately in detail.  
3.1.2 Calix[4]arenes in drug delivery 
Functionalised calix[4]arene derivatives have been investigated both as drugs and 
as drug delivery vectors. Their delivery mechanisms include host-guest inclusion, 
micelle and vesicle formation.157 Host-guest inclusion utilises the complimentary 
hydrophobicity of drugs and the cavity of calix[4]arenes. The most commonly used 
amphiphilic calixarene in drug delivery is p-sulphonatocalixarene. p-
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sulphonatocalix[4]arene 1 has been reported by different groups to encapsulate 
small molecules such as dinuclear platinum complex, topotecan, irinotecan and 
Vitamin B6 (Figure 3.2).146,158,159  
 
 
Figure 3.2  Examples of drugs which have been encapsulated in calixarene 1. 
Amphiphilic calix[4]arenes have the ability to self-assemble. They can 
spontaneously aggregate into micelles or vesicles under the right conditions to host 
lipophilic molecules (Figure 3.3).  
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Figure 3.3  Examples of calix[4]arene-based drug delivery strategies 
 dependant on forming micelles 
In terms of micelles, Zhu et al. described a PEGylated-calix[4]arene 2 micellar drug 
delivery system to encapsulate the photosensitizer chlorin e6.160 Another example 
was reported by Raston et al., using phospholipid calix[4]arene 3 micelles to 
deliver the antioxidant curcumin under conditions of oxidative stress.161 Apart from 
micelles, vesicles formed by amphiphilic calix[4]arenes are larger and often 
reported to carry hydrophilic ligands. Lee et al. reported tunable and stable vesicles 
based on amphiphilic calix[4]arene 4 to the host hydrophilic dye calcein. These 
vesicles dissipate to release calcein when the pH value drops from 7 to 5.162 A more 
recent and sophisticated vesicle system was reported by Liu et al., where p-
sulphonatocalix[4]arene 1 vesicles are loaded with doxorubicin, 8-hydroxypyrene-
1,3,6-trisulfonic acid (HPTS) and cationic protein protamine. The protein guest can 
be cleaved by trypsin, a natural serine protease. Disaggregation of the resulting 
vesicles is triggered by addition of trypsin. Controlled release of doxorubicin via 
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this vesicle system has been observed in both cell and mouse models.163 
3.1.3 Calix[4]arenes in gene delivery 
Gene therapy depends on transporting target genes into cells efficiently without 
causing elevated cytotoxicity. Calix[4]arenes serve as a perfect non-viral, 
preorganised platform to aid this process. In the field of calixarene-DNA 
interactions, cationic amphiphilic calixarene conjugates are commonly used as 
gene delivery agents.151 In order to interact with DNA/RNA, calix[4]arenes are 
modified with positively-charged functionalites on one rim. The electrostatic 
attraction between modified calix[4]arenes and the negatively-charged 
phosphodiester backbone causes the condensation of DNA, facilitating its uptake 
by cells. The lower rim (narrow edge) is normally functionalised with long aliphatic 
chains to minimise the critical micelle concentration (CMC). In order to bind to 
DNA, calix[4]arenes are required to be in the cone conformation to maximize the 
unequal distribution of hydrophilic/hydrophobic characteristics.  
The most popular hypothesis starts with formation of amphiphilic calix[4]arene 
micellar nano-particles, followed by the DNA wrapping around the pre-formed 
particles.151 In this way, amphiphilic calix[4]arene micelles could be considered 
acting like artificial histones. More densely packed micelles are favored due to the 
maximal presentation of positively-charged groups for ion pairing or hydrogen 
bond formation (Figure 3.4).151,164 Another proposed mechanism suggests that 
individual calix[4]arene amphiphiles bind directly to minor grooves or the 
phosphate backbone of duplex DNA structures. Similarly, this process involves ion 
pairing and hydrogen bond formation.126 The DNA-binding calixarenes attract each 
other and assemble into DNA-calixarene complexes (Figure 3.4).165 
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Figure 3.4  Proposed mechanism of calix[4]arene-induced nucleic acid 
 condensation. (a) Mechanism of nucleic acid binding after 
 micelle formation.151 (b) Mechanism of calix[4]arene-nucleic 
 acid binding before nucleic acid condenation.165  
In order to interact with oligonucleotides, guanidine, amine, imidazolium and 
polyamine groups can be inserted on the cone-shaped platforms (Figure 3.5).151,165-
169  
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Figure 3.5  Examples of calix[4]arene-based amphiphiles for gene delivery 
Such modified ligands are capable of transferring DNA (both linear and plasmid) 
across the cell membrane. As an example, amino-functionalised calixarene 5 was 
found to form solid lipid nanoparticles via layer-by-layer assembly and was shown 
to transfect plasmid DNA into the Madin-Darby canine kidney cell line.166 Other 
positively-charged, nitrogen containing calixarenes include tetraalkylammonium-
functionalised calixarene 6 and methylimidiazolium calix[4]arene 7, which possess 
long octyl chains on the lower rim. These are able to self-assemble into micelles of 
6 nm in diameter at low CMC (48 μM and 10 μM, respectively). In transfection 
experiments, calixarenes 6 and 7 were used with plasmid DNA encoded with 
luciferase. Effective cell transfection was observed in both human cervical cancer 
cell and monkey kidney fibroblast-like cell lines.  
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Ungaro’s group developed a series of guanidium functionalised calixarenes to study 
calixarene-induced nucleic acid condensation. Calixarene 8 exhibitied efficient 
plasmid transfection in human rhabdomyosarcoma cell lines.165 Later Ungaro’s 
group developed arginine grafted tetralysinocalix[4]arene 9 to achieve 55% to 82% 
DNA transfection in human rhabdomyosarcoma, cervical cancer cell, mouse 
neuroblastoma and equine adipose-derived stem cell lines.167  
Other notable examples of gene delivery include the cationic choline-conjugated 
calixarene 10, which was able to form virus-sized nanoparticles with plasmids for 
gene delivery.168 Apart from small calixarene conjugates, dendritic calixarene-
based scafolds were also used in gene delivery. The amino-functionalised 
multicalix[4]arene 11 was also demonstrated to transfect genes into Chinese 
hamster ovary cell with negiligable cytoxicity.169  
3.1.4 Calix[4]arene derivatives as drugs 
Apart from delivering drugs and nucleic acids into the cells, calix[4]arenes 
derivatised with functionalites to achieve receptor or enzyme binding have also 
been developed. Existing examples have expanded the use of calixarenes in 
targeting various diseases such as viral infections, bacterial infections and 
malignancy.  
Calix[4]arenes tethered with glycosides 
Lectins are a family of specific sugar-binding proteins expressed on the cell surface 
in various organisms. They are involved in many biological recognition processes 
in nature. The binding affinity of polysaccharides towards lectin can be enhanced 
by the number of saccharide units presented via non-covalent interactions; this is 
known as the ‘glycoside cluster effect’.170 The calix[4]arene scaffold itself serves 
as a perfect dendrimer platform to present a sufficient bulk of diverse carbohydrate 
motifs for lectin recognition.171  
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In an antiviral study, calix[4]arene 12 conjugated with N-acetylneuraminic acid via 
click chemistry (Figure 3.6) was shown to have a 83-fold increase in binding 
affinity on haemagglutinin expressed on the surface of influenza virus A.172,173  
 
 
Figure 3.6  Examples of calix[4]arenes tethered with carbonhydrate motifs. 
In Ungaro’s group, the study of glycocalix[4]arene was focused on treating cholera. 
Glycocalix[4]arene 13 (Figure 3.6) bearing ganglioside GM1 mimic was synthesed 
and tested with cholera toxin, a protein complex174 secreted by bacterium Vibrio 
cholerae. This protein complex is responsible for massive fluid release in a cholera 
infection.175 It was found that its affinity towards cholera toxin was increased by 4-
fold compared with its mimicking target, GM1 pentasaccharide.176  
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In the study of lung infection, a calix[4]arene tethered with galactose was used as 
an anti-adhesive agent aganst Pseudomonas aeruginosa. Matthews and Vidal 
reported a calixarene conjugate 14 with a Kd in the nanomolar range against LecA, 
a soluble lectin expressed by Pseudomonas aeruginosa.177 Futher studies showed 
that designed glycoclusters on the calixarenes prevented lung infection by 
Pseudomonas aeruginosa in a mouse model.178  
In 2014, another example using glycocalix[4]arene chemistry was published; 
lactosyl and galactosyl motifs were attached on either cone calix[4]arenes or the 1, 
3-alternate structure. The resulting gylcocalix[4]arenes were then tested with Gal-
3 protein, a lectin heavily involved in cancer metastasis and migration. The study 
showed that cone-shaped lactosylcalixarene 15 (Figure 3.6) possessed the highest 
affinity for Gal-3 lectin.179 
Calixarene in protein-binding studies 
Calix[4]arenes in the cone conformation can be decorated with peptide motifs for 
peptide-protein interactions; as a result, modified calixarenes have the potential to 
block protein-protein interactions. In light of the shape of antibodies, Hamilton and 
co-workers proposed the idea that calix[4]arene analogues can be modified to 
mimic an artificial binding surface for several proteins.180 In the late 1990’s, 
calixarene 17 (Figure 3.7) was shown to bind cytochrome C, a critical protein in 
the electron transport chain in mitochondria.181 Later studies confirmed that 
calix[4]arene 16 forms a 1:1 complex with cytochrome C and blocks the heme 
edge.182 Another study on calix[4]arene 16 showed that the protein mimic on the 
calix[4]arene also inhibits α-chymotrypsin at a nanomolar level, suggesting a 
multifunctional role.183 Calix[4]arene 17 (Figure 3.7), was shown to achieve potent 
platelet-derived growth factor (PDGF) inhibition (IC50= 250 nM, Figure 1.17).184  
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Figure 3.7  Examples of calix[4]arenes in protein-binding studies 
Other research has focussed on attaching pseudo peptides or amino acid motifs onto 
calix[4]arenes to achieve biological effect on receptors and proteins. For example, 
calix[4]arene 18 (Figure 3.7) with an arginine methyl ester on the upper rim was 
shown to be a reversible inhibitor of the voltage-gated potassium channel.185 This 
effect was attributed to the relatively small size of the lower rim, which can enter 
the channel with ease, while cationic guanidines on the upper rim interact with the 
Asp-379 residue in the vestibule by ionic and hydrogen bonding.185 Another similar 
study used tetraguanidiniomethylcalix[4]arene 19 (Figure 3.7), which had a fixed 
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lower rim and was shown to bind p53-R337H, a mutant form of the tumour 
suppressor protein p53.186 In the mutant p53-R337H, an important salt-bridge 
between Arg337 and Asp352 is lost, which destabilized the mutant compared to 
wild-type p53. Furthermore, calixarene 19 can strongly enhance the thermal 
stability of p53-R337H by wedging into two of the four monomers via hydrophobic 
interaction ion-pairing and hydrogen bonding.186  
Calixarene derivatives have also been investigated as tools drugs in the studies of 
epigenetics. As an example, arylamidocalixarene 20 (Figure 3.7) was developed as 
a potent histone deacetylase (HDAC) inhibitor with three positions on the upper 
rim functionalised with anthracene while the remaining position is functionalised 
with an aryl carboxylate. This calixarene was found to possess an in vitro IC50 of 
0.14±0.02 μM against an HDAC enzyme derived from human cervical cancer cell 
nuclear extracts. In silico modeling suggested that its anthracene substituents 
interacts with two tyrosine residues in pocket A (Tyr 91) and pocket C (Tyr 264) on 
the surface of HDAC via π-π stacking as well as participating in a cation-π 
interaction with a lysine residue in pocket A (Lys19). Meanwhile, the carboxylate 
binds to the crucial Zn(II) cations in the pocket.187 
In antiviral studies a proteomimetic calixarene 21 (Figure 3.7) was shown to block 
HIV-1 entry into cells via binding to the exterior surface of gp120. It projects an 
aromatic isophthalate spacer on the upper rim which is crucial for targeting gp120, 
possessing a submicromolar-range anti-HIV IC50 for 0.65± 0.07 μM. Additionally, 
21 is active againist BMS-378806 resistant HIV strains from human patients.188,189 
Apart from modifying the calixarene into protein-binding ligands, Consoli and co-
workers used a calix[4]arene functionalised with folate acid as a tumour targeting 
motif and nitrobenzoxadiazole (NBD) as a fluorescent cargo (22, Figure 3.8).190 
The folate-acid conjugate was shown to enter neoplastic cells via folate receptor-
mediated endocytosis.191 In cell imaging experiments, 22 showed cellular uptake in 
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human cervical cancer cells, mouse embryonic fibroblasts and human malignant 
melanoma cell lines. Among them, the cervical cancer cells had the highest level 
of folate receptor expression whereas the melanoma cell line had only a modest 
folate receptor expression level. The results showed that after being treated with 10 
μM calix[4]arene 22 for 3 hours, mouse embryonic fibroblast cell line had only 
internalised 10% of the fluorescent ligand while human malignant melanoma cell 
line had internalised 37% calix[4]arene 22 compared to that internalised by the 
human cervical cancer cells. Internalisation of compound 22 by human cervical 
cancer cells was also shown to be blocked by administration of free folic acid.190 
This showed the presence of folic acids on the upper rim of the calix[4]arene was 
effective at achieving receptor-specific internalisation.  
 
Figure 3.8  Folate-acid appended calix[4]arene-based imaging ligand: FA-
    C4-NBD 
3.1.5 Calixarenes interacting with nucleic acid secondary structures 
Calixarene conjugates have been extensively used as nucleic acid condensing 
reagents, as discussed in Section 1.4.2. But their sequence-specific DNA-binding 
properties are less well-known. By carefully tuning the functionalites on the 
calix[4]arene, they can be used to target nucleic acids, for example as DNA 
intercalators192 and as major groove binders126 for duplex DNA. In addition, there 
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are also some examples of calixarenes targeting G-quadruplexes.192-196   
Methylazacalix[6]pyridine 23 (Figure 3.9) was the first recorded calixarene 
compound interacting with G-quadruplex forming sequences.193 It has been shown 
via circular dichroism that calixarene 23 is able to induce the formation of c-Kit 
and c-MYC G-quadruplexes.193 Molecular docking suggested that 
methylazacalix[6]pyridine 23 exists in a flexible conformation in solution. It binds 
to the nucleic bases on the loop region of these two G-quadruplexes,193 but does 
not binds to double-helical DNA. Additionally, the binding mode towards different 
intermolecular G-quadruplexes was investigated.194 It was shown that 23 can 
increase the thermal stability of intermolecular G-quadruplexes formed from T12 
(5ʹ-TAGGGTTAGGGT-3ʹ, dimeric) and H12 (5ʹ-TTAGGGTTAGGG-3ʹ, tetrameric) 
by 4 and 7 °C, repectively.194 Docking experiments demonstrated that methyl-
azacalix[6]pyridine 23 possesses a twisted cone conformation when bound with 
one pyridine subunit intercalating into the cavity at the 3’-terminal of the 
intermolecular G-quadruplex. Computational docking also indicated that 
compound 23 should additionally be able to bind other intramolecular G-
quadruplexes such as thrombin-binding DNA aptamer,195 c-kit and Bcl-2. 
Methylazacalix[6]pyridine 23 also possessed the lowest free energy of binding 
towards intermolecular hTelo G-quadruplexes compared to other 
methylazacalixpyridines with different pyridine numbers (MACP-n, n= 4, 7, 8, 
9).194  
 
Figure 3.9  Methylazacalix[6]pyridine 23, the first studied calixarene-based 
    G-quadruplex interacting compound. 
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In another example, calixarenes functionalised at the lower rim with amine groups 
were shown to interact with the G-quadruplex forming sequences from the human 
telomere and promoter region of c-MYC.196 hTeloG and c-MYC G-quadruplexes 
were treated with calix[4]arene 24 (Figure 3.10) and circular dichroism melting was 
performed to monitor the conformational changes. Calix[4]arene 24 was found to 
bind and stabilise both G-quadruplex types. However, the thermal stability of these 
G-quadruplexes were only increased by 2.7 °C.196 Further circular dichroism 
experiments suggested that addition of calix[4]arene 24 altered the conformation 
of hTeloG from anti-parallel to parallel. In supporting cell-based studies, 
calix[4]arene 24 also showed significant anti-proliferative effect towards human 
breast cancer, androgen-sensitive prostate adenocarcinoma, primary glioblastoma  
and dermal fibroblast cell lines even at 1 μM concentration. However, the anti-
proliferative effects of calix[4]arene 24 were not clearly linked to its G-quadruplex 
stablising effect.196  
 
Figure 3.10 Chemical structure of calix[4]arene 24 
Calixarenes functionalised with DNA-binding polycyclic-aromatics were shown to 
bind to duplex DNA (Figure 3.11).192 In silico modeling shows that the pyrene 
groups on calix[4]arenes 25 and 26 are able to intercalate into DNA base pairs and 
the whole calix[4]arene structure can insert into the minor groove of B-DNA. 
Cytotoxicity experiments showed that 26 possessed high potency against the 
human thyroid cancer cell line, with an IC50 of 95 nM.192  
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Figure 3.11 Chemical structure of polycyclic aromatic hydrocarbons-  
   presenting calix[4]arenes 25 and 26 
In Schrader’s group, a flexible calixarene dimer 27 functionalised with 
guanidinium groups was developed (Figure 3.12).126 27 was shown to intercalate 
into the major groove of B-DNA with a 0.6:1 to 0.8:1 (dimer vs DNA) stoichiometry. 
These were determined to have a Kd between 0.2 and 1.3 μM, depending on the 
DNA sequence used.126 The binding was also supported by data obtained from 
ethidum bromide displacement assays, UV-Vis melting and circular dichroism 
experiments. Further NMR experiments and computer modeling together showed 
that dimer 27 bridges up to nine base-pairs in B-DNA.126 The authors indicated that 
further modification of 27 may lead to sequence-selective DNA recoginition.126 
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Figure 3.12 Calix[4]arene dimer 27 that binds to the major groove of doube- 
   helical DNA 
3.2  Aim 
There is an opportunity for investigating the use of the calix[4]arene scaffold in 
binding DNA structures further. Given the beneficial properties of calix[4]arene 
derivatives, such as defined conformation,140 cell-permeablity,140,169 and potential 
for multi-valency,140 a novel family of calixarene-based DNA-interacting ligands 
can be designed and made. In short, this proof-of-concept project can be divided 
into 4 small goals to achieve. 
1) To prepare a series of amino functionalised calixarenes featuring suitable 
 substituents for conjugation at the lower rim. 
2) To prepare compementary derivatives of DNA binding motifs which can be 
 attached to the calixarene.  
3) To prepare calix[4]arene conjugates containing DNA binding moieties. 
4) To investigate the interaction of the calix[4]arene-conjugates with DNA using 
 FID, DNA FRET melting and circular dichroism.  
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3.3  Results and discussions 
3.3.1 Calixarene conjugate design 
In a previous study in the Matthew’s group, a mono-pyrene-substituted amino-
calix[4]arene (28, Figure 3.13)197 was prepared and preliminary studies using 
FRET melting experiments indicated that it interacts with DNA. However, a 
detailed study had not been undertaken. 
 
Figure 3.13 Fluorescent amino-calix[4]arene 28  
Given the previous work in synthesising this compound, it was decided to use a 
similar approach initially to conjugate DNA binding moieties to a calix[4]arene 
scaffold. Thus the individual components would need to be compatible with the 
Huisgen cycloaddition to form the triazole ring.  
Copper catalysed azide-alkyne cycloaddition 
Copper catalysed azide-alkyne cycloaddition (CuAAC), also commonly reffered to 
as the ‘click’ reaction, is a widely used chemical reaction to create a covalent 
linkage between two molecules. The cycloaddition without any catalysts was first  
discovered by Rolf Huisgen198 in the 1960s; thereafter in the late 1990s, both 
Morten Meldal199 and Karl B. Sharpless200 in separate studies showed it was 
possible to achieve regioselectiviy using copper (I) catalysts. This reaction has 
become a prominent synthetic procedure in various medicinal chemistry research 
Chapter 3 Synthesis of Fluorescent Calix[4]arene Derivatives and Investigation of Binding to DNA 
80 
 
areas,201 including small molecule ligands,202 glycobiology,203 bioconjugates,204,205 
nanocarriers,206 and macrocyclics.207 This reaction can be described as a 1,3- 
dipolar cycloaddition, where the chemically inert azide group and propargyl group 
are non-regioselectively bonded together (Scheme 3.1a). However, the presence of 
Cu (I) cations, the regiochemistry is restricted to only a 1, 4-substituted pattern 
(Scheme 3.1b),199,200 as well increasing the rate of reaction by a factor of 107. 
Alternatively, with the help of a Ruthenium catalyst, 1,5-substituted 
regioselectivity is also available.206 (Scheme 3.1c). However, to date, CuAAC has 
been applied far more frequently than its ruthenium complex counterpart. 
 
Scheme 3.1  a) Huigsen alkyne-azide cycloaddition without catalyst, both 1,4-
 substituted and 1,5-substituted products are formed. b) Copper(I) 
 cation catalysed alkyne-azide cycloaddition. c) Ruthenium 
 complex catalysed alkyne-azide cycloaddition 
In the proposed mechanism, the reaction is initiated by coordination between an 
alkyne and one Cu (I) cation (Scheme 3.2). This results in a decreased pKa for the 
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alkyne-terminal hydrogen. This proton is later replaced by another copper (I) cation 
to form Cu(I)-acetylide I.208 This structure was stablised by an other copper (I) 
cation. The source of copper (I) cations can be from either copper (I) iodide209 or 
prepared in situ from CuSO4 reduction in the presence of sodium ascorbate.200 Also, 
normally some organic bases, such as TEA, DIPEA or tris-(benzyl-
triazolymethyl)amine (TBTA), are added to ligate copper (I) cations and increase 
their solubility in organic solvent.207 The entry of the azide group into the catalytic 
cycle (Scheme 3.2) immediately gives a metallocycle 2. The resulting complex 
undergoes a ring contraction to get a stable copper triazolide 3. In the last step, the 
copper (I) cation on the 5ʹ- position of 1,2,3-triazole is replaced by protons from 
the environment due to pKa preference again (Scheme 3.2).208 With the help of 
copper (I), CuAAC occurs about seven orders of magnitude faster than the 
uncatalysed cycloaddition.208 
 
Scheme 3.2  Proposed mechanism of copper catalysed azide-alkyne 
 cycloaddition208 
In CuAAC, the resulting planar 1,2,3-triazole group is a chemically-inert 
heteroaromatic group with a proton signal at around 7 ppm on 1D 1H NMR. This 
group can be also considered as a Z-amide bond mimic (Figure 3.14).201  
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Figure 3.14  Structural comparison between the Z-amide and 1,2,3-triazole 
A lone pair on the N3 atom in the triazole resembles that on the carbonyl oxygen 
while the C4 atom possess similar electrophilic and polarised properties to the 
carbonyl carbon. Unlike the amide bond, 1,2,3-trazole is completely resistant to 
hydrolysis under physiological conditions. Additionally, the two nitrogen atoms 
(labelled N2 and N3 in Figure 3.14) resemble hydrogen bond acceptors whereas the 
proton on the C5 atom can act as a hydrogen bond donor. A higher dipole moment 
on the 1,2,3-triazole group suggested an increase in peptide bond mimicry 
compared to the original carbonyl amide.201 Thus 1,2,3-triazole is widely accepted 
as an enhanced pharmacophore rather than a conventional linkage.210 Another 
difference between Z-amide and 1,2,3-triazole is the distance between two 
substituents, where the distance in the triazole is about 1.1 times larger than that of 
Z-amide. 
There are further advantages for using CuAAC to assemble molecules. Firstly, large 
molecules can be easily adorned with the necessary alkyne and azide functionality. 
Secondly, CuAAC can be achieved in a large variety of solvent systems, such as 
water, THF, acetone, DMSO, DMF or water/acetonitrile. Thirdly, the reaction 
usually can be carried out within a large range of temperatures (eg between 0°C to 
160 °C) and pH values (4 to 9), indicating the robustness of the reaction.201 In 
addition, most products are purified with simple work-up procedures without 
recrystallisation and chromatography.201,208 However the toxicity of copper (I) in 
living systems was recorded as a major drawback for CuAAC, as reactive oxygen 
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species (ROS) can be generated by copper (I), ascorbate and atmospheric 
oxygen.211 Current research has extended the idea of CuAAC towards copper-free 
‘bioorthogonal chemistry’,212,213 where large biomolecules can be linked with 
fluorescent molecules without interfering with their native biochemical processes. 
In bioorthogonal chemistry, the conventional aryl alkyne can be replaced with an 
alkyne activated by ring strain (Figure 3.15).214 Another way to improve cell 
survivability is to add sacrificial reductants to counter ROS.215-217 
 
Figure 3.15  Examples of activated alkynes (BARAC & TMTH) and reductant 
 (THPTA) in bioorthogonal chemistry215,218,219 
Calixarene conjugate design 
To investigate the potential of lower-rim functionalised calixarenes to bind to DNA 
structures further, a series of first-generation ligands were designed incorprating 
DNA probes, such as pyrene and a derivative of the dye Nile Red (Figure 3.16a). 
Pyrene was selected as the major DNA interacting motif due to its known 
interactions with i-motifs and G-quadruplexes (Figure 3.16a).172,173,187 NRD-2 has 
previously been shown to bind to c-kit G-quadruplex and down-regulated the 
corresponding gene expression in human gastric carcinoma cells.220  
 
All compounds were fixed in the cone conformation and designed to possess 
hydrophilic amine groups on the upper rim (Figure 3.16b) to enhance solubility in 
aqueous media. Three different platforms, mono-substituted, 1,2-disubstituted and 
1,3-disubstituted calixarene, were investigated to explore the structure-activity 
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relationships.  
 
Figure 3.16  a) two DNA binding motifs selected in the proof-of-concept 
 studies; b) three amino-functionalised calixarene platforms 
 bearing alkyne in the proof-of-concept studies 
 The proposed first generation of calixarene conjugates are shown in Figure 3.17.  
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Figure 3.17  First-generation amino-calix[4]arene conjugates with DNA- 
    interacting moieties 
3.3.2 Preparation of clickable calix[4]arene platforms 
Preparing p-tert-butylcalixarene 
To synthesis the clickable mono, 1,2- and 1,3-alkyne functionalized calix[4]arenes, 
a general procedure previously described by Karthauser was followed (Scheme 
3.3).197 
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Scheme 3.3  Synthetic route to prepare mono-propargylated calixarene 33, 1,3-propargylated calixarene 37 and 1,2-propargylated calixarene 41 
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Synthesis of the calixarene conjugates started first by preparation of p-tert-
butylcalixarene 29. In this reaction, the first step is base-catalysed phenol-
formaldehyde polymerization at 120°C, followed by the breaking of the polymer-
chain, and the reorganization of the fragments into four-membered macrocycles 
which was then precipitated from the mixture with ethyl acetate (Scheme 3.4).221 
The amount of base added is crucial since it determines the number of phenols in 
the final calixarene system. It was found that addition of 0.03-0.04 equivalents of 
sodium hydroxide facilitates the formation of calix[4]arene while 0.3 equivalents 
of sodium hydroxide facilitates the synthesis of calix[6]arene.222,223  
 
Scheme 3.4  Synthesis of p-tert-butylcalix[4]arene 29 
The resulting compound 29 was an off-white powder isolated in 50% yield. The 
structure was confirmed using 1H NMR spectroscopy, which was consistent with 
the literature (Figure 3.18).221  
 
Figure 3.18  1H-NMR spectrum of Compound 29 (p-tert-butylcalix[4]arene) 
Compound 29 is a highly symmetrical molecule. However, the two protons on the 
methylene bridge exhibit a very interesting property in the 1H NMR spectrum 
(Figure 3.18). These two protons experience very different chemical environments. 
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The proton pointing upwards (Hexo) has a lower chemical shift (3.5 ppm) than that 
of the proton pointing downwards (Hendo) (4.2 ppm); since the latter is closer to the 
O atom (Figure 3.18). Thus the diastereotopic effect results in a pair of doublets 
with a coupling constant of 13.5 Hz. 
The cone conformation of compound 29 was retained at room temperature due to 
the hydrogen bonding at the lower rim. However, it changes its conformation freely 
at higher temperatures from cone to partial cone, 1,2-alternate or 1,3-alternate.149 
Alkylating the lower rim helps to block this transannular rotation, essentially 
locking its conformation150,224 and consequentially improving the calix[4]arene’s 
solubility in non-polar solvent.225 In order to lock the conformation of compound 
30, any aliphatic chain longer then ethyl can be applied.150,224  
Synthesis of mono-propargyl calix[4]arene platform 
In order to prepare mono-substituted amino-functionalised calix[4]arene 33, the 
synthetic route in Scheme 3.5 was used.197  
Scheme 3.5  Synthetic route towards clickable calixarene 31 
In the first step, 29 was stirred for 30 minutes with a mixture of barium oxide and 
barium hydroxide at 30 °C prior to the addition of propyl bromide. 
In this step, different bases can be used to achieve regioselective alkylation through 
metal templating effects in the SN2 Williamson ether formation. Barium was chosen 
for tri-propylayion due to its ability to strongly co-ordinate only one phenolic 
residues preventing alkylation due to its size and electropositivity.226 
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After stirring the reaction mixture overnight, water was poured into the reaction 
mixture to precipitate the crude product. The crude product was collected and 
recrystallised in DCM/methanol to yield 30 as a white crystalline solid (69% yield). 
Propargylation of the remaining phenol was carried out using sodium hydride as a 
strong base and propargyl bromide (Scheme 3.5).The small Na+ holds the cone 
conformation of calixarene by coordinating all four oxygens on a single face. Tthe 
final phenol anion formed by deprotonation is able to react with bromide 
nucleophile in an SN2 reaction mechanism.177 
After the hydroxyl group of 30 was activated by treatment with sodium hydride for 
at least one hour, propargyl bromide was added into the reaction mixture and stirred 
overnight. The crude product was precipitated with the addition of water, then 
collected and recrystalised in DCM and methanol to yield mono-propargylated 
compound 31 in 89% yield. Preparation of 31 was confirmed using 1H NMR 
spectroscopy (Figure 3.19).  
 
Figure 3.19  Proton splitting pattern in the 1H NMR spectrum of 31 
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For the monopropargylated derivative 31, there is a single plane of symmetry 
resulting in three separate environments within the calixarene (Figure 3.19). Thus 
additional inequivalence of the methylene bridge protons was observed (HC and HD 
at 4.5 ppm，HA and HB at 3.1 ppm). The introduction of propyl groups can be 
clearly seen from the two signals at 3.7 ppm and 3.9 ppm with an integration of 2 
and 4 respectively representing the OCH2 group, whilst the propargyl group can be 
identified at 4.95 ppm and 2.35 ppm for the OCH2 and C≡CH protons which show 
characteristic long range coupling of 2.5 Hz.  
In order to improve the water solubility of the calixarene, modifications were then 
applied to the upper rim to introduce an amine group. The initial step is ipso 
nitration to replace the p-tert-butyl group (Scheme 3.6). This step can be achieved 
via several methods, such as such as KNO3/AlCl3, HNO3/CH3COOH and 
HNO3/Ac2O. 227 Among them, the combination of HNO3/CH3COOH is 
advantagous due to its high yield and reaction kinetics.227 
Scheme 3.6  Synthetic route from 31 to 33 
Nitration was achieved by adding a mixture of 100% nitric acid and glacial acetic 
acid into the proparglated compound 31 dissolved in DCM (Scheme 3.6). The 
reaction mixture turned from colourless to deep-blue immediatedly after the 
addition of nitric acid, and then slowly changed to orange at which point the 
reaction was quenched with addition of cold water. After aqueous workup, the 
product 32 was recrystalised from DCM/methanol to give a off-white crystalline 
solid (62% yield). 
The nitro groups were then reduced using Sn(II)Cl2·2H2O. Other reduction 
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methods which have been used with calixarenes include hydrazine with Raney 
nickel or palladium with either hydrazine or hydrogen.228,229 The later two methods 
are not suitable for calixarene 31, as they could potentially reduce the propargyl 
group on the lower rim as well as the desired nitro groups. Thus the first method 
was selected as a mild reduction procedure. The insoluble starting material 31 was 
initially suspended in refluxing ethanol with Sn(II)Cl2·2H2O overnight. When the 
reduction of 31 was complete, product 32 was soluble in ethanol. The crude amino-
intermediate 32 was obtained as a brown-colored solid with a simple aqueous 
workup with DCM and used in the next step without further purification.  
The amine groups in 32 were then protected as the Boc derivatives by stirring with 
Boc-anhydride and DIPEA for 18 hours.230 It is to avoid gradual degraration of the 
unprotected amine group on 32 over time.231 The product 33 was purified via 
column chromatography, giving a 34% yield over two steps. The preparation of 
calixarenes 31, 32 and 33 were confirmed with 1H NMR spectroscopy (Figure 3.20) 
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Figure 3.20  Comparison of chemical shifts in 1H NMR spectrum between  
    compound 31, 32 and 33 
Comparing compound 31 and 32 (Figure 3.20), the three singlets around 1.25 to 
0.90 ppm in 31 for p-tert-butyl groups are not present in the 1H NMR spectrum for 
compound 32, confirming the replacement of the p-tert-butyl groups with nitro 
groups. In addition, the chemical shifts of the aromatic protons were shifted to the 
higher peak positions due to the electron-withdrawing effects of the nitro group on 
the aromatic rings.  
Comparing 32 with 33 (Figure 3.20), the chemical shifts for the aromatic protons 
in 33 were shifted back due to the electron-donating effect of the amine. The 
installation of the Boc-protecting group was observed through three singlets around 
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1.5 ppm (tert-butyl groups) and three small singlets at 6.38 and 5.92 ppm (amide). 
The critical propargyl group was not affected by the reduction with Sn(II)Cl2·2H2O. 
This can be revealed by the two proton signals at 4.86 ppm and 2.31 ppm (Figure 
3.20).  
Preparation 1, 3-dipropargyl calixarene platform  
In order to introduce two propargyl groups on the distal phenols, a different 
alkylation procedure was required for the first step (Scheme 3.7). p-tert-Butyl 
calixarene 29 was heated at reflux in acetone with potassium carbonate for 30 
minutes, followed by addition of propyl bromide.232 K2CO3 was chosen as a mild 
base to deprotonate only two diagonal phenol and hold the whole calixarene 
structure in a cone conformation.150,232 After stirring the reaction mixture for 18 
hours, water was added to precipitate the crude product. The crude product were 
collected and recrystalised in DCM/methanol to yield the pure product as a white 
crystalline solid (46% yield).  
Scheme 3.7  Synthetic route to 1,3-dipropargyl calixarene platform 37 
In the next step, as previously sodium hydride was used used as a strong base to 
deprotonate the remaining phenol groups on 34 to allow the installation of 
propargyl, yielding the desired product (77%). This is because sodium hydride used 
in the reaction was a strong base capable of deprotonate the remaining protons. 
Meanwhile its templating effect is weak as well.150 Formation of 35 was confirmed 
with NMR spectroscopy (Figure 3.21).  
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 Figure 3.21  Proton splitting pattern in the 1H NMR spectrum of compound 35 
For 1,3-dipropargylated compound 35 (Figure 3.21), it has two planes of symmetry 
(dashed line in Figure 3.21) passing through two diagonally located aromatic rings. 
The methylene groups connecting two adjacent aromatic rings were spotted as two 
doublets at 4.5 ppm (HA) and 3.2 ppm (HB). Lower-rim propyl proton signals on 
compound 35 are demonstrated as three proton peaks at 3.7 ppm, 2.0 ppm and 1.1 
ppm. The propargyl group was observed as two proton signals at 5.01 ppm and 2.35 
ppm for the OCH2 and C≡CH protons which show characteristic long range 
coupling of 2.5 Hz. 
Upper rim modification on 35 was achieved by following the same procedures for 
33 (Scheme 3.8). The yield for 36 was 48% after recrystalisation from 
DCM/methanol and the yield for 37 was 25% over two steps after column 
chromatography. 
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Scheme 3.8  Synthetic route from 35 to 37 
The structures of products 36 and 37 were confirmed with 1H NMR spectroscopy 
(Figure 3.22). Conversion of p-tert-butyl groups to nitro groups was observed 
thtough the deletion of two large singlets at 1.30 ppm and 0.8 ppm in the spectrum 
of product 36. The chemical shifts of aromatic protons on the compound 36 was 
moved from lower field to higher field (7.1 ppm to 8.4 ppm and 6.4 ppm to 7.1). 
The presence of the Boc-protected amino group on the calixarene 37 was verified 
with the appearance of two singlets around 1.5 ppm. There were also two singlets 
at 6.5 ppm and 6.0 ppm in the spectrum of 37 representing the amide proton on the 
Boc-protected amine group. The protons on the propargyl group were not affected 
by the reduction as verified by the doublets at 4.92 ppm and the triplets at 2.34 ppm. 
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Figure 3.22  Comparison of chemical shifts in 1H NMR spectrum between  
    compound 35, 36 and 37 
Preparation 1, 2-dipropargyl calixarene platform  
As with the distally functionalised molecule 37, the synthesis of proximally 
functionalised 41 requires a different first alkylation step (Scheme 3.9). Compound 
29 was stirred with a large excess of sodium hydride in DMF, followed by the 
addition of 2.2 equivalent of propyl bromide.233 Sodium hydride as a strong base is 
able to deprotonate all four phenol protons on the lower rim. 2 equivalent of sodium 
hydride was able to achieve the 1,2-deprotonation by statistics preference.The 
reaction mixture was precipitated with addition of water after stirring overnight, 
followed by purification via column chromatography to yield a white crystalline 
solid 38 (31% yield). The next step was to install the propargyl group to the 
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remaining two adjancet hydroxyl group to prepare 39 in a an analogous manner to 
33 and 37 (79% yield).  
 
Scheme 3.9  Synthetic route to 1,3-dipropargyl calixarene platform 41 
The structure of calixarene 39 was confirmed using 1H NMR spectroscopy (Figure 
3.23). Compared to 31 and 35, calixarene 39 gives a more complex spectrum as the 
plane of symmetry passes through the two methylene bridges linking two 
propargylated or propylated aromatics (Figure 3.23). Diastereotopic proton signals 
for the methylene bridge show a clear (1+2+1) pattern in integration at 4.50 ppm 
and 3.25 ppm, which is consistent with the methylene bridges having 6 different 
chemical environments. The presence of the propyl groups in compound 39 were 
demonstrated by the three proton signals at 4.70 ppm, 2.10 ppm and 1.10 ppm, with 
an integration of 4, 4 and 6, respectively. The presence of propargyl group was 
confirmed as two proton signals at 4.78 ppm and 2.42 ppm for the OCH2 and C≡CH 
protons which show the characteristic long range coupling of 2.5 Hz.  
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Figure 3.23  Proton splitting pattern in the 1H NMR spectrum of compound 39 
Later conversions from 39 to 41 (Scheme 3.10) follow the same procedures as that 
for Boc-amino calixarenes 33 and 37. The yield from 39 to 40 was 39% and the 
yield from 40 to 41 was 45%.  
 
Scheme 3.10  Synthetic route from 39 to 41 
Preparation of 40 and 41 were also confirmed using 1H NMR spectoscopy (Figure 
3.24). As described previously for 32 and 36, removal of the p-tert- butyl group 
was shown as the missing two singlets at 1.1 ppm in compound 40 and a shift of 
the aromatic proton signals towards the higher field comparing to compound 39 
(6.80 ppm to 7.60 ppm). The presence of the Boc-amino groups on the upper rim 
of the calixarene 41 was confirmed with the emergence of two singlets at 1.5 ppm, 
a shift of aromatic proton signals back towards the lower field (7.60 ppm to 6.60 
Chapter 3 Synthesis of Fluorescent Calix[4]arene Derivatives and Investigation of Binding to DNA 
99 
 
ppm) and the presence of amide protons at 6.2 ppm. After reducing the nitro group 
to the amine in 40, the propargyl group on the lower rim of 41 was not affected. 
This can be concluded from that the propargyl protons at 4.60 ppm and 2.32 ppm. 
 
Figure 3.24  Comparison of chemical shifts in 1H NMR spectrum between  
    compound 39, 40 and 41 
3.3.3 Preparation of DNA-interacting moieties 
After the preparation of alkyene-bearing calix[4]arene platforms, making DNA-
secondary structure-targeting motifs were required. Two DNA-intercalating 
moieties were proposed (Figure 3.25). Pyrene, when appended to a calix[4]arene 
has previously been shown to intercalate into double helical DNA192 and when 
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covalently attached to oligonucleotides has been demonstrated to cap i-motif 
structures.124 Thus pyrene is an interesting group to be investigated further. 
Additionally, a Nile Red derivatives (NRD) was also chosen as it is a known small, 
fluroscent G-quadruplex binding compound which has been shown to decrease c-
kit gene expression.25   
 
Figure 3.25  Azido-functionalisesd DNA-interacting moieties prepared to 
 append on amino-calix[4]arene 
Azido-functionalised Pyrene 
In order to incorporate the dyes to the calixarene, functionalisation as the azides 
was required. Clickable pyrene derivatives were made according to established 
methods in the Matthews group.209 1-Pyrenemethanol 42 was brominated with PBr3 
to obtain compound 43, which was then treated with sodium azide in DMF to obtain 
the final azido-functionalised pyrene 44 with only one carbon chain (Scheme 3.11). 
The preparation of 44 was confirmed using 1H NMR spectroscopy. The 
experimental data was consistent with the existing literature.209   
 
Scheme 3.11  Synthesis of 1-azidomethylpyrene 44 
Azido-functionalised Nile red derivatives 
The Nile red derivative was synthesized as previously described (Scheme 3.12).220 
The reaction starts with modifying the aliphatic linker 45 bearing bromine to the 
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azide-containing aliphatic chain 46 by treatment with sodium azide in water. 
Compound 47 was made from 2,3-dichloro-1,4-naphtoquinone and 3-amino-4-
hydroxy anthranilic acid via condensation. (I performed this step with Rouven 
Becker, a project student worked in our lab before.) Then the side chain was 
introduced under anhydrous conditions in the presence of Ghosez reagent to make 
compound 48, which was finally obtained via column chromatography to give a 
red-colored solid (75% yield). 
 
Scheme 3.12  Synthesis of clickable Nile Red 48  
The structure of 48 was confirmed using 1H NMR and IR spectroscopy (Figure 
3.26). In the 1H NMR spectrum of 48, proton signals on the aliphatic chain can be 
found at 3.75, 3.50 and 2.05 ppm, while signals for the aromatic protons on the Nile 
red were observed from 8.5 to 7.5 ppm. The amide proton of 48 was assigned at 9.6 
ppm. In the IR spectrum, there was an absorbance at 2107 cm-1, indicating the 
presence of azide group. 
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Figure 3.26  1H NMR and IR spectra of compound 50 
3.3.4 Conjugating DNA-interacting moieties with amino-functionalised 
  calix[4]arenes via CuAAC 
As discussed in Section 3.1.2, two main methods have been developed for the 
CuAAC reaction between azides and alkynes.200,209 Both of them were investigated 
in a preliminary screen to determine the best conditions for the click reaction on 
the calixarenes (Scheme 3.13).  
The solubility of amino-calix[4]arene 33 in DMF at room temperature was poor, so 
the reaction required heating to dissolve all the components. Thus 33 and pyrene 
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were dissolved in DMF at 90°C; sodium ascrobate and CuSO4·5H2O or CuI was 
added to catalyse the reaction and after 2 or 3 hours the reaction was quenched by 
removal from the heat and the addition of cold water. After aqueous workup, the 
crude brown-colored product was purified with column chromatography in DCM 
and acetone.197  
When comparing the results with the catalysts, the combination of sodium 
ascorbate and CuSO5·5H2O was chosen for subsequent reactions due to its higher 
yield (60% vs 40%).  
 
Scheme 3.13  Two methods for copper-catalysed azide-alkyene cycloaddition  
    (compound 49 an example) 
All other calixarene conjugates were prepared in the analogous way for 49 with 
CuSO4·5H2O and sodium ascorbate (Scheme 3.14), reaction yields for each 
conjugate are provided in Table 3.1.  
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Scheme 3.14  Synthetic routes to different calixarene conjugates with CuAA 
 
DNA binding moiety Calixarene conjugtes, yield(%) 
Mono-propargyl 33 1, 3-dipropargyl 37 1, 2-dipropargyl 41 
Pyrene 44  Calixarene 49, 60% Calixarene 50, 61 % Calixarene 51, 52% 
NRD 48   Calixarene 52, 37% Calixarene 53, 31% N/A 
Table 3.1  Reaction yields of CuAAC for calixarene conjugates 
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3.3.5 Boc-group deprotection  
Mono-pyrene substituted calixarene 28 
To remove the Boc protecting groups, 49 was dissolved in DCM and treated with 
gaseous HCl to obtain 28 as a brown colored solid (Scheme 3.15).197,234 Other 
methods to remove the acid-labile Boc protecting groups include addition of TFA 
or HCl in dioxane.165,190 However, gaseous HCl was chosen because it reacts with 
Boc group quickly and the work up involves simply removing excess DCM solvent 
in vacuo.  
 
Scheme 3.15  Boc group deprotection for calixarene conjugates (compound 28 
    as an example) 
Compound 28 was purified via rp-HPLC for the biophysical assays to give the final 
compound as a dark yellow crystalline solid (33% over two steps). The chemical 
structure of compound 28 after purification was confirmed using 1H NMR (Figure 
3.27), with the triazole proton (proton on the 1, 2, 3-triazole group) been seen at 
7.79 ppm.  
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Figure 3.27  1H NMR spectrum of compound 28 
Protons on the carbon between the 1,2,3-triazole and pyrene were identified as the 
singlet at 6.38 ppm, while protons on the carbon between the triazole and oxygen 
were at 5.07 ppm, confirmed by HSQC (Figure 3.28) and HMBC (Figure 3.29). In 
the HSQC spectrum (Figure 3.28), both the peaks at (6.38, 52.36) and (5.07, 66.27) 
ppm represents two methylene groups. These are the two methylene groups invoved 
in the discussion below. In the HMBC spectrum (Figure 3.29), when exciting the 
carbon at 52.36 ppm, a long-range coupling proton signal was detected in the 
aromatic region at 8.08 ppm in the pyrene region, suggesting that the methylene 
group having the carbon signal at 51.82 ppm (HB) is closer to the pyrene. When 
exciting the proton at 5.06 ppm in the 1H NMR spectrum, another long-range 
coupling carbon was detected at 154.40 ppm. The carbon signals in turn have an 
interaction with a proton peak at 6.14, which corresponds to an aromatic proton on 
the calixarene. This signal at 5.06 ppm in the 1H NMR spectrum was assigned to 
the protons on the methylene group connecting the triazole group and aromatic ring, 
assigned as HA. The protons on the calixarene (Hcalix) were also found to be 
interating with proton HA in the HMBC spectrum (Figure 3.29) instead of HB, 
further confirming the idea that HA was at (5.07, 66.27) ppm and HB was at (6.38, 
52.36) ppm in the HSQC spectrum (Figure 3.28).  
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Figure 3.28  HSQC spectrum of compound 28 
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Figure 3.29  HMBC spectrum of compound 28  
1,3-dipyrene substituted calixarene 54 
Distally pyrene-substituted calixarene 50 prepared from the 1,3-diproparglated 
calixarene platform 37 and pyrene 44, was also deprotected with gaseous HCl in 
DCM/methanol (Scheme 3.16), the crude product after solvent evaporation was 
purified with precipitating from diethyl ether at 0°C. The structure and purity of 
calixarene 54 was confirmed with 1H NMR spectroscopy (Figure 3.30).  
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Scheme 3.16  Synthetic route towards compound 54  
 
 
Figure 3.30  1H NMR spectrum of calixarene 54 
As described in Section 3.3.4, the singlet at 7.85 pm can be assigned as the click 
protons in the structure, while the singlet at 6.24 ppm belongs to 4 protons on the 
methylene group connecting pyrene and triazole. Due to the fact that compound 54 
possesses two planes of symmetry, the proton signals are reltively simple from 4.0 
ppm to 0.1 ppm. Two doublets at 4.0 and 2.8 ppm represent the protons on the 
methylene bridge of calixarene and the triplet at 3.2 ppm is for the protons on the 
propyl groups next to the oxygen (Figure 3.30). Other lowfield protons can be 
assigned to respectiveprotons as described in section 3.3.2 for 37. 
1,2-dipyrene substituted calixarene 55 
Compound 51 after column chromatography was deprotected with gaseous HCl in 
DCM/methanol (Scheme 3.17). The solvent was removed in vacuo to obtain a 
brown colored crystalline solid. The crystals were then purified via precipitation 
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from diethyl ether at 0°C.  
 
Scheme 3.17  Synthetic route towards compound 55 
For compound 55, attaching the pyrene motif to two adjacent aromatic rings results 
in changes in the splitting patterns of the proton signals in the 1H NMR spectrum 
(Figure 3.31). Further investigation of the proton signals from 6.25 to 2.25 ppm 
was achieved COSY spectscopy (Figure 3.32).  
 
Figure 3.31 1H NMR spectrum of compound 55 
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Figure 3.32 COSY spectrum of compound 55 in deutrated methanol 
As shown in the COSY spectrum (Figure 3.32), protons giving rise to the signals at 
4.25, 4.10 and 3.60 ppm are coupled with protons at 3.10, 2.80 and 2.40 ppm. These 
protons can be assigned as the diastereotopic protons on the methylene bridge. The 
proton signals at 6.10 and 4.50 ppm do not couple with any other protons signals 
on the spectrum, thus these protons should be close to the triazole bridge. As 
described in Section 3.3.4, protons on the methylene bridge connecting triazole and 
pyrene usually have higher chemical shifts. Thus the signal at 6.10 ppm can be 
assigned as the methylene between the triazole and the pyrene moiety. The signal 
at 4.50 ppm can be assigned to the methylene connecting triazole and oxygen atom. 
Compared to compound 28 and 54, proton HH and proton HG (Figure 3.31 and 
Figure 3.32) are split. 
Mono-NRD tethered calix[4]arene conjugate 56 
Mono-NRD appended calixarene 52 was made in an analogous way to 29 and 54 
(Scheme 3.18). The red colored crude product after deprotection with gaseous HCl 
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was redissolved in methanol and precipitated using diethyl ether for 5 to 6 times 
before structural characterization (Scheme 3.18).   
Scheme 3.18  Preparation of mono-NRD substituted calix[4]arene 56 from 52 
Product 56 was confirmed with 1H NMR spectroscopy with the click proton found 
at around 8.26 ppm to 8.5 ppm. (Figure 3.33).  
 
  
Figure 3.33  1H NMR spectrum of calixarene 56 
As shown in Figure 3.33, the NRD was identified as several multiplets from 8.0 
ppm to 7.3 ppm, which were accompanied by two triplets (4.6 ppm and 3.7 ppm) 
and one multiplet at 2.4 ppm representing the aliphatic linker on the NRD binding 
moiety. The methylene bridges on the mono-substituted calixarene 56 were 
identified as 4 doublets from 4.25 ppm to 4.0 ppm and 3.4 ppm to 3.0 ppm. Protons 
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on the carbon atom (Ha) connecting the oxygen on the lower rim and triazole group 
were found at 4.9 ppm. 
1, 3-diNRD substituted calix[4]arene conjugate 57 
Distally NRD-substituted calixarene 53 was separated from the reaction mixture 
via column chromatography, which was further deprotected and purified in an 
anlogues way to prepare calixarene 57 (Scheme 3.19). 
 
Scheme 3.19  1, 3-diNRD substituted calix[4]arene 57 from 53 
 
The structure of calixarene 57 as its hydrogen chloride salt was confirmed with 1H 
NMR spectroscopy (Figure 3.34).  
Chapter 3 Synthesis of Fluorescent Calix[4]arene Derivatives and Investigation of Binding to DNA 
114 
 
 
Figure 3.34  1H NMR spectrum of calixarene 57 
As described for 56 (Figure 3.34) the proton on the triazole group was found at 8.40 
ppm and the NRD moiety can be recognised as several multiples from 8.2 to 7.4 
ppm. Protons on the carbon atom connecting the oxygen on the lower rim and 
triazole group were found at 5.4 ppm. Compared to 56, protons on the methylene 
bridges split into two doulets at 4.5 ppm and 3.3 ppm (overlapped with residual 
methanol signal). 
3.3.6 Preparation for biophysical experiments. 
Before any biophysical assays, the prepared ligands (pyrene-appended and NRD-
appended calix[4]arene) were tested for their solubility in water and buffer. 
Solubility results for these five ligands are provided in Table 3.2. As it can be seen 
on the table, though all ligands prepared are soluble in pure water, their solubility 
in buffer is generally reduced. With increasing complexity in the structure and 
sodium concentration in buffer, ligand solubility in buffers containing sodium 
chloride decreases. Thus compound 28 and compound 54 were the two main 
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ligands used in the biophysical experiments. Since compound 54 is still not soluble 
in high NaCl buffer, it was tested in buffers containing 5 mM NaCl instead of 100 
mM NaCl. For compound 28, both 100 mM NaCl and 5mM NaCl buffers were 
used in the biophysical experiments. In this case, the use of 5mM NaCl buffer for 
compound 28 was mainly to act as a comparison towards compound 54.  
 
Table 3.2 Solubility table for ligands (ligand concentration: 200 μM,  as soluble and 
 as insoluble) 
3.3.7 FRET melting assay 
Calixarene conjugates made were screened via FRET based DNA melting analysis 
to investigate whether they interact with DNA as described in Section 2.2.3. 
At the beginning, 100 μM 28 was tested with hTelo G-quadruplex and duplex DNA 
at pH 7.4 in 100 mM sodium chloride buffer (10 mM sodium cacodylate). This is 
close to the physiologically relevant ionic and pH conditions in the cell. The result 
(Figure 3.35 and Figure 3.36) showed that compound 28 does not have any effect 
on duplex DNA (DS), but has a minimal thermal stabilising effect on human 
telomeric G-quadruplexes (ΔTm ≈ 5°C). This value is higher than that for the 
previously disclosed compound 25 (ΔTm ≈ 2.7 °C), using similar concentrations and 
buffer conditions (K+ instead of Na+) measured using CD melting.196 
 
Compound MilliQ Water 5mM NaCl, 
10 mM 
NaCaco, pH 
5.5 
100 mM NaCl, 
10mM  
NaCaco, pH 
5.5 
5 mM NaCl, 
10 mM 
NaCaco, pH 
7.4 
100 mM NaCl, 
10 mM 
NaCaco, pH 
7.4 
28      
54      
55      
56      
57      
Chapter 3 Synthesis of Fluorescent Calix[4]arene Derivatives and Investigation of Binding to DNA 
116 
 
30 40 50 60 70 80 90
0.0
0.2
0.4
0.6
0.8
1.0
1.2
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
Temperature (C)
 hTeloG
 hTeloG + 28
 
Figure 3.35 Normalised FRET DNA melting curves for human telomeric G-
quadruplexe compound 28, [FREThTeloG] = 0.2 µM, [Compound 
28] = 100µ M, [sodium cacodylate] = 10 mM, [NaCl] = 100 mM, 
pH = 7.4, Fluorescent emission was measured at 533 nm. 
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Figure 3.36 Normalised FRET DNA melting curves for duplex DNA with 
compound 28, [FRETDS] = 0.2 µM, [Compound 28] = 100 µM, 
[sodium cacodylate] = 10 mM, [NaCl] = 100 mM, pH = 7.4, 
Fluorescent emission was measured at 533 nm. 
Chapter 3 Synthesis of Fluorescent Calix[4]arene Derivatives and Investigation of Binding to DNA 
117 
 
Further experiments focused on investigating whether compound 28 has any 
binding affinity towards i-motif structures. As in Figure 3.37, after addition of 28 
to the FRET-labelled DNA, the fluorescence signals for DNA remain quenched 
regardless of the increase of temperature. Given the previous experiments with the 
FRET labelled DNA, this indicates that there is not a non-specfic interaction with 
the fluorophores. Thus, this phenomenon indicates two plausible situations: strong 
DNA stabilisation at tested concentration or oligonucleotide condensation; both 
indicate interaction with DNA. Similar phenomena were observed for compound 
54 (Figure 3.38). Since compound 54 was not soluble in high salt buffer (100 mM 
NaCl), it was tested at low salt buffer (5 mM NaCl) instead; compound 28 was 
tested at the same conditions for comparison. Regardless, in both high and low salt 
conditions, both 28 and 54 show quenched fluorescence up to 95°C. 
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Figure 3.37 Original FRET DNA melting curves for hTelo and c-myc i-motif 
with compound 28, [FRETDNA] = 0.2 µM, [Compound 28] = 
100 µ M, [sodium cacodylate] = 10 mM, [NaCl]high salt = 100 mM, 
[NaCl]low salt = 5 mM, pH = 5.5. Fluorescent emission was 
measured at 533 nm. 
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Figure 3.38 Original FRET DNA melting curves for hTelo and c-myc i-motif 
with compound 54, [FRETDNA] = 0.2 µM, [compound 54] = 
100 µM, [sodium cacodylate] = 10 mM, [NaCl] = 5 mM, pH 5.5. 
Fluorescent emission was measured at 533 nm. 
In order to explore this phenomenon, FRET-melting experiments were 
implemented with a gradient of ligand concentration for compound 28 (Figure 
3.39). The first derivative charts provides the information about rate of change in 
fluorescence at each temperature on a original FRET-melting curves. The minimum 
value of the 1st derivative of the melting curves reveals the melting transition. If a 
ligand stabilises DNA secondary structure, then increasing concentrations of ligand 
should give a shift of sigmoidal curves in the original FRET-melting data and a 
corresponding shifts in minimum temperature in the 1st derivatives of the curves. 
Using this approach, the 1st derivative chart in Figure 3.39 indicates that melting 
temperature always remains at 45 °C, despite the changes in ligand concentration. 
This suggests addition of ligand does not stabilize the structure. This phenomenon 
was consistent with sequences from hTeloC and c-MYCC under both conditions. 
This indicates that DNA-ligand interactions could result in condensation or 
precipitation of the DNA. 
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Figure 3.39 FRET DNA melting experiments on Compound 28 with hTelo i-
motif at pH 5.5 (1st derivatives in fluorescence) [FREThTeloC] = 
0.2 µM, [sodium cacodylate] = 10 mM, [NaCl] = 100 mM, pH 5.5. 
Fluorescent emission was measured at 533 nm. 
As the experiments with G-quadruplex and double helical DNA showed very little 
indication of precipitation, and these were performed at pH 7.4, as opposed to the 
slightly acidic conditions for the i-motif forming sequences, there are a few 
variables which could account for the differences observed in the properties on 
ligand binding. In order to investigate whether calix[4]arene-induced DNA 
condensation is pH-dependent, the G-quadruplex and duplex DNA sequences were 
also tested under analogous conditions but instead at pH 5.5, to mimic the 
experiments performed with i-motif DNA. The data is shown in Figures 3.40 & 
3.41. It is clear that there is also a quenching of the fluorescence until the end of 
the experiment. This may suggest that compound 28 and 54 are able to condense 
G-quadruplexes and duplex DNA at pH 5.5. This effect was observed in both 100 
mM NaCl and 5 mM NaCl buffer conditions. This suggests that the acidic buffer 
conditions amplify the condensation effect and is not an effect which is necessarily 
dependent on sequence or structure.  
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Figure 3.40 FRET DNA melting experiments on compound 28 and 54 with 
hTeloG at acidic conditions, [FREThTeloG] = 200 nM, [ligand] = 
100mM, [NaCl]high salt = 100 mM, [NaCl]low salt = 5 mM,, [sodium 
cacodylate] = 10 mM, pH 5.5. Fluorescent emission was measured 
at 533 nm. 
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Figure 3.41 FRET DNA melting experiments on compound 28 and 54 with 
double helical DNA at acidic conditions, [FRETDS] = 200 nM, 
[ligand] = 100 mM, [NaCl]high salt = 100 mM, [NaCl]low salt = 5 
mM, [sodium cacodylate] = 10 mM, pH 5.5. Fluorescent emission 
was measured at 533 nm. 
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In contrast, the experiments with the i-motif forming sequences were repeated in 
buffers at pH 7.4 to mimic the previous experiments on G-quadruplex and duplex 
DNA. At pH 7.4, previously with duplex and quadruplex DNA, no fluorescence 
quenching effects were observed. Whereas addition of compound 28 and 54 to the 
i-motif forming sequences, a quenching effect is observed. Typically at 
physiological pH, the fluorescence is initially high at the start of the experiment for 
i-motif forming sequences which are more stable under acidic conditions (Figure 
3.42a). This is because, at this pH the structure is not completely folded. Addition 
of either 28 or 54 gives rise to a reduction in fluorescence signal at room 
temperature (at the start of the melting experiment), implying induced DNA folding. 
A DNA-melting transition can then be observed in the FRET-melting assay for 
these samples (Figure 3.42a). This phenomenon was consistent with both hTeloC 
and the sequence from c-MYC (Figure 3.42b). 
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Figure 3.42 FRET DNA melting experiments on compound 28 and 54 with 
hTeloC or c-MYCC at pH 7.4, a) hTeloC, b) c-MYCC; 
[FRETDNA]= 0.2 µM, [NaCl]high salt = 5 mM, [NaCl]low salt = 10 
mM , [sodium cacodylate] = 10 mM, [ligand]= 100 µM. 
Fluorescent emission was measured at 533 nm. 
To explore the nature of this, both of the compounds 28 and 54 were examined at 
different concentrations (Figure 3.43). For both compounds a dose-dependent 
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increase in melting temperature was observed. Each time the effect can be reversed 
by increasing temperature. This is particularly interesting as both hTeloC and c-
MYCC typically requires acidic pH to fold completely. These experiments 
therefore indicate that these maybe examples of ligands which can induce folding 
of i-motif in the absence of acid.  
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Figure 3.43 FRET DNA melting experiments on compound 28 and 54 huamn 
telomeric motif at pH 7.4 ; a) compound 28, [NaCl] = 5 mM, b) 
compound 54, [NaCl] = 5 mM, c) compound 28, [NaCl]= 
100mM ; [FREThTeloC]= 0.2 µM, [sodium cacodylate] = 10 mM, 
[ligand]= 0 - 100 µM. pH = 7.4. Fluorescent emission was 
measured at 533 nm. 
In order to assess whether this effect was related to the pyrene motif attached to 
compound 28 and 54, a reference compound, compound 58 (Figure 3.44), was used 
as a control. It was found that compound 58 has similar effects compared to 
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compound 28 and 54 with hTeloC at pH 7.4 both in 100 mM NaCl and 5 mM NaCl 
buffer. (Figure 3.44a and Figure 3.44b), but not to such a large extent. 
 
 
Figure 3.44 FRET DNA melting experiments on compound 58 on hTeloC at 
pH 7.4; [FREThTeloC]= 0.2 µM, [NaCl] = 5 mM, [sodium 
cacodylate] = 10 mM, [compound 58]= 5 µM. a) [NaCl] = 100 
mM, b) [NaCl] = 5 mM. Fluorescent emission was measured at 
533 nm. 
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By comparing compounds 28, 54 and 58 in the FRET-melting experiments in 5 mM 
NaCl buffer (Figure 3.45), it is possible to see that the compound 28, bearing one 
pyrene motif on the lower rim of the calixarene, possesses the highest stabilisation 
potential to hTeloC at pH 7.4 (Tm = 77°C), followed by compounds 58 (Tm = 61°C) 
and 54 (Tm = 58°C). These results suggest that the pyrene-motif on the lower rim 
may facilitate the interaction of hTeloC at pH 7.4. Surprisingly, it seems that the di-
pyrene substituted compound 54 possesses reduced stabilization potential 
compared to the mono-substituted compound 28. This could be because of steric 
effects due to the size of the two appended pyrene moieties. In the literature, it has 
previously been suggested that there was the possibility that the two pyrene 
moieties on the di-substituted calixarene 54 could have intermolecular π-π stacking 
interactions.209 Thus, if the stabilization mechanism is based on π-π stacking on the 
end of i-motif, the mono-substituted calix[4]arene will behave better than the di-
substituted calix[4]arenes, due to the absence of the intermolecular π-π stacking 
effects. For compounds 28 and 58, some of the the melting curves appear to have 
two transitions before the sample is completely unfolded, suggesting a plausible 
second melting event in the process.  
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Figure 3.45 FRET DNA melting experiments on compound 28, 54 and 58 on 
hTeloC at pH 7.4; [FREThTeloC] = 0.2 µM, [NaCl] = 5 mM, 
[sodium cacodylate] = 10 mM, [ligand]= 5 µM. Fluorescent 
emission was measured at 533 nm. 
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3.3.8 FRET titration assay 
FRET melting experiments monitor only one fluorophore attached on the 
oligonucleotides. As calixarene 58, 28 and 54 appear to be folding i-motif forming 
sequences into i-motif even at pH 7.4, further investigations of ligands with DNA 
were carried out via a FRET titration, monitoring both fluorophores. The FRET 
titration was conducted via titrating the ligands into FRET-labelled 
oligonucleotides and monitoring the fluoroscence changes over a wavelength range 
on the spectra. By excitating the FAM fluorophore at 490 nm, as decribed in Section 
1.3.3, a folded DNA structure will gives a significant fluorescent emission at 580 
nm as a TAMRA emission, however, unstructured DNA will gives a corresponding 
FAM emission at 533 nm, as no FRET is taking place when the fluorophores are 
far apart. By continuously titrating ligand solution into the FRET-labelled DNA, a 
change in fluorescence signals will be observed whether there is folding or 
unfolding upon interaction.  
With this technique, compound 28, 54 and 58 were first studied with FRET-labelled 
hTeloC (100 nM) at pH 7.4 (Figure 3.46). At pH 7.4, when FAM is excited, the 
major fluorescence emission is observed at 533 nm. If a ligand helps to fold the 
hTeloC DNA into i-motif structure (or even a hairpin), the fluorescent emission for 
TAMRA should increase and the fluorescent emission for FAM should decrease. 
As compound 28 was titrated into this sample, the fluorescent signal for FAM 
(emission at 533 nm) was found to decrease; however, no concomitant fluorescent 
signal enhancement for TAMRA (580 nm) was observed (Figure 3.46a). Similar 
results were observed for compounds 54 and 58 as well (Figure 3.46b & c). This 
may suggest that the folding and stabilization effects observed in Figures 3.42, 3.43 
and 3.44 result from calixarene-induced condensation of i-motif forming sequence.  
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Figure 3.46 FRET titration of compound 28, 54 and 58 with hTeloC at pH 7.4; 
(a) compound 28, (b) compound 54, (c) compound 58; 
[FREThTeloC]= 0.1 µM, [NaCl] = 5 mM, [sodium cacodylate] = 
10 mM. Fluorescent emission was measured from 500 nm to 650 
nm. 
In order to explore whether compound 28 has any effects with other DNA 
secondary structures, analogous titration experiments were performed with the G-
quadruplex forming sequence from the human telomere, hTeloG (Figure 3.47).  
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Figure 3.47 FRET titration of compound 28 with hTeloG at pH 7.4; 
[hTeloC]= 0.1 µM, [NaCl] = 100 mM, [sodium cacodylate] = 10 
mM.. Fluorescent emission was measured from 500 nm to 650 nm. 
The fluorescence emission at 580 nm indicated that hTeloG sequences forms folded 
G-quadruplex at pH 7.4 in the buffer conditions used. As compound 28 was titrated 
into the system, the fluorescence at 580 nm drops. This phenomenon is consistent 
with the data from Figure 3.35 in Section 3.3.7, implying calixarene-induced DNA 
condensation or precipitation is occuring.  
3.3.9 FID assay on calix[4]arene conjugates 
As described in Section 2.2.4, i-motif fluorescent intercalator displacement is a 
potential tool to study the relative affinity of i-motif binding ligands. FID has also 
previously been used to give an indication of calixarene-DNA interactions (Section 
2.3.5).126 In order to study the plausible binding between calixarenes and human 
telomeric i-motif, the FID assay was selected as a supporting method to study the 
relative binding affinity of the calixarene conjugates. 
In order to elucidate the possibility of calixarene conjugates interacting with 
thiazole orange, the UV absorbance of compounds 28, 54 and 58 was measured at 
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pH 5.5 as well (Figure 3.48). From the spectra, compounds 28 and 54 possess a UV 
absorbance of from 250 to 370 nm while calixarene 58 does not have any noticeable 
UV absorbance above 350 nm. Since in the FID system, the excitation wavelength 
is at 440 nm, the fluorescent excitation and emission should not be affected.  
 
 
 
 
 
Figure 3.48 UV absorbance of calixarene conjugates at pH 5.5, a) compound 
28, b) compound 54, c) compound 58,  [sodium cacodylate] = 10 
mM. UV absorbance measured from 200 nm to 800 nm.  
Compounds 28, 54 and 58 were then tested in the FID assay using fluorescence 
spectroscopy. As shown in Figure 3.49, i-motif DCs for the three compounds were all 
determined to be around 7.8 μM (28, i-motifDC50 = 7.8 ± 1.3 μM; 54, i-motifDC50 = 7.6 
± 2.4 μM; 58, i-motifDC50 = 7.9 ± 0.8 μM)and any differences between three 
calixarenes in binding human telomeric i-motif were within the error of experiment. 
This indicates the binding affinities of three compounds are almost the same. 
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However comparing to mitoxatrone and tobramycin discussed in Section 2.2.4, the 
i-motif DCs for three calixarenes (compound 28, 54 and 58) were relatively low, 
indicating that their binding affinity towards human telomeric i-motif is not as good 
as mitoxatrone and tobramycin (mitoxatrone, i-motif DC = 1.8 μM and tobramycin, i-
motif DC = 2.4 μM, Section 2.2.4). 
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Figure 3.49 TO displacement calculation based on hTelo i-motif FID assay on 
calixarenes 28, 54 and 58 at pH 5.5 in 10 mM sodium cacodylate 
buffer. [hTeloC] = 1μM, [TO] = 2μM, [ligand]= 0 ~ 5μM. The 
sample was excited at 430nm and the fluorescence emission was 
measured at 450 nm. 
3.3.10 Circular dichroism  
As the isothermal FRET titration experiments appeared to indicate the sample was 
precipitating or condensing, but this could have been complicated by the 
fluorophores, circular dichroism titration assays were also used to provide an 
insight using a different technique with unmodified DNA (Figure 3.50).  
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Figure 3.50 Circular dichroism spectra for calixarene with hTeloC at pH 7.4; 
a) compound 28, b) compound 54, c) compound 58, [hTeloC]= 
10 µM, [NaCl] = 100 mM, [sodium cacodylate] = 10 mM. 
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In the spectrum of hTeloC at physiological pH, the positive band at 274 nm and the 
negative band at 248 nm are consistent with unstructured, single-stranded DNA. 
For comparison, folded i-motif, at acidic pH gives rise to a positive band at 288 nm 
and a negative band at 255 nm (Figure 3.50).  
As can be seen in Figure 3.50a, with the increasing concentration of compound 28 
in hTeloC containing solution at pH 7.4, the intensity of CD signals for hTeloC 
decreased, indicating precipitation or DNA condensing events. When performing 
the circular dichroism on compound 54 and 58, it is possible to see that the 
conformation of hTeloC did not change even 50 equivalent of ligands were titrated 
with the nucleic acids before clear compound precipitation happened in the circular 
dichroism cuvette (Figure 3.50). In this experiment, clear precipitation was 
observed, however, the concentration at which these experiments were performed 
was 10 times higher than those within the FRET-experiments, so this is not 
particularly surprising.  
3.4  Conclusion 
In order to prepare the calixarene conjugates, novel amino-functionalised 
calixarene platforms bearing alkynes, such as calixarene 33, 37 and 41, were 
prepared via existing methods from p-tert-butylcalixarene. These platforms all 
adopt the cone conformation and feature Boc-protected amine group on the upper 
rim and alkynes on the lower rim. Two fluorescent DNA binding moieties bearing 
azides: pyrene 44 and Nile Red 48, were also prepared. Conjugating the calixarene 
platforms with the DNA binding moieties was performed by copper-catalysed 
alkyene-azide cycloaddition. In total, five calixarene conjugates were made and 
purified. Among them, compounds 28 and 54 featuring pyrene moieties were tested 
for binding to several oligonucleotides due to their comparatively good solubility 
in buffer. Thought the other three calixarene conjugates are all soluble in water, 
their solubility were very poor in even 5 mM NaCl and 10 mM sodium cacodylate 
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buffer (both at pH 7.4 and pH 5.5) and unsuited for biophysical studies.  
A series of FRET DNA-melting assays and FRET titrations, indicate that 
compounds 28 and 54 are able to condense several types of oligonucleotides, 
including sequences that forms G-quadruplexes and i-motifs. Calixarene-conjugate 
induced DNA condensation is stable at acidic pH, even up to 95°C but at pH 7.4 
can be reversed via introducing heat, which was observed in melting experiments. 
This indicates that these experiments, rather than showing a melting event, they are 
possibly indicating a cloud point for the ligand-DNA complex.235,236 It has 
previously been reported that amphiphilic calix[4]arenes with long aliphatic chains 
can condense oligonucleotides with ease,140 but previously it was thought that the 
long chains were required for this to occur. This work indicates that, even with 
shorter aliphatic chains (where n = 3), this is also possible. 
As well as the FRET-based and circular dichroism experiments, the i-motif FID 
assay developed in the Section 2 was also used to assess the binding affinity of 
calixarenes 28, 54, and 58 at pH 5.5. It was confirmed that the binding affinity 
between these three calixarenes and hTeloC was the same within error (DC50 = 7.5 
μM) and were weaker than the model compound involved in the FID assay, such as 
mitoxatrone (i-motifDC50 = 1.8 μM) and tilorone (i-motifDC50 = 2.1 μM). 
Although the original goal in this chaper was to find calixanene conjugates 
targeting DNA secondary structures, there is still a lot of useful information 
provided from the study. In this project, it was also first time that FRET DNA-
melting experiments, FRET-titrations and the TO-FID assay were used to study 
oligonucleotide condensation by calix[4]arenes, providing examples of new tools 
to study ligand-induced DNA condensation. These fluoroscopy-based experiment 
techniques could provide a quick and good indication of DNA condensation. 
Among them, FID assay can even be used to quantify the relative binding affinity. 
From this project, the lesson learned from a medicinal chemistry prospective is that 
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in designing biologically active calixarene conjugates, solubility is a key issue 
which requires considerable consideration. 
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4.1  Introduction 
In this chapter, an attempt to use calixarene as a platform presenting cyclic RGD 
peptide was disclosed. The aim of this study was to target receptors expressed on 
tumour tissue, such as integrin.  
4.1.1 Metastasis and Integrins  
In the early stages of malignancy, cancer cells cluster into a single mass forming a 
benign tumor, which can be completely removed by surgery if caught at this stage. 
However, in the later stages, neoplastic cells obtain the ability of metastasis, 
invading the surrounding tissue and migrating to distant organ sites via blood and 
lymphatic vessels.237,238 Metastasis is one of the key features for malignances and 
it contributes to over 90% of the mortality from solid tumors.239 To eradicate 
metastasis successfully is a challenging task. Tumour cell metastasis starts with 
invasion of the surrounding tissue around the primary tumour. 239 Then tumor cells 
enter the bloodstream directly or via lymphatic nodes, to begin their journey 
towards distant organs. They stop at the first capillary bed encountered, extravasate 
the bloodstream and land on the ‘foreign’ tissue.239  
In order to achieve proliferation, metastasis and migration, neoplastic cells have to 
interact with the extracellular matrix (ECM), an interlocking network of fibrous 
proteins, proteoglycans hyaluronic acid and chondroitin sulfate.240 The ECM is also 
decorated with a wide range of signalling components that are crucial to cell 
adhesion, such as fibronectin, laminin, vitronectin and collagen-IV. These 
signalling components all binds to a family of extracellular receptor, integrins, to 
achieve their biological impacts.240 
Integrins are divalent cation-dependent heterodimeric membrane glycoproteins 
mediating adhesion to the ECM (Figure 4.1).241 Apart from ECM, integrin also 
binds to immunoglobulin, growth factors, cytokines and matrix-degrading 
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proteases. The structure of integrin consists of two non-covalently associated α-
subunit and β-subunits. Up to now, 18 α-subunits and 6 β-subunits have been found, 
assembling into 24 distinct subtypes in the integrin family. Among these, αVβ5, αVβ3 
and α5β1 subtypes have beens show to be involved in metastasis of solid tumor and 
angiogenesis.241-243 
 
Figure 4.1: Diagram of integrin activation and bidirectional signal tranduction. 
The structure of the α- and β-subunits are quite similar. The rod-shaped subunits 
possess a very large extracellular recognition region for protein binding. A single 
transmembrane region connects the large extracellular head-domain and the much 
smaller cytoplasmic tail (Figure 4.1).241 Integrins are involved in the regulation of 
multiple consitutively activated pathways in neoplastic cells, such as Src, Rho 
GTPases, FAK and Erk.241 Cellular signaling mechanism of integrins are very 
different from other receptors since they possess unique bi-directional signaling 
pathways.244 Extracellular ligation unbends and elongates the dimer and separates 
the folded cytoplasmic domain on α- and β- subunits, allowing association of the 
cytoplasmic tail with signaling complexes and the cytoskeleton. Conversely, 
intracellular ligation between integrins and actin-binding proteins also promotes 
the separation of the extracellular domain and enhances integrin binding to 
substrate proteins on ECM.244 Integrins themselves possess limited kinase activity. 
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However, by clustering themselves and recruiting multiple kinases and adaptor 
proteins to form focal adhesion complexes, integrin can play a vital role in cancer 
metastasis, embryonic development and immunological function.245 Pathologically 
relevant subtypes crosstalk with growth factor receptors and exert their influence 
on oncogene expression as well.238 Integrins serve as transmembrane links between 
extracellular contacts and actin-microfilament. Loss of integrin ligation also 
contributes to initiation of cell apoptosis.  
Integrin αVβ3 
Integrin αVβ3 was the first αV integrin to be correlated with pathological 
angiogenesis.241 It is normally expressed on endothelium cells on blood vessels in 
human biopsy samples is stimulated via angiogenic growth factors such as TNFα, 
IL8 and Basic fibroblast growth factor (bFGF) and cannot be detected in normal 
human tissue.245 Inhibition of integrin αVβ3 by antagonism has been shown to 
blocked angiogenesis and inhibits tumour growth in multiple animal models 
including human tissues. 246-248 In the field of cancer research, Integrin αVβ3 is the 
most intensively studied subtype in the family. Overexpression of integrin αVβ3 was 
found associated with bone metastasis249 and resistance of chemotherapeutics in 
breast cancer.250 In the study of glioblastoma, overexpression of integrin αVβ3 was 
detected in the invasive margins of the tumour.251 The mRNA of β3 integrin is 
detected with a high abundance in tumour associated gastric mucosa, serving as an 
interesting prognostic marker for gastric carcinoma. 252 In melanoma, αVβ3-
expressing facilitate tumour survival, invasiveness and growth. 253,254  
Integrin αVβ5 
Integrin αVβ3 crosstalks with the FGF receptor and facilitates angiogenesis 
downstream. 242 A similar event was observed between integrin αVβ5 and VEGF-2 
receptor.242 In pancreatic cancer, hyperactivity of the EGF pathway has been 
correlated with integrin αVβ5. Interestingly, integrin αVβ5 is only active after being 
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activated by EGF triggered SRC phosphorylation of the p130CAS substrate domain 
and subsequent activation of the GTPase RAP1A.255 Although pathological 
angiogenesis does not necessarily require β5 subunits,256 integrin αVβ5 is more 
prevalent on cerebral cavernous malformations than integrin αVβ3.257  
4.1.2 cRGD peptide 
In studies of fibronectin on the ECM in the early 1980s, Rouslahti and 
Pierschbacher found a tetrapeptide sequence, Arg-Gly-Asp-Ser (RGDS), which 
plays a vital role in cell attachment.258-260 Later, other integrin binding substrates 
on the ECM, such as laminin, vitronectin and collagen-IV were also found that 
contained the tripeptide RGD sequence in their binding site.261-264 This marked the 
beginning of utilising RGD peptides to target integrins (Figure 4.2). Up to now, 
there are at least seven integrin subtypes found to bind the RGD peptide.265,266  
 
Figure 4.2: Native RGD-peptide structure 
The conformation of the RGD peptide affects its binding affinity drastically since 
in the natural ligands for integrin, the RGD sequence was presented in a rigid form. 
Thus in the development of synthetic integrin-binding ligands, cyclic peptide 
strategies have been applied. In cyclised systems, the RGD sequence is flanked by 
other amino acids to form a rigid ring, enhancing the binding affinity.267 Compared 
to linear RGD sequences, cyclic RGD (cRGD) peptides are around 10-fold more 
potent.268 Apart from enhancing affinity, cyclic peptides also offer the advantage of 
lower proteolytic degradation of the peptide.267 Cyclic peptide strategies have also 
been applied and shown to increase the selectivity of the RGD sequence. Linear 
RGD peptide sequences lack selectivity to specific integrin subtypes while a kinked 
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cyclic pentapeptide 59 (cRGDfV) possess high selectivity towards integrin αVβ3 
and αVβ5 and stretched cyclic hexapeptide 60 also has integrin αIIβ3 selectivity 
(Figure 4.3).269  
 
Figure 4.3: Structures of penta-peptide 59 specific for integrin αVβ3 and αVβ5 & 
   cyclic hexapeptide 60 specific for integrin αIIβ3 
Cilengitide 
In the past 10 years, several RGD-based integrin ligands have been developed. The 
most important one among them is c(RGDf[N-Me]V), known as Cilengitide (EMD 
121974, developed by Merck KGaA, 61 Figure 4.4).270 It binds integrin αVβ3 with 
sub-nanomolar affinity (αVβ3IC50 = 0.58 nM) and low-nanomolar affinity to integrin 
αVβ5 and α5β1. In terms of selectivity, cilengitide exhibits a 1000-fold preference 
towards integrin αVβ3 over platelate integrin αIIbβ3 (αIIbβ3IC50 = 860 nM).271 
Cilengitide fulfills its antineoplastic effect by inhibiting angiogenesis and inducing 
growing endothelium cell apoptosis via blocking the interaction between integrins 
with their ECM ligands, inhibiting proliferation and increasing apoptosis in cell 
lines and causing tumor regression.247,272-274 Cilengitide is the only anti-integrin 
cRGD peptide being tested in Phase III clinical trials against glioblastoma275 and 
in Phase II clinical studies for metastatic melanoma,276 non-small cell lung 
cancer277 and prostate cancer.278,279 However, it has failed to show significant 
improvement in the overall survival in its Phase III clinical studies for 
glioblastoma.275 Cilengitide incorporates a N-methylated valine. Here, the N-
methylated amino acid provides further metabolic stability and improved 
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bioavailability to the peptide drug.280,281 The guanidinium group on the arginine 
was shown to bind in a narrow groove in the αV subunit by forming salt bridges 
with two aspartate residues on αV subunit. An aspartate residue on the cilengitide 
coordinates with divalent cations such as Ca2+ and Mg2+, while the glycine in the 
middle provides steric restrictions to the cyclopentapeptide. These three crucial 
amino acid residues cannot be changed. The D-phenylalanine on the cilengitide 
imposes optimal side chain orientation and hydrophobic interactions with 
integrin.270  
 
Figure 4.4  Cilengitide 61 
c(RGDfK) 
Cyclic RGDfK 62 (Figure 4.5) was developed by Kessler and his co-workers.282 
Compared to cligentide, c(RGDfK) is a relatively simple molecule and has a low 
nanomolar-range binding affinity towards integrin αVβ3 (αVβ3IC50 = 4.2 nM) and 
high selectivity over integrin αIIβ3 (αIIβ3IC50 = 1800 nM).282 c(RGDfK) has been 
extensively used as cell-recognition motif or cell adhesion enhancer after 
attachment to other biomaterials, such as dendrimers,283 nanoparticles284 and 
radioactive isotope-containing compounds.285  
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Figure 4.5  c(RGDfK) 62 
Peptidomimetics containing RGD peptide  
The RGD peptide can also be presented by non-peptide scaffolds. RGD peptide 
presented by a 4-aminoproline molecule, 63 (Figure 4.6), shows nanomolar 
inhibition affinity to integrin αVβ3 and sub-micromolar inhibition affinity to 
integrin αVβ5.286 A similar inhibition affinity to integrin αVβ3 and αVβ5 can also be 
observed in a peptidomimetic 64 (Figure 4.6) featuring a 7,5-fused bicyclic 
lactam.287 Compounds 63 and 64 have even longer half-lives comparing to 
cilengitide. Peptidomimietics can also be functionalised with other substituents on 
the non-peptide scaffold, enabling incorporation on other biomaterials.288  
 
Figure 4.6  Peptidomimetics 63 and 64 
Cyclic RGD peptide made from cellular recombination 
Oxidation of remote thiols on cysteine to form a disulfide bond is a common 
strategy for peptide macrocyclisation.289 This method was also applied to cyclic 
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RGD peptide.290 Peptide 65 (Figure 4.7) was originally found via phage display and 
is over 200 times more potent than the commonly used linear peptide.291 Peptide 
65 has the potential to conjugate onto virus or proteins by recombinant means. In 
addition, conformational studies suggested that peptide 65 can adopt two additional 
conformations possessing lower binding affinity other than its preferential bicyclic 
structure.292 
 
Figure 4.7 Peptide 65 
4.1.3 Tumour targeting strategy via cRGD peptide 
Although cilengitide failed to progress beyond Phase III clinical trials, targeting 
integrin αVβ3 and αVβ5 via cyclic RGD peptide is still a good anti-metastasis 
strategy. In recent years, considerable effects have been focused on using cyclic 
RGD peptides as tumour targeting motifs for drug delivery and imaging purposes. 
Diagnostic Imaging 
In oncology, early discovery and treatment of malignancy can drastically elongate 
patients’ life expectancy through treatment of the cancer via surgery or 
chemotherapeutics or radiotherapeutics at a very early stage. Oncologists rely on 
medical imaging methods to make the correct diagnosis. Cancer-related integrins, 
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such as αVβ3 & αVβ5, are highly correlated with angiogenesis, thus serving as 
interesting targets for early tumour diagnostics. In the field of medical imaging, 
RGD peptide conjugated compounds can be used in positron emission tomography 
(PET), molecular magnetic resonance imaging (mMRI) and optical imaging.293 
PET generally requires a radioactive tracer, usually 18F or 68Ga compouds. RGD-
based PET tracers have already been used for patients (Figure 4.8). Among them, 
[18F]Galacto-functionalised peptide 66 was the first FET tracer to be studied in 
human.294 The lysine of c(RGDfK) was derivatised with a 18F-labelled sugar moiety 
via an amide bond. It takes around 200 minutes to prepare before being used and 
the radiochemical yield is about 30%.295 Compound 66 had been studied for 
patients with breast cancer, melanoma and sarcoma in clinical trials.294,296 Another 
similar example was compound 67, a PET tracer developed by Siemens Molecular 
Imaging Inc. In their preparation, radioactive 18F was conjugated to the galactose 
using ‘click’ chemistry. Conjugate 67 takes about 90 minutes to prepare and is more 
suitable for automated synthesis.297 Conjugate 68 (NOTA-RGD) was made by 
coupling SCN-Bz-NOTA to c(RGDyK). By incubating with 68Ga cation for 5 
minutes, the radioactive form of 68 was made by cation caging.298  
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Figure 4.8 Examples of RGD peptide incorporated PET tracer 66, 67 and 68 
When RGD-peptide are conjugated with fluorophores, conjugates can be used for 
optical screening. Compared to radioactive tracers in tumour imaging, RGD-
conjugated fluorophores are easier to prepare, cost-effective and safer.299 Near 
infrared (NIR) fluorophores are of great interest to scientists due to their easy 
synthesis and chemical and optical modifications. Their well-established bio-safety 
prolife will also benefit translational and clinical studies. However, the majority of 
the NIR fluorophores are not tumour-specific, requiring conjugation of tumour-
recognising motifs for cancer diagnosis.299 The first cRGD peptide conjugated 
fluorophore was a Cyanine 5.5 with c(RGDfK) or c(RGDyK) (Figure 4.9). 
Conjugate 69 was tested targeting on Kaposi’s sarcoma in animal model via 
dynamic fluorescence imaging, showing increased uptake in tumour. Another 
conjugate 70 has been studied in a human orthotopic brain tumour in a mouse 
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xenograft model via 3-D optical imaging,300,301 showing promising tumour imaging 
result (IC50 = 42.9 nmol/L). The signal-to-noise ratio almost reached 2:1 24 hours 
after the administration of 70.  
 
Figure 4.9 Peptide conjugate 69 and 70, the first generation Near infrared  
   fluorophore incorporated with cyclic RGD peptide 
Mono-RGD appended fluorescent ligands normally showed impaired integrin 
binding compared to cyclic RGD peptides without fluorescent tags.302 A method to 
overcome this drawback is to use multivalent platform to increase the number of 
peptide motifs (Figure 4.10). Conjugate 71 is the peptide-dimer tagged with 
Cyanine 5.5 while conjugate 72 was the peptide-tetramer tethered with Cyanine 5.5. 
Both 71 and 72 are derivatives of 70. In testing with human glioblastoma 
astrocytoma cells, 71 showed doubled binding affinity (IC50 = 27.5 ± 1.2 nmol/L) 
compared to monomer 70 (IC50 = 42.9 ± 1.2  nmol/L) while 72 demonstrated 
almost 4-fold binding affinity (IC50 = 12.1 ± 1.3 nmol/L) compared to 70.302 
However, both 71 and 72 failed to show significant enhancement in tumour imaging 
compared to 70. This might due to the fact that multimerisation of RGD changes 
the size of the conjugate, overall charges and hydrophilicity of the peptide, thus 
altering the in vivo pharmacokinetics and clearance from non-targeted tissue.302  
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Figure 4.10  cyclic RGDyK tethered dimer 71 & tetramer 72  
Apart from fluorescent and radioactive tags, nanoparticles, such as quantum dots 
(QDs), magnetic iron oxide nanoparticles, polymeric nanoparticles, carbon 
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nanotubes and gold nanoparticles, can also be used as imaging agent in tumour 
diagnostics.299 Quantum dot 73 made from CdTe coated with ZnS was the first 
RGD peptide-labeled QDs (Figure 4.11). After the attachment of c(RGDyK), 73 
showed integrin-specific binding to integrin–positive human breast cancer and 
primary glioblastoma cell lines in ex vivo experiments.303 In the later experiment in 
mice, 73 showed increased signal intensity and improved photostability compared 
to conjugate 70 as a reference agent.303  
 
Figure 4.11 Quantum dot 73 tethered with cyclic RGDyK peptide   
Drug delivery  
Nanoparticles within certain sizes, normally 20 to 400 nm in diameter, are able to 
target tumours in living organisms passively via enhanced permeability and 
retention (EPR) effect. The EPR effect is attributed to abnormal fluid transport 
dynamics in tumour vessels as a result of uncontrolled angiogenesis, providing 
second order targeting.304 Thus, in order to further enhance nanoparticles’ tumour 
targeting, incorporating tumour targeting motifs, such as cyclic RGD, on the 
surface of nanoparticles is a sensible choice. As it can enhance internalisation by 
tumour cell presenting high levels of integrin. 
Cyclic RGD functionalised nanoparticles 74 encapsulating doxorubicin were found 
to possess a 15-fold increase in anti-metastatic activity compared to nanoparticles 
without RGD coating in a doxorubicin-insensitive murine C26 colon carcinoma 
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model (Figure 4.12).290,305,306 
 
Figure 4.12 cRGD-Mal-PEG-tethered Long circulating liposomes (LCL) 
system carrying doxorubicin 258,259 
In a later study, biodegradable PLAG-based nanoparticles functionalised with 
linear RGD peptide (75) or RGD peptidomimetics (76) have been loaded with 
paclitaxel and showed targeted cytotoxicity towards neoplastic endothelium both 
in in vitro and in vivo models (Figure 4.13).307  
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Figure 4.13 PLAG-based nanoparticle bearing linear RGD peptide 75 and 
RGD peptidomimetics 76 carrying paclitaxel for drug delivery  
Biomolecules such as proteins and anticancer nucleic acids, can be grafted with 
RGD peptide to target angiogenesis and metastasis.241 The clinical use of tumour 
neocrosis factor-α against malignancy was restricted by its general toxicity. 
However, by incorporating RGD4C peptide to the protein via DNA recombination, 
modified TNF molecule shows antitumour effects in mice at subnanogram doses 
when co-administrated with melphalan.308 The same strategy was applied on 
TRAIL, endostatin and Interleukin 2 to show targeted antineoplastic 
effects.147,309,310  
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Another study in the RGD delivery strategy is to deliver nucleic acid, such as DNA 
or RNA oligomers into the cell, either acting as targeted gene expressing or gene 
silencing approaches in gene therapeutics. Unmodified DNA and RNA cannot get 
across the cell membrane easily due to their negative charges. Apart from that, 
selectivity of gene therapeutics is generally very poor as well. Thus incorporating 
RGD peptide to nanoparticles loaded with nucleic acids is expected to reduce the 
side effects as well as increase the efficacy in gene therapeutics.241 Developed 
RGD-tagged nucleic acid delivery system includes siVEGFR2, siPLXDC1, anti-
HIF-1α siRNA, anti-miR-296 AMO and so on.311-314  
4.1.4 Cyclic RGD peptide and macrocycles 
Although the cyclic RGD strategy is widely used in targeting tumour tissue, 
examples of cRGD peptide tethered calix[4]arene are quite limited. One example 
is to use the calix[4]arene as a rigid platform to lock the conformation of the RGD 
peptide (Figure 4.14).315 Compound 78 was made via solid phase peptide synthesis 
from a calixarene platform bearing amine and carboxylic acid on the upper rim (77). 
However there is no published biological data on the activity of this compound (78).   
 
Figure 4.14 Example of cyclised GRD peptide on calixarene 78 
In another approach, a cryptophane host is conjugated with cyclic RGD peptide 
(conjugate 79, Figure 4.15).316,317 Nano-structure 79 was prepared to perform 
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fluorescence imaging in cells via an Alexa Fluor® 488 fluorophore. 79 binds αvβ3 
abd αIIbβ3 integrin with nanomolar affinity (IC50 = 20-30 nM) but possessing 
moderate cytotoxicity to human lung fibroblasts at relevant biosensing 
concentrations. Cellular internalisation experiments were monitored by confocal 
laser scanning microscopy and hyperpolarized 129Xe NMR with human pancreas 
cancer and lung fibroblasts cell lines. It was found that 79 had better internalisation 
in pancreas cancer cells than in lung fibroblast cells, suggesting a viable targeted 
delivery of cryptophane to tumour tissue.316    
As introduced in Section 1.4.3, calixarenes act as a good platform for targeting 
receptors and enzyme binding. Given the platforms already synthesied within this 
thesis, this provided a good foundation to develop a new platform for presenting a 
cyclic RGD peptide.  
 
Figure 4.15 cRGD tethered cryptophane 79 
 
 
 
Chapter 4 Synthesis of cRGD-Conjugated Calix[4]arenes 
153 
 
4.2  Aims 
The aim of this project is to explore the possibility of applying calixarenes as a 
platform to present cyclic RGD peptide and fluorescent labels to achieve a 
bioimaging function in a single molecule. The strategy to achieve this and separate 
aims are: 
1)   Synthesise a cyclic RGD peptide functionalised with an alkyne moiety  
2) Synthesis of a derivatised calix[4]arene featuring orthoganol functional 
groups to enable two consecutive click reactions to introduce two different 
types of functionalization 
3) Synthesis of an appropriate fluorescent tag which can be added to the 
calixarene platform 
4) Construct the calixarene target calixarene conjugates bearing fluorophores 
and cyclic RGD peptides 
4.3  Results and discussion 
4.3.1 Calixarene conjugate design 
In order to develop a bioimagining system, three major components needs to be 
considered: the targeting ligands, fluorophore and the linker. In this project, 
calix[4]arene was selected as the linker mainly due to its well-known multivalency 
(Figure 4.16) and also the prior experience developed in the duration of this PhD. 
The presence of four binding positions on the upper-rim of the calixarene which 
can be functionalised with cyclic RGD peptide combined with the potential to 
functionalise the lower rim of the calixarene with fluorescent substituents or NIR 
imaging agents makes it a suitable linking molecule.  
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As described in Section 4.1.3, the direct attachment of fluorophores or toxins to a 
cyclic RGD peptide has been shown to reduce its relative binding affinity to 
integrin. Given the calixarene platform can offer multiple sites for recognition, it is 
hypothesized that the accociated multivalency may overcome this problem. 
 
Figure 4.16  Target molecule for cRGD-conjugated calix[4]arene-based  
    imaging ligand. 
In order to make the target molecule, a retrosynthetic analysis of calixarene bearing 
cyclic RGD peptide and fluorophore was implemented (Scheme 4.1). As described 
in Section 3.3.2, boc-protected aminocalix[4]arene platforms had already been 
synthesised, it was decided to use the “clickable” calixarene 33 (see Section 3.3.2) 
as the platform from which to start. The lower rim of 33 can be functionalised with 
an azide bearing fluorophore. The amino group on the upper rim of the resultant 
fluorescent calixarene can be deprotected with acid and then converted into 
diazonium under acidic conditions. The diazonium can be easily replaced by azide 
via electrophilic aromatic substitution. Then four cyclic RGD peptide molecules 
modified with a propargyl group can then be installed on the upper rim of the 
calixarene. 
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Scheme 4.1  Retro-synthetic analysis of target molecule to previously  
    synthesised compound 33 (Section 3.3.2). 
Thus the whole project was divided into several small projects as demonstrated 
below. (Figure 4.17)  
 
 
Figure 4.17 Project flow chart for planning. 
4.3.2 RGD peptide design 
RGD peptides have a very unique structure-activity relationship. Using compound 
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61 (cilengitide, Section 4.1.2) as an example, the argnine, glycine and aspartate 
were crucial to the activity of the peptide (Figure 4.18).269 D-phenylalanine on the 
ligands can be replaced with D-tyrosine.318,319  
 
Figure 4.18 Structure-activity relationship of compound 61   
The only variable amino acid residue is the N-methylated valine and the majority 
of chemical alternation have been made at this position. Lysine is usually chosen 
as the fifth variable amino acid due to its easy functionalisation on the ɛ-amino 
group (compound 80, Figure 4.19). It can be conjugated with other substituents 
using peptide coupling itself or through ‘click’ reactions after being modified to the 
azide (compound 81, Figure 4.20).283,302,320  
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Figure 4.19  cliclkable azide-c(RGDyK)80 used in the study. 
Figure 4.20  Chemical structure of DOTA-conjugated multivalent cyclic-RGD 
    dendrimer 81 for tumour imagining purpose 
However, for this project an amino acid capable of being functionalised as an 
alkyne was required. Thus, serine was chosen as the fifth variable amino residue to 
replace lysine (compound 83, Figure 4.21). The binding affinity of cRGDfS 
towards integrin αVβ3 was still in low nanomolar range (αVβ3IC50 = 12 nM).282  
In addition, the hydroxyl group on the serine need to be propargylated to perform 
the click reactions required when making the conjugates. This could also be the 
first example for a propargyl group attached cyclic RGD peptide, possessing many 
different applications aside the purpose intended for this project. 
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Figure 4.21  A comparison of protected form of cyclic RGFfS(O-Prp) 83 &  
    reported clickable cyclic RGD peptide 82. 255,273  
The target cyclic pentapeptide was designed to be stable under basic conditions and 
for protecting group cleavage on the side chain to be performed with acid. In order 
to make this peptide, retrosynthetic analysis was performed. As shown in Scheme 
4.2, the Fmoc protected forms of four amino acids are commercially available. Only 
the propargylated serine need to be specially prepared before the synthesis of the 
peptide.  
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Scheme 4.2  A retrosynthesis view on proposed cyclicpeptide 83 which would 
    be able to be ‘click’ onto any suitable azide-functionalised system. 
The preparation of cyclic pentapeptide 83 can be performed via liquid phase 
peptide synthesis strategy or solid phase peptide synthesis (SPPS). In this project, 
SPPS was chosen due to its easy handling, relatively fast peptide propagation speed 
and easier purification. 
4.3.3 Preparation of Fmoc-L-Serine (O-Propargyl)-OH 
O-Propargyl modification of the serine was conducted by alkylating the hydroxyl 
group of Boc-protected serine 84 (Scheme 4.3).321 The pKa value of the hydrogen 
on the hydroxyl group in 84 is around 17 to 18. Thus in these examples, excess 
sodium hydride was used as a strong base. Deprotonation of the hydroxyl was 
carried out at 0°C  
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Scheme 4.3  Preparation of amino acid 86 for SPPS 
When the carboxylic acid is deprotonated (pKa ≈ 4), it forms a conjugated system 
with the carbonyl group (Scheme 4.4) which helps to protect the α proton adjacent 
to the carbonyl in a strong alkaline conditions.  
 
Scheme 4.4  The conjugation on the carboxylic acid helps to protect α proton 
    on the amino acid. 
As described in Section 3.3.1, propargyl bromide was used as bromine is a good 
leaving group. The reaction mixture was monitored via thin layer chromatography 
(TLC), using a ninhydrin stain. However, product 85 after column chromatography 
still contained a substaintial amount of acetic acid, which was removed by forming 
an azeotrope with toluene and evaporating several times. The product 85 was 
confirmed by 1H-NMR spectroscopy (Figure 4.22), where the characteristic 
terminal proton peak on the triple bond, which exists as a triplet, was found at 2.46 
ppm. The obtained spectroscopic data for 85 was in agreement with literature.321  
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Figure 4.22  Confirmation of propargyl installation on amino acid 85 via  
    1H NMR spectroscopy 
The next step was to remove the boc protecting group using trifluoroacetic acid 
(TFA) and then to install an Fmoc protecting group to prepare amino acid 86 which 
is suitable for automated synthesis.322 Fmoc-N-hydroxysuccinimide ester was used 
as the Fmoc-donating reagent in this reaction. By deprotonation of the amine on 
the serine with a mild base, the Fmoc protecting group can be easily attached to the 
amine end of the amino acid. The product 86 was purified via column 
chromatography and yielded a white solid as the pure product (61% yield). The 
product 86 was confirmed with using NMR spectroscopy, with a distinctive doublet 
at 5.65 ppm in deuterated chloroform representing the amide proton. The 1H-NMR 
spectrum data for 86 was in consistent with literature data (Figure 4.23).322 In the 
COSY spectrum of 86, the terminal proton on the propargyl group (Hb) was 
confirmed as the triplex at 2.44 ppm, which was correlated with (dash-line) the 
singlet at 4.17 ppm. The α proton on the amino acid was annotated as the the doublet 
at 4.54 ppm (Hc). Which is correlated to (solid line) another three proton signals at 
5.68 ppm (He), 4.02 ppm (Hd) and 3.81 ppm (Hd) respectively. In the HSQC 
spectrum, the proton on the amide (He) was expected to lose its signal. The α proton 
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on the amino acid was expected to be the only proton attached to a carbon while 
the two protons attached the propargyl group (Ha) was shown to attached to the 
same carbon. The HSQC spectrum further confirmed the assignment of protons on 
the COSY spectrum. 
Figure 4.23  Confirmation of 86 via 1H NMR and COSY spectrum 
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Figure 4.24  HSQC spectrum of 86 
4.3.4 SPPS on cyclic RGDfS(O-Prp) 
There are two main synthetic strategies used in SPPS, the Fmoc (fluoren-9-
ylmethloxycarbonyl) strategy and the Boc (tert-butoxycarbonyl) strategy, named 
after the protecting groups on amino acid N-terminal amino group.323 In this case 
the synthesis of linear peptide 87 was carried out via an Fmoc SPPS strategy 
(Scheme 4.5) analogous to a previously published synthesis of a cyclic RGD 
peptide.323  
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Scheme 4.5 Proposed SPPS-based synthesis routine on cyclic peptide 83 
In order to cyclise the peptide, 2-chlorotrityl choride resin was chosen as the 
immobilized phase in the synthesis due to its ability to provide a free carboxylic 
acid on the C terminal on the peptide after cleavage (Scheme 4.5).324-326  
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Fmoc-glycine was the first amino acid to be chosen to attach to the resin, which 
means the further macrocyclisation was performed between glycine and aspartate. 
The reason to do this is because the free rotation of amino group on the glycine 
would facilitate the final cyclisation in the future whilst other more restricted side-
chain bearing amino acids do not have this advantage.325 
2-Chlorotritylchloride resin was highly sensitive towards moisture and water. Thus 
loading of the first amino acid, Fmoc-glycine, on the resin needs to be done under 
Argon and using dry solvent.325 After properly drying the resin, UV spectroscopy 
was used to assess the loading efficiency of Fmoc-glycine (see Section 6.4.2). The 
quantity of other amino acids used in the later synthesis was calculated based on 
UV-absorption.324 
In the next step, 20% piperidine in DMF was used as a nucleophilic base to 
deprotect the Fmoc-group on the glycine due to its alkalinity (pKa = 11). The 
byproduct of this step can be easily washed away with DMF, leaving immobilised 
glycine with a free amine group on the resin. The Kaiser test327,328 was used as the 
indicator to indicate the success of Fmoc removal (see Section 6.4.2).  
The Kaiser test was a colorimetric test for the presence of free amine group.327,328 
The Kaiser test requires heating a mixture of resin with the peptide-loaded resin. 
Incompleted peptide coupling procedure or deprotection on Fmoc-protecting group 
is normally demonstrated as the development of a blue color (a negative Kaiser 
test), while a finished peptide coupling procedure was usually illustrated by the 
naturally yellow color of ninhydrin (positive Kaiser test). The mechanisms of the 
colour change of ninhydrin stain and Kaiser Test are demonstrated in Scheme 
4.6.323 
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Scheme 4.6 Mechanism of the Kaiser test.323 
In the next coupling step, HBTU,329-331 in the presence of DIPEA, was used as the 
coupling reagents to form the peptide bond between Fmoc-Arg(Pbf)-OH and 
glycine (Scheme 4.7). Because of the existing conjugated system in a carboxylic 
acid, synthesis of the peptide bond requires the acid to first be activated.332 
Coupling reagents, such as DCC,333 EDCI,334 PyBOP335 and HBTU,331 can be to 
activate the C-terminal carboxylic acid or activated esters or acid halides.332 HBTU 
was chosen because of its safety, its good solubility in classical solvent and fast 
reaction rate. It was also cheaper than HATU, the reagent previously described in 
the synthesis of the cyclic-RGD peptide.329 
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Scheme 4.7  Reaction mechanism in HBTU assisted peptide coupling 
The success of the amino acid coupling can also be monitored by Kaiser test 
(Section 6.4.2) as successful coupling will result in no color change in the Kaiser 
solution containing the resin.  
The next step was to deprotect the Fmoc protecting group on the N-terminal amine 
group. This was achieved by washing the resin with 20% piperidine in DMF several 
times, as previously described.325 Subsequently, Fmoc-Ser(O-Prp)-OH, Fmoc-D-
Phe-OH and Fmoc-Asp(O-tBu)-OH was added on to the peptide chain after the 
removal of Fmoc group on the previous amino acid was confirmed with the Kaiser 
test (see Section 6.4.2). 
After the final removal of Fmoc protecting group on the aspartate, the linear penta-
peptide 87 was cleaved from the resin with trifluoroethanol and acetic acid.324 This 
mixture results in a cleavage of the peptide from the resin without affecting the acid 
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labile protecting group on the aspartate and arginine. After using toluene to 
azeotrope off the excess acetic acid, the crude product 87 was purified with 
preparative-HPLC to give a yellow-colored powder (38% yield). The structure of 
87 was assigned with 1H-NMR spectroscopy (Figure 4.25) with the propargyl side 
chain being clearly identified by the terminal proton peak seen at end proton 2.90 
ppm. The methyl groups of Pbf-protecting group on the arginine side chain can be 
found as several singlets between 3.0 to 1.5 ppm. The aromatic protons on D-
phenylalanine can be identified as multiplets at 7.3 ppm. Additional high-resolution 
mass spectroscopy (HRMS) was obtained as well (Figure 4.26). The ionised form 
of 87 was found at 949.4098 in m/z (Calculated as [C44H63N8O12S]+).  
 
Figure 4.25  1H NMR spectrum of linear peptide 87
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Figure 4.26  HRMS spectrum of 87 
4.3.5 Cyclisation of the linear peptide  
Head-to-tail cyclisation of linear peptide 87 was achieved with HBTU in 
acetonitrile under very dilute conditions ([linear peptide] ≤ 1mmol/L).325 The 
reaction was carried out under room temperature for 120 hours with several 
additions of extra HBTU reagent into the reaction system. The reaction was 
monitored with Kaiser test to ensure the starting material was depleted as the 
cyclised peptide should give a negative result in Kaiser test. After the work-up, 
cyclised, side-chain-protected pentapeptide 83 was purified with preparative HPLC 
to obtain a yellow-white-coloured solid. The side-chain protected peptide 83 was 
confirmed with analytical HPLC (98%) and HRMS ([M+Na]+ : 931.3982 in m/z) 
(Figure 4.27).  
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Figure 4.27  Analytical HPLC trace of purified and protetcted cyclic  
    RGDfS(O-Prp) 83 and its HRMS spectrum 
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4.3.5 Preparation of fluorescent reporter 
In terms of the fluorophore, a coumarin motif was chosen due to its strong 
fluorosence emission. In this project, 3-azido-7-hydroxycoumarin 91 (Scheme 4.) 
was selected because it is not fluorescent when the azide group on the C7 position 
is present. After the ‘click’ reaction, non-fluorescent 3-azido-7-hydroxycoumarin 
becomes fluorescent, with an emission at 500 nm.336 This property can also be 
utilised as an indicator for the attachment of coumarin in the ‘click reaction’. 
Azide-bearing clickable coumarin was synthesised according to existing methods 
(Scheme 4.8).336 By stirring 2,4-dihydroxy benzaldehyde (88), N-acetyl glycine (89) 
and sodium acetate in acetic anhydride at reflux overnight, 3-acetamido-7-
acetoxycoumarin 90 as an intermediate was formed as yellow-colored solid after 
reaction workup. Then the intermediate was heated at reflux in 2:1 37% 
HCl/ethanol for 1 hour to deprotect the hydroxyl group and amine. Then the 
reaction mixture was cooled down to 0°C and sodium nitrite added to form 
diazonium salt form of the coumarin. The diazonium was then replaced with azide 
in the solution to form 3-azido-7-hydroxy coumarin 91. The structure of coumarin 
91 was consistent with the existing 1H NMR spectrum in the literature.336  
 
Scheme 4.8  Preparation of coumarin 91 for click reaction 
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4.3.6 Preparing the calixarene-dye conjugate 
Two different calixarenes were developed featuring the coumarin dye on the lower-
rim. In the first case, azido functionality was introduced directly to the upper-rim 
of the calixarene 92, in the second, a spacer was introduced between the upper-rim 
and calixarene core to form 93. These two strategies (Scheme 4.9) enabled an 
investigation of whether four cyclic peptides could be directly appended to the 
calixarene or whether steric effects would require a spacer to be present. 
Additionally, it would allow a comparison of the biological effects of more or less 
flexible calixarene derivatives.  
 
Scheme 4.9 Two proposed calix[4]arene-coumarin conjugates 92 and 93 for 
click chemistry 
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Preparation of 92 
The azido-coumarin 91 was attached to calix[4]arene 33 using the ‘click’ reaction 
conditions described in Section 3.3.4 (Scheme 4.10).197  
Scheme 4.10  Preparation of calixarene 94 
After treating with copper sulphate and sodium ascorbate in DMF at 80°C 
overnight, the reaction mixture turned fluorescent under UV light, indicating that 
the ‘click’ reaction had occured. The reaction was terminated by evaporating the 
solvent in vacuo. And the brown-colored crude product was purified with column 
chromatography to afford a light-yellow-coloured solid (81.3% yield). The 
chemical structure of this calixarene-coumarin conjugate 94 was assigned with 1H-
NMR spectroscopy, which is in agreement with the literature (Figure 4.28).197 
Calixarene 94 was used as the starting material for 92 and 93 (Scheme 4.9). 
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Figure 4.28  1H-NMR spectrum of Boc-amino calixarene-coumarin conjugate 
    94 
After deprotecting the amino group on the upper rim of calixarene 94 with gaseous 
HCl, the azide was introduced on the upper rim. In this step, sodium nitrite was 
used to form diazonium salt under 0°C, then replacing the diazonium with azide to 
form calixarene 92 as described in Section 4.3.3 (Scheme 4.11).337  
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Scheme 4.11  Preparation of calixarene 92 
The installation of azide group was confirmed using IR spectroscopy, which gives 
a distinct and strong transmittance peak at 2106 cm-1 (Figure 4.29). As can be seen 
from Figure 4.29, Boc-protected calixarene 94 does not possess the strong IR 
absorbance at 2106 cm-1 while azido-functionalised calixarene 92 does.  
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Figure 4.29  IR spectrum of calixarene 94 & calixarene 92 
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After purification by column chromatography, the product of this reaction was 
confirmed with 1H-NMR spectroscopy and HRMS (Figure 4.30). This confirmed 
that the 4 amine groups on the upper rim of the calixarene 95 were all replaced with 
azide. As seen in Figure 4.30, the peaks from 4.25 to 4.50 ppm and 3.0 to 3.20 ppm 
are from the protons on the methylene bridges connecting adjacent aromatic 
rings,confirmeing a symmetrical calixarene structure (as described in Section 3.3.2 
and 3.3.5) and installation of 4 azide groups on the upper rim of calixarene 92. The 
completion of the reaction was also supported with HRMS, with a mass of 
978.3515 for [C49H45N15O7Na]+ in m/z.  
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Figure 4.30  1H-NMR spectrum and HRMS spectrum of calixarene 92 
Preparation of 93 
Deprotected calixarene 94 can also be functionalised with 6-azido hexanoic acid 
(97)190 to create a flexible structure for clickable RGD peptide to bind (Scheme 
4.12).  
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Scheme 4.12  Synthesis routine for calixarene 93 
Linker 97 was obtained via stirring compound 96 with sodium azide in DMF at 
50 °C for 3 hours (Scheme 4.12). The bromine was substituted with azide via an 
SN-2 mechanism. After working up the reaction, the product was obtained as a 
orange-coloured oil. The introduction of the azide group was confirmed with IR 
spectroscopy (Figure 4.31) and its NMR spectrum was in accordance with literature 
data.190  
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Figure 4.31  IR spectrum of 6-azido hexanoic acid 93, 94 and linker 97  
Deprotected 94 was then coupled to 6-azido hexanoic acid in the presence of HBTU 
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and DIPEA as described in Section 4.3.4. After purification by column 
chromatography, the product was confirmed with IR (Figure 4.31) and 1H NMR 
spectroscopy in deutrated MeOH (Figure 4.32). The protons pointing inwards on 
the methylene bridges are clearly spotted from 4.36 to 4.47 ppm as two doublets. 
This indicated four upper-rim transformations have been made. In the IR spectrum 
(Figure 4.31), the azide for 93 can be seen at 2100 cm-1, indicating the success of 
installing azide functionalities on the calixarene platform. The outward-pointing 
protons on the methylene bridges in 1H-NMR spectrum may overlapped with the 
solvent residue peaks.  
 
Figure 4.32   1H-NMR spectrum on 93 in deuterated methanol 
4.3.7 Model reaction: Coupling of cyclic RGDfS(O-Prp) to coumarin dye 
In order to study whether propargyl-modification of the cyclic RGD peptide was 
compatible with undertaking a ‘click’ reaction, a model reaction linking cyclic 
peptide 83 directly to coumarin 91 first was undertaken (Scheme 4.13). The 
fluorescence of the coumarin will increase drastically after the ‘click’ reaction, 
which serves as a perfect indicator for the reaction progress. After deprotection, the 
Chapter 4 Synthesis of cRGD-Conjugated Calix[4]arenes 
180 
 
peptide-coumarin conjugate 99 itself can be used as a reference compound in later 
cell based experiments.  
Unlike the previous click reactions, a chelated copper (I) source, 
tetrakis(acetonitrile) copper (I) hexafluorophosphate, was used in the click reaction 
with the peptide.200,338-340 Using chelated copper (I) source was expected to reduce 
the possibility that the amide bond on the peptide might chelate the copper (I) cation 
and thus complicate the purification steps followed. 
 
Scheme 4.13  Reaction scheme of peptide-coumarin conjugates 98 and 99 
Peptide 83, coumarin 91 and the chelated copper (I) source were stirred under argon 
in a sealed reaction system at room temperature. When DIPEA was added into the 
reaction system, the reaction mixture became fluorescent instantly under UV light, 
indicating the formation of the triazole group on the coumarin.  
This confirmed that the protected cRGDfS(O-Prp) was suitable for the click 
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reaction, and can be applied to the two coumarin-appended calixarene platforms.  
The resulting crude reaction mixture was deprotected with TFA, triisopropylsilane 
(TIS) and water. The presence of TFA helps to cleave the acid labile protecting 
groups on the side chain, such as the tert-buytl group aspartate on the and the Pbf 
group on the arginine.323 Triisopropylsilane was widely used as a peptide cleavage 
scavengers in peptide chemistry, protecting the newly deprotected side chain 
functionalites against the strong acid.341  
The reaction mixture was then dried on vaccum and ready for further purified by 
semi-preparative or preparative HPLC.  
The product was confirmed using 1H NMR spectroscopy, HSQC and HRMS 
(Figure 4.33 & Figure 4.34). When dissolving 99 in deuterated DMSO, the amide 
protons from the peptide structure can also be detected, including the amide proton 
on arginine side chain (Figure 4.33). The click proton can be assigned as a sharp 
singlet at 8.5 ppm. Four α protons (apart from the glycine) on the cyclic peptides 
can be assigned as four red dots shown in the HSQC spectrum (within the circule, 
Figure 4.33b). The intergration of protons on 1H NMR spectrum matched the 
number of protons on 99. Additional HRMS (Figure 4.34) further confirmed the 
structure of 99, with a peak found at 804.3058 in m/z as the ionised form of 99 
(Calculated as [C36H42N11O11]+). Thus it was shown that the alkyene group on 
cyclic peptide 83 was able to perform CuAAC and the use of chelated copper is 
able to catalyse the CuAAC in the presence of cyclic RGD peptide. 
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Figure 4.33  1H NMR and HSQC spectrum on 99 in deutrated-DMSO 
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Figure 4.34  HRMS spectrum for the purified 99 
4.3.8 Incorporating cyclic RGDfS(O-Prp) to the calix[4]arene-coumarin 
conjugate 
Click reaction between calixarene 92 and peptide 83 
The last and the most critical step in this project was to install cyclic RGD peptide 
to the fluorescent calixarene-coumarin conjugates, followed by final deprotection 
in TFA to prepare 100 and 101 (Figure 4.35).  
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Figure 4.35  Target molecules, 100 and 101, for synthesis in this project 
In an attempt to make 100, the fluorescent calixarene platform 92 and protectd 
peptide 83 was treated with CuSO4·5H2O and sodium ascorbate in DMF under 
argon at room temperature for four days to make protected conjugates 102 (Scheme 
4.14). The reaction mixture was tested by TLC, which indicated that there were still 
a substantial amount of unreacted 92 left in the reaction mixture (Scheme 4.14). 
Heating the reaction mixture to 50°C for another 3 days or subsequently 80 °C for 
another 5 days did not result in any observable changes to the mixture by TLC. This 
might be due to the relatively bulky 83 not being able to installed on the crowded 
upper rim of calix[4]arene due to steric hindrance. Alternatively this may be due to 
the choice of copper (I) source.   
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Scheme 4.14  Click reaction between 92 and 85 did not work. 
Click reaction between calixarene 93 and peptide 83 
In contrast treatment of 93 with 81 in DMF in the presence of tetrakis (acetonitrile) 
copper (I) hexafluorophosphate was more succesful (Scheme 4.15), yielding a 
green colored crystalline crude product after evapourating the solvent.   
 
Scheme 4.15  Click reaction between 93 and peptide 83 
The crude product was deprotected using TFA and TIS and analysed by mass 
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spectrometry (Figure 4.36).  
The HRMS Spectrum of the crude material showed that the starting material for 93 
was not detected. Deprotected clickable cRGD peptide was detected as the largest 
peak ([M+H]+) at 601.2721 in m/z, while the final product were conformed at 
953.6990 ([M+4H]4+) and 1271.2623 ([M+3H]3+) in m/z. Surprisingly, no other 
significant peaks were observed from 1407 to 3900. This means that all four azides 
on 93 were reacted with the propargyl group on the peptide, suggesting the 
completion of the reaction.   
 
Figure 4.36  High-Res Mass Spectrometry of 101(crude sample) 
The crude product was then purified via preparative HPLC. Formation of product 
101 was then confirmed using MALDI and analytic HPLC (Figure 4.37). The 
expected ion for calixarene 101 ([M+H+]) was found at 3811.8 in the MALDI 
spectrum with high purity (96.4%).  
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Figure 4.37 Analytical HPLC trace (solvent trace substracted) of purified 
calixarene conjugate 101 and MALDI mass spectrum of 101 
4.4  Conclusions 
In this study, a novel cyclic peptide-dye conjugate 99 and cyclic RGD-appended 
calixarene-based fluorescent probe 101 were synthesised and characterised. This 
was acheived through the synthesis of a novel cyclic RGD peptide, 83, bearing a 
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propargyl group for ‘click’ reactions. It was shown that this peptide can be utilised 
in ‘click’ reactions using a chelated copper source. It was also shown that when 
azido functionalite was directly attached to the upper rim of the calixarene ‘click’ 
reactions with cRGDfS(OPrp), using CuSO4 and sodium ascorbate were 
unsucesful. This is likely to be due to steric hinderance on the upper rim although 
the role of the copper source may also be important. 
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5.1  Overview 
This thesis has described one i-motif ligand screen method and the application of 
calix[4]arene to target DNA secondary structures and integrin. Chapter 1 provides 
a comprehensive overview of DNA, focusing on DNA secondary structures. 
Particular emphasis has been placed on i-motifs, including their biological 
relevance, methods for studying them and current ligands. 
In Chapter 2, an i-motif ligand screening method was established based on 
fluorescent intercalator displacement. Five fluorescent probes were tested and 
thiazole orange was chosen as the fluorescent intercalator due to its ‘light-up’ 
fluorescent properties upon binding to human telomeric i-motif. The binding 
stoichiometry and stabilisation effect of thiazole orange towards human telomeric 
i-motif was also studied. The feasibility and accuracy of this screening method was 
evaluated with previously known i-motif binding ligands, such as mitoxatrone, 
TMPyP4, tilorone and tamoxifen. A plate reader based i-motif ligands screen was 
then developed using thiazole orange and human telomeric i-motif. The high-
throughput screen method was assessed with a compound library containing 960 
biologically active ligands. It was found that tobramycin was an effective ‘hit’ 
compound in the screen, which interestingly did not show noticeable activity in a 
comparative screen based on FRET DNA melting. The binding of tobramycin 
towards human telomeric i-motif was further studied via SPR and circular 
dichroism. The binding affinity of tobramycin was found to be of the same 
magnitude (23 ± 3.7 μM) as that for mitoxatrone, a previously known i-motif 
binding ligand. However, it was also found that tobramycin binds to duplex DNA 
structure with even higher affinity, indicating poor selectivity between different 
DNA secondary structures. 
In Chapter 3, the synthesis of five calixarene conjugates tethered with DNA binding 
moieties was described. The interaction of two compounds, 28 and 54, were studied 
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with G-quadruplexes and i-motifs DNA sequences due to their relatively good 
solubility in water. FRET DNA melting experiments indicated that both 28 and 54 
were able to condense G-quadruplex and i-motif forming sequences from human 
telomere and c-MYC promoter. This calixarene-conjugatre induced DNA 
condensation is stable at acidic pH even at 95°C. However, it was shown to be 
reversible at pH 7.4 when heat was applied. The DNA condensation induced by 28 
and 54 was verified using other experiments, including FRET titration, circular 
dichroism and FID assay.  
In Chapter 4, a proof-of-concept study exploring the binding of peptide 
functionalised calix[4]arenes to integrin cell membrane receptors was described. A 
cyclic RGD peptide featuring an alkyne group, 83, was designed and synthesized 
using a solid phase Fmoc strategy. This was combined, through ‘click’ chemistry, 
with a calixarene functionalized with a fluorescent coumarin dye motif. Direct 
introduction of the cyclic peptide at the upper-rim was not successful and may be 
due to either steric hinderance at the upper-rim or the choice of catalytic copper (I) 
source. In contrast, the ‘click’reaction between 83 and 93 was successful and the 
product 101 was purified using preparative HPLC and confirmed by MALDI. 
5.2  Future work 
Due to the fact that this thesis is divided into three components, future works will 
be described in the chapter order. 
In Chapter 2, a high-throughput i-motif screen had been performed on a compound 
library containing 960 ligands. The result was the first time to show tobramycin 
binds to human telomeric i-motif structure. Thus the future work for this chapter 
will be further exploring other compound libraries with high-throughput screen 
method as well as the binding studies of tobramycin. 
In our group, there is another compound library available for ligand screen, which 
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contains another 1500 bioligically active ligands. This library can be used with FID 
high-throughput screen method in the future, aiming to find more i-motif binding 
compounds as well as further testing the accuracy of this high-thoughput screen 
method.  
Further exploring tobramycin will give us more information about its binding 
towards human telomeric i-motif. Mass spectrometry,342 X-Ray diffraction343,344 
and NMR345,346 are all within the scope in the following studies. These tools will 
provide detailed information about the binding between human telomeric i-motif 
and tobramycin, which paves the way to achieve structural selectivity via 
modifying tobramycin in the future.  
In Chapter 3, 28, 54 and 58 were proved to reversibly condense various 
oligonucleotides with at pH 7.4. However, their abilities has not been compared to 
other commonly used amphiphilic calixarenes in the same conditions yet. Thus in 
the next step, other calixarenes featuring longer aliphatic chain (> 3) and amine 
functionalised upper rim can serve as comparisons to 28, 54 and 58. 
In order to study 28, 54 and 58, other experimental techniques such as 
polyacrylamide gel electrophoresis and dynamic light scattering, can be applied as 
well. Gel electrophoresis provides more accurate information about the condensing 
of oligonucleotides while dynamic light scattering provides the size of 
condensation particles directly.347,348 Both of these techniques have been used to 
study calixarene induced DNA condensation before. Apart from these two 
techniques, SPR can also be used to directly study the binding affinity of calixarene 
conjugates with oligonucleotides.  
For Chapter 4, future work will involve the testing of 99 and 101 with integrin 
positive/negative cell lines and integrin binding ligands or antibodies. Synthetically 
additional conjugates featuring NIR active dye molecules, to achieve in situ tumour 
imaging in animal models could be prepared. Additionally the cyclic peptide 83 can 
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be conjugated to other systems, such as nanoparticles or nanocarriers to achieve 
integrin targeting.  
Finally, there are currently no examples of calixarenes functionalised with 
oligonucleotides or PNA sequences and their application in targeted drug delivery. 
Building on the integrin targeted calix[4]arene, the lower rim could be 
functionalised with DNA and drug molecules incorporated through annealing with 
complimentary DNA/RNA sequences. Dissociation of the structure and release of 
the drug could then be achieved following internalization through i-motif formation 
at endosomal pH (Scheme 5.1). A similar approach has previously been described 
for gold nanoparticles based delivery.12,349 
 
Scheme 5.1 Proposed oligonucleotide-grafted calixarene conjugates for 
targeted cytotoxicity 
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6.1  General procedures 
All chemicals were purchased from Sigmal-Aldrich, Acrôs Organics, Alfa Aesar, 
MerckMillipore or Thermo Fisher Scientific and used without any further 
purification. 
NMR spectroscopy was performed at 293K, unless otherwise stated, using a 
Bruker Ultrashield Plus 400 MHz spectrometer (operating at 400 MHz for proton 
and 100 MHz for carbon). Deutrated solvents for NMR spectroscopy were obtained 
from VWR international, Sigmal-Aldrich and Goss scientific. The NMR spectra 
were processed with MestReNova (version 6.0.2-5475). The spectra were 
calibrated to the residual deuterated solvent peak. Chemical shifts in 1H NMR 
spectrum are presented in δ (ppm) followed by brackets containing multiplicity(s: 
singlet, d: doublet, t, triplet, q:quartet, m: multiplet, br:broad). 13C NMR spectras 
are only presented with chemical shifts. 
Thin-layer chromatography was performed with Merck Kieselgel 60 F254 plates 
and spots were visualized with UV-light or stained using ninhydrin or p-
anisaldehyde.  
Column chromatography was performed with Aldrich 60 silica gel at room 
temperature with a positive pressure of air. 
Melting points were measured with an electrothermal Mel-temp melting point 
apparatus.  
Infrared spectroscopy were performed with an FT-IR spectrometer with ATR 
attachment. The data are presented in wavenumbers (cm-1). 
Opitical rotation of chiral compounds were measured via an ADP220® 
polarimeter at 25°C.  
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Oligonucleotides were purchased from Eurogentec, purified via reverse-phase 
HPLC. Solid DNA samples were dissolved in MilliQ water to prepare stock 
solution of 100 μM for labelled and 1 mM for unlabelled oligonucleotides. Final 
concentration of oligonucleotide stock were confirmed via UV absorbance at 260 
nm with a Nanodrop® ND-1000 spectrophotometer according to the calculated 
extincition coefficients provided by Eurogenetec.  
Name  Sequence 5ʹ to 3ʹ 
hTeloG d(GGGTTAGGGTTAGGGTTAGGG) 
hTeloC d(TAACCCTAACCCTAACCCTAACCC) 
c-MYCC d(TCCCCACCTTCCCCACCCTCCCCACCCTCCCCA) 
FREThTeloG FAM-d(GGGTTAGGGTTAGGGTTAGGG)-TAMRA 
FRETDS FAM-d(TATAGCTATA-HEG(18)a-TATAGCTATA)-TAMRA 
FREThTeloC FAM-d(TAACCCTAACCCTAACCCTAACCC)-TAMRA 
FRETc-MYCC FAM-d(TCCCCACCTTCCCCACCCTCCCCACCCTCCCCA)-TAMRA 
FRETHIF-1αC FAM-d(CGCGCTCCCGCCCCCTCTCCCCTCCCCGCGC)-TAMRA 
BiotinhTeloC Biotin-d(TAACCCTAACCCTAACCCTAACCC) 
Biotinc-MYCC Biotin-d(CCTTCCCCACCCTCCCCACCCTCCCCA) 
BiotinDS Biotin-d(GGCATAGTGCGTGGGCGTTAGC) 
complimentDS  d(GCTAACGCCCACGCACTATGCC) 
Table 5.1 Oligonucleotide sequences used in Chapter 2 and Chapter 3 
a HEG(18), Hexaethylene glycol 18 ,is a spacer between two complementary sqeuences of duplex 
DNA sequences. 
DNA annealing was performed by heating the sample at 95°C in a heat block for 
5 minutes and then cooling down to room temperature slowly overnight.  
High-resolution Mass Spectrometry were performed with LTQ orbitrap XL, 
ultrafleXtreme (MALDI) or Xevo G2-S and recorded by the EPSRC UK National 
Mass Spectrometry Facility in Swansea University.  
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MALDI-TOF mass spectroscopy were carried out with a Kratos Axima CFR 
MALDI Mass Spectrometer. α-cyno-4-hydroxycinnamic acid was used as matrix. 
Analytical RP-HPLC were carried out with an Agilent Technologies 1200 series 
chromatograph with an Agilent Technologies® ZORBAX Eclipse XDB-C18 (5 μM, 
4.6 x 150mm) at 25°C.  
Solvent A: 100% HPLC-grade methanol + 0.1% TFA. 
Solvent B: 100% MilliQ-water + 0.1% TFA. 
Gradient: Solvent A to Solvent B in 25 minutes. Flow rate = 1 mL/min. Detection 
wavelength = 214 nm/254 nm.  
Semi-preparative RP-HPLC were carried out with Agilent Technologies 1200 
series chromatograph with an Agilent Technologies ZORBAX Eclipse XDB-C18 
(5 μm, 9.4 × 250 mm) column with a flow rate of 4 mL/min (same gradient as used 
in analytical RP-HPLC). 
Preparative RP-HPLC were carried out with an Agilent 1260 Infinity using an 
Agilent Eclipse XDB-C18 column (5 μM, 21.2 × 150 mm).  
Solvent A: 5% methanol in water + 0.05% TFA. 
Solvent B: 5% water in methanol + 0.05% TFA. 
Gradient: Solvent A to Solvent B in 20 minutes. Flow rate = 20 mL/min. Detection 
wavelength = 254 nm.  
Data obtained in the studies was processed by Microsoft Office Excel and 
presented in Origin 8.0. 
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6.2  Experimental for Chapter 2 
6.2.1 Fluorescence Spectroscopy 
Fluorescence spectra were measured on a Horiba Jobin Yvon Fluorolog® 
fluorimeter with a Starna Scientific type 28/9-F quartz cuvette with 1 cm path 
length. All experiments were performed in triplicate. 
DMSO stock solutions of the probes were diluted to 2.5 μM in 10 mM sodium 
cacodylate buffer at pH 5.5. DNA samples were prepared by diluting to 500 μM in 
10 mM sodium cacodylate buffer at pH 5.5. In the experiments, 200 μL of probe 
(2.5 μM) was added into the cuvette then 1 μL of DNA (at 500 µM) was added to 
mimic the 1:1 binding event. After mixing and allowing 5 minutes to equilibrate, 
spectra were measured using the following settings: 1.0 nm increment, 0.5 
integration time and 5 nm excitation and emission slit widths. The fluorescence was 
measured at the respective excitation and emission maxima.   
Flouorescence enhancement measurements on TO were performed in collaboration 
with Tasnim Mahmound, using TO diluted to 5.0 μM in 10 mM sodium cacodylate 
buffer at pH 5.5. DNA samples were diluted to 100 μM in 10 mM sodium 
cacodylate buffer at pH 5.5. In the experiments, 200 μL of TO (2.5 μM) was added 
to the cuvette and a fluorescence spectrum taken to observe the fluorescence in the 
buffer conditions in the absence of DNA. DNA was then titrated into the sample 
using the prepared 100 µM stock, mixed, allowed to equilibrate for 5 minutes then 
excited at 430 nm; fluorescence emission spectra were measured from 440 to 650 
nm.  
6.2.2 UV Spectroscopy 
UV spectroscopy was performed in collaboration with Joe Neaverson. Samples 
were measured using an Agilent Technologies Cary 60 UV-vis spectrophotometer 
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with a Starna Scientific type 28/9-F quartz cuvette of 1 cm path length. The samples 
were scanned over a range of 350-550 nm at a rate of 300 nm/s with a data interval 
of 0.5 nm at room temperature. Samples containing only buffer were measured and 
subtracted from the data. All experiments were performed in triplicate. 
Continuous variation (Job’s) binding analysis was performed on measuring the UV 
absorbance of TO. 200 µL samples containing hTeloC DNA with TO were made 
up in 10 mM, pH 5.5 sodium cacodylate buffer. The individual concentrations of 
DNA and TO varied between 0 and 20 µM but the total concentration of DNA + 
TO remained constant at 20 µM. Job plots were constructed by plotting UV 
absorbance at 497.5 nm against the ratio of TO to hTeloC i.e. [TO]/([TO] + 
[hTeloC]).  
UV titrations to determine binding affinity were performed using hTeloC (5 µM) 
in 50 mM sodium cacodylate buffer at pH 5.5. 10 μM stock of TO was prepared in 
sodium cacodylate 50 mM buffer at pH 5.5 for titration into the 200 µL cuvette 
filled with 5 µM hTeloC to give concentrations of 0, 1.25, 2.5, 3.75, 5, 7.5, 10, 15 
and 20 µM. The UV-vis spectra of 50 mM sodium cacodylate buffer at pH 5.5 with 
cooresponding amount of DMSO was recorded and subtracted from data obtained 
with TO. Experiments were performed in triplicate.  
Binding curve fitting by least squares method was carried out using different 
binding models corresponding to 1:1 (Equation 2.1 in Section 2.3.2), 2:1 (Equation 
2.2 in Section 2.3.2) and n:1 (Equation 5.1) stoichiometry.130-132 
1:1 binding model 
[𝑇𝑂] + [𝐷𝑁𝐴] ⇌ [𝑇𝑂 ∙ 𝐷𝑁𝐴]                                  𝐾1 
Equation 2.1     
𝜃 =
𝑛𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
       𝑛 = 1 
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Where: θ = fraction of binding measured, K1 = equilibrium association constant for 
the binding sites.131,132  
2:1 independent binding model 
[𝑇𝑂] + [𝐷𝑁𝐴] ⇌ [𝑇𝑂 ∙ 𝐷𝑁𝐴]                                  𝐾1 
[𝑇𝑂 ∙ 𝐷𝑁𝐴] + [𝑇𝑂] ⇋ [𝑇𝑂 ∙ 𝐷𝑁𝐴 ∙ 𝑇𝑂]                𝐾2 
Equation 2.2    
θ = fraction of binding measured, K1 and K2 = equilibrium association constants for 
the first and second binding sites.130-132  
n:1 binding model (multiple independent binding sites) 131,132 
𝑛[𝑇𝑂] + [𝐷𝑁𝐴] ⇌ [𝑛𝑇𝑂 ∙ 𝐷𝑁𝐴]                            𝐾1 
Equation 5.1     
θ = fraction of binding measured, K1 = equilibrium association constant for the 
binding sites, n = number of independent binding sites 131,132 
6.2.3 Circular dichroism spectroscopy. 
Circular dichroism spectroscopy was performed in collaboration with Joe 
Neaverson. Oligonucleotides (10 µM) were diluted in buffer at the respective pH 
and concentration as detailed, to give a total volume of 200 µL for each sample and 
were annealed. Circular dichroism spectra were recorded using a Jasco J-810 
spectropolorimeter with a Starna Scientific type-21 quartz cuvette of 1 mm path 
length. Scans were performed at room temperature from 220 nm to 320 nm with a 
𝜃 =
𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑] + 2𝐾1𝐾2[𝐿𝑖𝑔𝑎𝑛𝑑]
2
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑] + 𝐾1𝐾2[𝐿𝑖𝑔𝑎𝑛𝑑]2
 
𝜃 =
𝑛𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
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scanning speed of 200 nm/min, a response time of 1 s, pitch of 0.5 nm and a 
bandwidth of 2 nm. Blank samples containing only the respective buffer were 
recorded and subtracted from the data obtained later. For each sample, TO or 
tobramycin was titrated directly into the cuvette containing the DNA using pipette 
and solutions were thoroughly mixed and given an equilibrium time for 5 minutes 
before recording spectra. All spectra at each aliquot shows an average of three scans.  
6.2.4 FRET melting experiments. 
FRET melting experiments were performed in collaboration with Joe Neaverson. 
Solutions of fluorescently labelled DNA (0.4 µM) were made up in sodium 
cacodylate buffer at the respective concentration and pH as detailed and annealed. 
Thiazole orange 50 µM was prepared in sodium cacodylate. Serial dilutions of 25, 
12.5, 6.25, 3.125, 1.56 and 0 µM thiazole orange were used in combination with 
0.4 µM of each FRET-labelled DNA sequence for the FRET melting experiments 
by pipetting 10 µL of each appropriate DNA and thiazole orange solution (total 20 
µL) into PCR tubes from QIAgen. The samlples in the PCR strips were heated from 
25 to 95°C at a rate of 1°C per minute. Fluorescence melting curves were obtained 
using a QIAgen Rotor-Gene Q-series PCR machine using an excitation wavelength 
of 483 nm and detection wavelength of 533 nm. Each experiment was performed 
in duplicate.  
6.2.5 i-motif FID assay using TO.   
TO was diluted to 2 µM sample in 10 mM sodium cacodylate buffer at pH 5.5. 
hTelo i-motif in water was used without being annealed and made into 50 µM stock 
in buffer. Tested ligands, including TmPYP4, tilorone, mitoxatrone, tamoxifen and 
tyrothyricin, was prepared into 50µM in 10 mM sodium cacodylate buffer at pH 
5.5. 196 µL of TO sample was added into a Starna Scientific type 28/9-F quartz 
cuvette of path length of 1 cm. Fluorescence spectra were measured on a Horiba 
Jobin Yvon Fluorolog fluorimeter, excited at 430 nm. The excitation and emission 
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slit width were both set as 3 nm. The integration time was set as 0.1 s and increment 
was set as 10.0 nm. The resulting background emission fluorescence intensity at 
450 nm was normalised as 0%. To this solution, 4 µL of hTelo-i-motif was added 
and mixed with the TO sample. 5 minutes later, a second background fluorescence 
spectrum was taken when the sample was excited at 430 nm. The fluorescence 
emission intensity here at 450 nm was normalized as 100% fluorescence. Then the 
respective ligand was titrated in 1 µL aliquots and the emission spectrum measured 
from 450 nm to 650 nm.  
6.2.6 HT-IM-FID assay 
Each IM-FID assay was conducted in a 384-well microplate (Corning® Low 
Volume 384 well Black Flat Bottom Polystryrene NBS TM Microplate). The 
temperature was kept constant at 25°C during the whole experiment. Wells on the 
microplate were filled with 40 μL of a pre-prepared testing cocktail ([hTeloC]= 
0.5 μM, [TO]= 1.0 μM, [sodium cacodylate]= 10 mM, pH= 5.5). Then 0.5 μL 
ligand solution (1 mM in DMSO) was added into each well. At least three control 
wells on each plate were prepared of just DNA in buffer and another three reference 
wells on each plate were prepared with DNA and TO in buffer. Plates were read 
ising a BMG CLARIOstar plate reader. The excitation filter in the experiments 
were set from 400 to 430 nm, the emission filter was set from 460 to 480 nm. The 
read of the signal was defined as the intergration of fluorescent intensity from 460 
to 480 nm. Each scan was carried out three times. The basal fluorescence signal 
(Fc0) were assigned as the average fluorescence intensity read from the control well. 
The 100% fluorescence intensity read (Freference) was assigned as the average 
fluorescence intensity read from reference wells. The average of three read (Fread) 
was calculated into Dx for each compound via Equation 2.3 in Section 2.3.4.  
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Equation 5.2    𝐷𝑥 = 1 −
𝐹𝑥
𝐹0
= 1 −
𝐹𝑟𝑒𝑎𝑑−𝐹𝑐0
𝐹𝑟𝑒𝑓𝑒𝑟𝑒𝑒𝑛𝑐𝑒−𝐹𝑐0
        
Hit compounds were ranked according to Dx.  
6.2.7 Surface Plasmon Resonance 
Dr Clare Stevenson in John Innes Center kindly performed SPR experiments for 
the studies. These experiments were performed on a Biacore T200 instrumnet 
manufactured by GE Healthcare with a series S streptavidin (SA) coated gold chip 
(Biacore SA-chip). Experiments were carried out in a filtered and degassed running 
buffer (10 mM sodium cacodylate, 100 mM sodium chloride and 0.05% Tween, pH 
5.5).  
Oligonucleotide immobilisation 
Biotin-tagged hTeloC (biotinhTeloC) and c-MYCC (biotinc-MYCC) oligonucleotides 
were diluted to 1 μM in the running buffer while Biotin-tagged DS oligonucleotide 
(biotinDS) were annealed with its complimentary oligonucleotide (complimentDS) at 
1 μM in the running buffer. Biotinlated oligonucleotides were then injected at a 
flow rate of 10 μL/min in flow cells 2, 3 and 4, leaving the flow cell 1 empty s a 
blank. The success of oligonucleotide immobilization was checked via the sensor, 
reaching appromximate 500 response unit (RU).  
Tobramycin titration 
Tobramycin were diluted in the running buffer from 10 mM stock solution in 
DMSO to concentrations of 500, 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 
0.39 and 0 μM via serial dilutions.  
Tobramycin was tested for its binding affinity towards hTeloC, c-MYCC and 
duplex DNA using the affinity run wizards in the BIAcore T200 software at 25 °C. 
In a typical injection, samples were injected for 2 min as a flow rate of 30 μL/min, 
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followed by two 1 min injection of 1 M NaCl an one 1 min injection of running 
buffer for chip regeneration.  
The SPR experiments started with three startup (blank) cycles. Each of them were 
performed with blank injections of buffer only. Tobramycin in different 
concentrations was tested from 0 μM to 500 μM. 
The RU obtained was double referenced by substrating the three startup cycles and 
injections of buffer. Average equilibrium response for each injection was fitted 
using the affinity fit from the BIAcore T200 evaluation software v2.0 with a 1:1 
binding model (Equation 2.6 in Section 2.3.8). The data obtained were the average 
of two repeat runs.  
Equation 2.6     
Herein, θ is the fraction of binding. Req is the response read at equilibrium from the 
sensorgram at a given concentration whilst Rmax is the largerst response read at 
saturation. The binding constant Kd was defined as 1/K1.
132   
Ligand screening 
Hit compounds in Section 2.3.7 were tested at 50 μM in pH 5.5 running buffer 
(100 mM sodium chloride, 10 mM sodium cacodylate, 0.05% Tween). 
Oligonucleotide immobilization and ligand testing have been decribed previously. 
The response (RU) were measured only at 50 μM (ligand concentration) upon 
binding to DNA, which is propotional to the molecular mass on the chip surface. 
The theoretical Rmax was describes in an 1:1 binding stoichiometry (Equation 2.5 in 
Section 2.3.7) 
Equation 2.5   𝑅𝑚𝑎𝑥 =  
𝑀𝑊𝑙𝑖𝑔𝑎𝑛𝑑
𝑀𝑊𝑜𝑙𝑖𝑔𝑜
×𝑅𝑈𝑜𝑙𝑖𝑔𝑜×𝑖.  
𝜃 =  
𝑅𝑒𝑞
𝑅𝑚𝑎𝑥
=
𝑛𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
1 + 𝐾1[𝐿𝑖𝑔𝑎𝑛𝑑]
       𝑛 = 1 
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Herein the MWligand stands for the molecular weight of tested ligands whilst MWoligo 
stands for the molecular weight of the immobilised oligonucleotides on the chip. 
RUoligo is the average respond read of startup runs measured in SPR experiments 
(injections without ligands). i is the pre-set stoichiometry of binding, which equals 
1 if it is a 1:1 binding stoichiometry.  
6.3  Experimental for Chapter 3 
6.3.1 Synthesis of p-tert-butylcalix[4]arene 
The synthesis of p-tert-butylcalix[4]arene was performed according to literature.221 
 
5, 11, 17, 23-p-tert-butylcalix[4]arene (29) 221 
p-tert-butylphenol (200.0 g, 1.33 mol), NaOH (2.40 g, 60 mmol) and formaldehyde 
(130 mL, 37% wt, 1.74 mol) were mixed in a 3 L flange flask. The reaction mixture 
was heated to 120°C for 2 hours with mechanical stirring. The resulting orange-
coloured viscous solid were re-dissolved in diphenyl ether (1 L). A steam of air was 
introduced to the surface of diphenyl ether solution for at least 1 hour to remove 
the excess water in the reaction mixture. Then the reaction mixture was heated to 
reflux for another 3 hours. 1 L of ethyl acetate was added to the reaction mixture 
after it had been cooled to RT. The resulting crude product precipitated and was 
filtered. Then the crude product was washed with ethyl acetate (2 × 100 mL), acetic 
acid (2 × 50 mL), water (2 × 50 mL) and acetone (100 mL). After being dried in 
the oven (120 °C) overnight, the product was an off-white crystal powder 29 (90.53 
g, 42% yield). 1H NMR (400MHz, CDCl3) δ 10.34 (br s, 4H, ArOH), 7.91 (br s, 
8H, ArH), 4.26 (d, J = 13 Hz, 4H, ArCH2Ar),3.49 (d, J = 13 Hz, 4H, ArCH2Ar), 
1.21 ( br s, 36H, C(CH3)3), IR ν 3158, 2952, 2901, 2870, 2351, 1738, 1704, 1605, 
1556, 1538, 1480, 1472, 1467, 1454, 1392, 1361, 1305, 1231, 1199, 1123 cm-1, 
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Melting point: 344-346°C (decomposed). The spectroscopic data are consistent 
with that reported in the literature.221 
6.3.2 Preparation of calix[4]arene platforms 
Synthesis of calixarene platforms are, including mono-propargylated, 1,2- and 1,3- 
dipropargylated calixarenes following established methods in Matthews’ group. 
197,226 
 
5, 11, 17, 23-Tetra-tert-butyl-25, 26, 27-tripropoxy-28-hydroxy-calix[4]arene 
(30) 226  
A mixture of 29 (20.11 g, 31.03 mmol, 1 eq), barium oxide (7.15 g, 46.78 mmol, 
1.5 eq) and barium hydroxide octa-hydrate (33.82 g, 107.35 mmol, 3.45 eq) in 300 
mL of DMF was heated to 30°C for 45 minutes. n-Propyl bromide (60 mL, 660 
mmol, 20.0 eq) was then added into the reaction mixture and stirred for 18 hours at 
30°C. The cream colored reaction mixture was quenched with the addition of dilute 
HCl (10%, 100 mL). The reaction mixture was then extracted with DCM (3 × 200 
mL). The resultant organic phase was further washed with dilute HCl (10%, 3 × 
100 mL) and brine (2 × 200 mL) and then dried over anhydrous MgSO4. The 
solvent was removed in vacuo and a cream colored solid was obtained. The final 
white-crystalline product 30 (16.5 g, 69% yield) was recovered by triturating from 
DCM/methanol. 1H NMR (CDCl3, 400MHz) δH ppm= 7.13 (s,2H), 7.04 (s, 2H), 
6.50 (s, 4H), 5.57 (s, 1H), 4.36 (d, J = 15 Hz, 2H), 4.32 (d,  J = 15 Hz, 2H), 3.84 
(t, J = 8 Hz, 2H), 3.74 (t, J = 7.0 Hz, 2H), 3.22 (d, J =13.0 Hz, 2H), 3.15 (d, J =13.0 
Hz, 2H), 2.38-2.27 (m, 2H), 2.07-1.78 (m, 4H), 1.54 (s, 3H), 1.33 (s, 9H), 1.31 (s, 
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9H), 1.09 (t, J = 7.0 Hz, 6H), 0.94 (t, J =7.0 Hz, 3H), 0.82 (s, 18H), IR ν 3520, 
2957, 2872, 1694, 1603, 1555, 1537, 1481, 1477, 1386, 1360, 1298, 1240, 1196, 
1121, 1108cm-1, Melting point: 200-202°C. The spectroscopic data are consistent 
with those reported in the literature.226 
 
5, 11, 17, 23-Tetra-tert-butyl-25, 26, 27-tripropoxy-28-propargyloxy-
calix[4]arene (31) 177  
Calixarene 30 (16.5 g, 21.65 mmol, 1.0 eq) was stirred in 430 mL DMF stirring at 
room temperature. Sodium hydride (2.03 g, 84.58 mmol) was carefully added into 
the reaction mixture, followed after one hour by addition of propargyl bromide 
toluene solution (80% w/w in toluene, 10.63 g, 71.5 mmol). The reaction mixture 
was stirred for 18 hours, then quenched by addition of 400 mL water. The resultant 
white precipitate was collected by filtration. The precipitate was redissolved in 
methanol/DCM and the resultant brown organic phase was washed with dilute HCl 
(10%, 100 mL) and then brine (3 × 250 mL). The organic phase was dried over 
MgSO4, filtered and concentrated, to obtain sticky brown-colored oil. After 
trituration in methanol/DCM, the final product 31 was recovered as white-colored 
crystals (13.8 g, 80% yield). 1H NMR (CDCl3, 400 MHz) δH ppm= 7.02 (s, 4H), 
6.60 (d, J = 2.0 Hz, 2H), 6.54 (d, J = 2.0 Hz, 2H), 4.98 (d, J =2.0 Hz, 2H), 4.53 (d, 
J =13 Hz, 2H), 4.45(d, J= 13 Hz, 2H), 3.93 (t, J = 7.5Hz, 2H), 3.75 (t, J = 7.5 Hz, 
4H), 3.17 (d, J = 2.0 Hz, 2H), 3.14 (d, J =2.0 Hz, 2H), 2.40 (t, J = 2.0 Hz, 1H), 
2.22-2.08 (m, 2H), 2.06-1.93 (m, 2H), 1.56 (s, 1H), 1.28(d, J = 2.0 Hz, 18H), 1.07 
(t, J =7.5 Hz, 6H), 1.02 (t, J =7.5 Hz, 3H), 0.92 (s, 18H); IR ν 3561, 3478, 2956, 
2876, 2856, 1973, 1573, 1537, 1479, 1488, 1467, 1385, 1360, 1299, 1238, 1195, 
1122 cm-1; Melting point: 213-215°C. The spectroscopic data are consistent with 
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those reported in the literature.177 
 
5, 11, 17, 23-Tetra-nitro-25, 26, 27-tripropoxy-28-propargyloxy-calix[4]arene 
(32) 
Calix[4]arene 31 (6.5 g, 8.45 mmol, 1.0 eq) was dissolved in DCM (100mL) and 
stirred vigorously in a 250 mL round bottom flask. Then glacial acetic acid (35 mL, 
612.0 mmol) and nitric acid (98%, 35 mL, 840.4 mmol) were added into reaction 
mixture slowly. The color of the reaction mixture turned to dark-blue when 
concentrated nitric acid was added. The color of the reaction mixture turned slowly 
from dark-blue to orange over 5 minutes. After stirring for 20 minutes, the reaction 
mixture was quenched with addition of water (100 mL). After stirring for a further 
10 minutes, the reaction mixture was separated and the aquenous layer was 
extracted with additional DCM (50 mL). The organic layer was combined and then 
washed with brine (2 × 75 mL). The organic layer was dried over anhydrous MgSO4 
and DCM was evaporated in vacuo. The crude solid product was then redissolved 
in a small amount of DCM (≤ 5 mL) and then precipitated in methanol overnight 
to afford a pale-yellow colored solid as the pure product 32 (3.9g, 63% yield). 1H 
NMR (400MHz, CDCl3) δ 8.07 (s, 2H, ArH), 8.06(s, 2H, ArH), 7.16 (s, 4H, ArH), 
4.92(d, J = 2Hz, 2H, OCH2CCH), 4.60(d, J = 14Hz, 2H, ArCH2Ar), 4.55 (d, J = 14 
Hz, 2H, ArCH2Ar), 4.14 (t, J = 8 Hz, 2H, OCH2CH2CH3), 3.82 (t, J = 7 Hz, 4H, 
OCH2CH2CH3), 3.44 (d, J = 14 Hz, 2H, ArCH2Ar), 3.42 (d, J = 14 Hz, 2H, 
ArCH2Ar), 2.51 (t, J = 2 Hz, 1H, OCH2CCH), 1.98-1.87 (m, 6H, OCH2CH2CH3), 
1.10 (t, J = 8 Hz, 6H, OCH2CH2CH3), 0.97 (t, J = 7Hz, 3H, OCH2CH2CH3); 13C-
NMR (101 MHz, CDCl3) δ 162.8, 160.9, 160.2, 143.8, 142.9, 137.9, 136.6, 134.5, 
134.2, 124.8, 124.7, 123.4, 123.3, 78.2, 78.2, 78.0, 77.1, 60.7, 31.5, 31.1, 23.5, 23.4, 
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10.6, 10.0. IR: ν 3417, 3170, 2972, 2923, 1700, 1596, 1532, 1482, 1466, 1370, 
1366, 1296, 1240, 1214, 1152, 1060 cm-1; HRMS (ESI): calculated for 
C40H36N4O12H ([M+H]+): 769.2721. Found: 769.2708; Melting Point: 175-177 °C. 
 
5,11,17,23-Tetra-Boc-amino-25,26,27-tripropoxy-28-
propargyloxycalix[4]arene (33) 
Tin(II) chloride dehydrate (19.38 g, 85.89 mmol) was added to a mixture of 32 in 
ethanol (200 mL). The reaction mixture was heated to 90°C and stirred for 24 hours. 
The solvent was evaporated and the resulting white-pink solid was dissolved in 
NaOH (200 mL, 10%) and DCM (100 mL). Then the organic phase was separated 
and the aqueous phase was extracted with DCM (50 mL) and EtOAC (50 mL). The 
organic phases were combined and dried with Na2SO4 and the solvent was 
evaporated to obtain a brown-coloured crystalline solid (2.8 g). The solid was 
dissolved in DCM (100 mL) and Boc anhydride (10 g, 45.6 mmol) and DIPEA (3 
mL, 18.2 mmol) were added. The mixture was stirred for 18 hours before removal 
of the solvent in vacuo. Column chromatography (eluent: DCM:EtOAc = 15:1) 
afforded the product 33 as a white solid (1.23 g, 25 % yield). 1H-NMR (400MHz, 
CDCl3) δ 7.05 (s, 2 H, ArH), 7.04 (s, 2 H, ArH), 6.37 (s, 2 H, NHBoc), 6.26 (s, 2 
H, ArH), 6.24 (s, 2 H, ArH), 5.90 (s, 2 H, NHBoc), 4.85 (d, J = 3 Hz, 2 H, 
OCH2CCH), 4.43 (d, J = 13 Hz, 2 H, ArCH2Ar), 4.36 (d, J = 13 Hz, 2 H, ArCH2Ar), 
3.92 (t, J = 8 Hz, 2H, OCH2CH2CH3), 3.63 (t, J = 6 Hz, 4 H, OCH2CH2CH3), 3.10 
(d, J = 13 Hz, 2 H, ArCH2Ar), 3.08 (d, J = 13 Hz, 2 H, ArCH2Ar), 2.31 (t, J = 3, 1 
H, OCH2CCH), 1.96-1.81 (m, 6 H, OCH2CH2CH3), 1.53 (s, 9 H, C(CH3)3), 1.53 (s, 
9 H, C(CH3)3), 1.43 (s,18 H, C(CH3)3), 1.02 (t, J = 7 Hz, 6 H, OCH2CH2CH3), 0.90 
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(t, J = 7 Hz, 3 H,OCH2CH2CH3). 13C NMR (100Hz, CDCl3) δ 153.7, 153.4, 153.2, 
153.1, 152.4, 150.9, 137.8, 136.7, 134.0, 133.7, 133.3, 132.5, 132.0, 120.43, 120.4, 
119.4, 119.0, 81.0, 80.3, 80.3, 80.0, 74.7, 59.6, 31.7, 31.1, 28.6, 23.5, 23.2, 10.9, 
10.2; IR ν 3424, 2978, 2930, 2874, 1730, 1700, 1596, 1532, 1526, 1466, 1418, 
1366, 1296, 1242, 1214, 1152, 1060 cm-1; HRMS (ESI): calculated for 
C60H80N4O12NH4 [M+NH4]: 1066.6111, Found: 1066.6107 ;Melting Point: 182-
184 °C 
 
5, 11, 17, 23-Tetra-tert-butyl-25, 26, 27-tripropoxy-28-propargyloxy-
calix[4]arene (34) 226 
K2CO3 (5.66 g, 40.95 mmol) was added to a suspension of 29 (12.04 g, 18.74 mmol) 
in acetone (240 mL). The reaction mixture was heated to reflux for 1 hour. After 
the addition of 1-bromopropane (8.36 mL, 91.96 mmol), the reaction heated at 
reflux for 18 hours. The reaction mixture was filtered after cooling and the filtrate 
was evaporated to obtain the crude product. Then the crude product was re-
dissolved in DCM and the organic phase was washed with water (2 × 200 mL) and 
brine (200 mL). After drying over anhydrous MgSO4, the solvent was removed 
under reduced pressure to obtain a white-coloured solid. 34 was recrystallize from 
DCM/methanol as a white crystalline solid (6.05 g , 46% yield).1H NMR (400MHz, 
CDCl3) δ 7.90 (s, 2H, ArOH), 7.04 (s, 4H, ArH), 6.87 (s, 4H, ArH), 4.30 (d, J =13 
Hz, 4H, ArCH2Ar), 3.95 (t, J = 6.5 Hz, 2H, OCH2CH2CH3), 3.31 (d, J =13 Hz, 4H, 
ArCH2Ar), 2.03 (sext, J = 6.5 Hz, 4H, OCH2CH2CH3), 1.25 (m, 24H, C(CH3)3 
+OCH2CH2CH3), 0.99 (s, 18H, C(CH3)3). IR ν 3298, 2957, 2826, 1697, 1681, 1592, 
1556, 1538, 1485, 1360, 1297, 1200, 1196, 1125 cm-1, Melting point: 251-253°C. 
The spectroscopic data are consistent with that reported in the literature.226 
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5, 11, 17, 23-p-tert-butyl 25, 27-dipropoxy-26, 28-propargylcalix[4]arene (35) 
177 
Sodium hydride (1.3 g, 54.5 mmol) was added to a stirred solution of 34 (5.0 g, 
7.06 mmol) in DMF (250mL). After one hour, propargyl bromide (5 mL, 80 wt% 
in toluene, 56.20 mmol) was added and the reaction mixture was left stirring for 
another 18 hours. After water was added into the mixture, the resulting white 
precipitate was collected by filteration and re-dissolved in DCM (200 mL). The 
organic solution was then washed with water (2 × 100mL) and brine (100 mL). 
After being dried over MgSO4, the organic phase was evaporated under reduced 
pressure to obtain the crude product. The crude product was then titurated in 
DCM/methanol to yield a white-coloured product 35 (4.01 g, 77% yield). 1H NMR 
(400MHz, CDCl3) δ 7.09 (s, 4H, ArH), 6.45 (s, 4H, ArH), 5.01 (d, J = 2.5 Hz, 4H, 
OCH2CCH), 4.52 (d, J = 2.5 Hz, 4H, ArCH2Ar), 3.71 (t, J = 7.5 Hz, 4H, 
OCH2CH2CH3), 3.14 (d, J = 7.5 Hz, 4H, ArCH2Ar), 2.39 (t, J = 2.5 Hz, 2H, 
OCH2CCH), 1.99 (sext, J = 7.5 Hz, 4H, OCH2CH2CH3), 1.32 (s, 18H, C(CH3)3), 
1.07 (t, 6H, J = 7.5 Hz, OCH2CH2CH3), 0.83 (s, 18H, C(CH3)3); IR ν 3280, 2957, 
2862, 1556, 1538, 1479, 1386, 1360, 1300, 1279, 1261, 1240, 1198, 1121 cm-1; 
Melting point: 190-192°C. The spectroscopic data are consistent with those 
reported in the literature.177 
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5, 11, 17, 23-tetra-nitro 25, 27-dipropoxy-26, 28-propargylcalixarene (36) 
Glacial acetic acid (26.9 mL, 470.0 mmol) and 98% nitric acid (26.9 mL, 649 mmol) 
were added to a stirred solution of 35 (4.01 g, 4.96 mmol) in 162.5 mL DCM. The 
resulting blue-dark solution turned into orange after 2 hours. The reaction was 
quenched with addition of ice cold water (50 mL). The organic phase was washed 
with saturated NaHCO3 solution (100 mL), additional water (2 × 100 mL) and brine 
(100mL). After drying over MgSO4, the organic phase was evaporated under 
reduced pressure. The resulting yellow product 36 was collected and purified by 
column chromatography (eluent: DCM: Hexane = 50: 50 to 70: 30, 1.8 g, 48% 
yield). 1H NMR (400MHz, CDCl3) δ 8.20 (s, 4H, ArH), 7.1 (s, 4H, ArH), 5.01 (d, 
J = 2.5 Hz, 4H, OCH2CCH), 4.63 (d, J = 14.0 Hz, 4H, ArCH2Ar), 3.81 (t, J = 7.0 
Hz, 4H, OCH2CH2CH3), 3.45 (d, J = 14.0 Hz, 4H, ArCH2Ar), 2.54 (t, J = 2.5 Hz, 
2H, OCH2CCH), 1.96 (sext, J = 7.0 Hz, OCH2CH2CH3, 4H), 1.12 (t, J = 7.0 Hz, 
6H, OCH2CH2CH3); 13C NMR (100Hz, CDCl3) 160.6, 160.3, 144.0, 143.10, 138.0, 
133.9, 124.8, 123.27, 78.2, 78.2, 77.2, 61.0, 31.4, 23.5, 10.7; IR ν 3292, 2970, 2934, 
2872, 1586, 1518, 1454, 1342, 1266, 1264, 1210, 1160, 1094 cm-1 ; HRMS (ESI): 
calculated for C40H36N4O12H ([M+H]+): 765.2408. Found: 765.2386; Melting 
Point: 185°C (decomposed).  
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5, 11, 17, 23-Tetra-Boc-amino-25, 27-dipropoxy-26, 28-
propargyloxycalix[4]arene (37) 
SnCl2·H2O (18.5 g, 82.00 mmol) was added to a stirred suspension of 36 (4.2 g, 
5.49 mmol) in ethanol (200 mL) and heated at reflux (90°C) for 18 hours. After 
cooling, the solvent was evaporated under reduced pressure and the resulting solid 
was washed with NaOH solution (2 × 100 mL, 10%) and DCM (100 mL). The 
aqueous phase was extracted with DCM twice (2 × 75mL). The organic layer was 
combined, dried over anhydrous MgSO4 and evaporated under vacuum. The 
resulting crude product (2.43 g) was dissolved and stirred directly in DCM (25 mL). 
Boc anhydride (1.99 g, 9.12 mmol) and 0.33 mL DIPEA (0.33 mL, 2.00 mmol) 
were added into the reaction mixture. The reaction was left stirring overnight. Then 
the reaction mixture was evaporated with solvent and purified over column 
chromatography (eluant: DCM:Ethyl acetate = 15:1) to yield an off-white solid 37 
(1.1 g, 19% yield). 1H NMR (400MHz, CDCl3) δ 7.18 (s, 4H, ArH), 6.23 (s, 4H, 
ArH), 4.91 (d, J = 2.5 Hz, 4H, OCH2CCH), 4.47 (d, J = 13.5 Hz, 4H, ArCH2Ar), 
3.62 (t, J = 7.5 Hz, 4H, OCH2CH2CH3), 3.13 (d, J = 13.5 Hz, 4H, ArCH2Ar), 2.35 
(t, J = 2.5 Hz, 2H, OCH2CCH), 1.89 (sext, J = 7.5 Hz, 4H, OCH2CH2CH3), 1.51 (s, 
18H, Boc C(CH3)3), 1.41 (s, 18H, Boc C(CH3)3), 1.06 (t, J = 7.5 Hz, 6H, 
OCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 153.5, 152.3, 152.2, 150.8, 137.80, 
133.5, 133.3, 131.9, 120.3, 118.9, 80.7, 80.2, 79.8, 74.9, 59.9, 31.5, 28.4, 28.4, 23.5, 
10.9. IR: ν 3298, 2964, 2930, 2876, 1690, 1554, 1548, 1522, 1476, 1416, 1368, 
1246, 1210, 1152, 1070 cm-1; HRMS (ESI): calculated for C60H76N4O12NH4 
[M+NH4+]:1062.5798. Found: 1062.5794; Melting point: 181°C (decomposed).  
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5, 11, 17, 23-p-tert-butyl-25, 26-dipropoxy-27, 28-bis-hydroxycalix[4]arene  
(38)233 
Sodium hydride (1.71 g, 71.0 mmol) was added to a suspension of 29 (10 g, 15.56 
mmol) in DMF (300 mL). After 1 hour, 3.08 mL of 1-bromopropane (33.88 mmol) 
was added and the reaction mixture was left stirred for 18 hours. Water (500 mL) 
was added and the mixture was then filtered to obtain a white coloured crude solid 
product. The crude product was then dried and purified by column chromatography 
(eluant: DCM: Hexane = 1:1) to yield white crystalline product 38 (3.46 g, 31 %) 
1H NMR (400MHz, CDCl3) δ 8.90 (s, 2H, OH), 7.02-6.95 (m, 6H, ArH), 6.90 (m, 
2H, ArH), 4.50 (d, J = 13.0 Hz, 2H, ArCH2Ar), 4.31 (m, 3H, ArCH2Ar), 4.10-4.00 
(m, 2H, OCH2CH2CH3), 3.40-3.25 (m, 4H, ArCH2Ar), 2.09 (sext, J = 7.0 Hz, 4H, 
OCH2CH2CH3), 1.22 (s, 9H, C(CH3)3), 1.20 (s, 18 H, C(CH3)3), 1.10 (m, 27H, 
C(CH3)3+OCH2CH2CH3) IR ν 3377, 2959,2904, 2872, 1599, 1488, 1437, 1383, 
1360, 1316, 1292, 1258, 1210, 1195, 1124, 1103 cm-1; Melting point: 205-207°C. 
The spectroscopic data are consistent with that reported in the literature.233  
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5, 11, 17, 23-p-tert-butyl 25,26-dipropoxy-27,28-propargylcalix[4]arene (39) 
177 
Sodium hydride (0.34 g, 14.4 mmol) was added to a stirred solution of 38 (1.7 g, 
2.40 mmol) in DMF (160 mL). After one hour, propargyl bromide solution (80 wt% 
in toluene, 1.7 g, 19.5 mmol) was added and stirring was continued for 18 hours. 
Water (100mL) was added to quence the reaction. The resulting precipitate was 
collected by filteration and re-dissolved in DCM (250 mL). The organic solution 
was then washed with water (100 mL) and brine (100 mL). After being dried over 
MgSO4, the solvent was evaporated under reduced pressure to obtain the crude 
product. The crude product was titurated in DCM/methanol to obtain 1.45 g white 
solid 39 (1.45g, 78.9 %). 1H NMR (400MHz, CDCl3) δ 6.83 (d, J = 2.5 Hz, 2H, 
ArH), 6.79 (m, 4H, ArH), 6.75 (d, J = 2.5 Hz, 2H, ArH), 4.77 (d, J = 2.5 Hz, 4H, 
OCH2CCH), 4.64-4.38 (m, 4H, ArCH2Ar), 3.93-3.73 (m, 4H, OCH2CH2CH3), 3.2-
3.08 (m, 4H, ArCH2Ar), 2.43 (t, J = 2.5 Hz,  2H, OCH2CCH), 2.08 (m, 4H, 
OCH2CH2CH3), 1.09 (s, 18H, C(CH3)3), 1.07 (s, 18H, C(CH3)3), 1.04 (t, J = 7.5 
Hz, 6H, OCH2CH2CH3); IR ν 3311, 2952, 2872, 1600, 1471, 1425, 1410, 1388, 
1360, 1296, 1238, 1194, 1122, 1108 cm-1; Melting point 173-175 °C. The 
spectroscopic data are consistent with those reported in the literature.209 
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5, 11, 17, 23-tetranitro 25, 26-dipropoxy-27, 28-propargylcalixarene (40) 
Glacial acetic acid (25 mL, 436 mmol) and nitric acid (98%, 25 mL, 600 mmol) 
were added to a stirred solution of 39 (3.77g, 4.66 mmol) in 100 mL DCM. The 
color of the reaction mixture turned from yellow to dark blue, and then orange. 30 
minutes after the color of the reaction mixture turned orange, the reaction was 
quenched with addition of ice-cold water (100 mL) and saturated NaHCO3 solution 
(100 mL). The reaction mixture was extracted with DCM and then the organic 
phase was washed with water (2 × 100 mL) and brine (100 mL). After drying over 
MgSO4, the organic phase was evaporated under reduced pressure and then purified 
by column chromatography (eluent : 100% DCM) to yield yellow crystalline solid 
40 (1.4 g, 39 %) 1H NMR (400MHz, CDCl3) δ 7.63 (s, 4H, ArH), 7.59(s, 4H, ArH), 
4.80(d, J = 2.5 Hz, 4H, OCH2CCH), 4.67(d, J = 14.0 Hz, 1H, ArCH2Ar), 4.61(d, J 
= 14.0 Hz, 2H, ArCH2Ar), 4.55(d, J = 14.0 Hz, 1H, ArCH2Ar), 3.99 (m, 4H, 
OCH2CH2CH3), 3.44(m, 4H, ArCH2Ar), 2.57 (t, J = 2.5 Hz, 2 H, OCH2CCH), 1.95 
(m, 4H, OCH2CH2CH3), 1.04(t, 6H, OCH2CH2CH3); 13C NMR (100 MHz, CDCl3) 
δ 161.9, 159.7, 143.8, 143.0, 136.5, 136.4, 135.5, 135.4, 124.2, 124.1, 124.0, 78.2, 
78.1, 77.2, 77.0, 61.8, 32.0, 31.5, 31.0, 23.4, 10.3. IR: ν 3291, 2966, 2934, 2878, 
1586, 1518, 1458, 1341, 1304, 1264, 1206, 1092 cm-1 HRMS (ESI): calculated for 
C40H36N4O12H [M+H+]:765.2408; Found: 765.2414; Melting point: 190-192°C 
(decomposed). 
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5, 11, 17, 23-Tetra-Boc-amino-25, 26-dipropoxy-27, 28-
propargyloxycalix[4]arene (41) 
SnCl2·2H2O (9.22 g, 40.86 mmol) was added to a stirred suspension of 40 (1.40 g, 
1.8 mmol) in ethanol (100 mL) and heated to reflux (90 °C) for 48 hours. After 
cooling, the solvent was evaporated under reduced pressure. The resulting solid 
was washed with 10 % NaOH solution (150 mL) and DCM (50 mL). Then the 
aqueous phase was extracted with additional DCM (3 × 100 mL) until the 
precipitates vanished. Then all DCM layers were combined, dried over anhydrous 
MgSO4 and evaporated under vacuum. The resulting green-colored product (1.01 
g) was dissolved and stirred directly in DCM (50 mL). Then 4.0 g Boc anhydride 
(18.24 mmol) and 0.6 mL DIPEA were added into the reaction mixture. After 
stirring at room temperature overnight, the solvent was removed by evaporation 
and purified over column chromatography (eluant: DCM: ethyl acetate = 15:1) to 
yield an off-white solid 41 (0.862 g, 45% over two steps). 1H NMR (400MHz, 
CDCl3) δ 6.69 (m, 8H, ArH), 6.17(s, 2H, NHBoc), 6.15 (s, 2H, NHBoc), 4.67 (d, J 
= 2.5 Hz, 4H, OCH2CCH), 4.53 (d, J = 13 Hz, 2H, ArCH2Ar), 4.44 (d, J = 13 Hz, 
ArCH2Ar), 4.39 (d, J = 13 Hz, ArCH2Ar), 3.80 (m, 4H, OCH2CH2CH3), 3.13 (m, 
4H, ArCH2Ar), 2.39 (t, J = 2.5 Hz, 2H, OCH2CCH), 1.90 (sext, 4H, 
OCH2CH2CH3), 1.52 (br s, 9H, Boc C(CH3)3), 1.48 (br s, 27H, Boc C(CH3)3), 0.98 
(t, J = 7.5 Hz, 6H, OCH2CH2CH3); 13C NMR (101 MHz, CDCl3) δ 153.3, 153.2, 
152.8, 150.8, 135.83, 135.7, 135.0,  135.0, 133.1, 132.2, 119.8, 119.7, 119.5, 
119.5, 80.4, 80.0, 80.0, 77.1, 74.6, 60.7, 32.2, 31.5, 30.9, 28.4, 28.4, 23.3, 10.4; IR: 
ν 3296, 2978, 2932, 2874, 1810, 1756, 1710, 1692, 1600, 1546, 1474, 1418, 1368, 
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1292, 1246, 1210, 1154, 1066 cm-1; HRMS (NSI) m/z: Calculated for 
C60H76N4O12NH4 [M+NH4]+ 1062.5798; Found : 1062.5792. Melting Point: 179-
181 °C 
6.3.3 Synthesis of clickable DNA-interacting moieties 
 
1-bromomethylpyrene (43) 209 
Phosphorus tribromide (1.75 g, 6.45 mmol) was added to a stirred solution of 1-
pyrenemethanol (1.00 g, 4.30 mmol) in 5 mL of dry THF. After 30 minutes after, 
the reaction mixture was filtered and the solid residue was washed with diethyl 
ether to yield a yellow solid product 43 (932 mg, 79%). 1H NMR (400MHz, CDCl3) 
δ 8.39 (d, J = 9 Hz, 1H, ArH), 8.24 (m, 3H, ArH), 8.07(m, 4H, ArH), 5.27 (m, 2H, 
ArCH2Br); IR ν 3332, 3035, 2892.5, 2836, 1601, 1588.5, 1500, 1437, 1416, 1392, 
1373, 1314, 1271, 1239, 1220, 1201, 1179, 1141, 1109 cm-1; Melting point 155-
157 °C. The spectroscopic data are consistent with those reported in the literature. 
209 
 
1-azidomethylpyrene (44) 209 
Sodium azide (164 mg, 2.54 mmol) was added to a stirred 43 (0.50 g, 1.69 mmol) 
in anhydrous DMF (3 mL) at room temperature and heated to 60 °C for 6 hours. 
The reaction was cooled and quenched with water. The resulting aqueous phase 
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was extracted with diethyl ether (300 mL). The organic phase was dried over 
anhydrous MgSO4 and evaporated to obtain a wax like yellow-green solid 44 (387 
mg, 89%). 1H NMR (400MHz, CDCl3) δ 8.32-7.96 (m, 9H, ArH), 5.06 (br s, 2H, 
ArCH2N3); IR 3042, 2889, 2099, 2079, 1927, 1875, 1603, 1597, 1589, 1509, 1489, 
1458, 1435, 1418, 1392, 1340, 1314, 1252k, 1245, 1226, 1194, 1181, 1100 cm-1 
Melting point: 65-67 °C, The spectroscopic data are consistent with those reported 
in the literature. 209 
5.3.4 Synthesis of clickable NRD for G-quadruplexes binding 
 
3-azidopropan-1-amine (46) 217,350 
A solution of sodium azide (4.0 g, 61.5 mmol, 3.4eq) in H2O (20 mL) was slowly 
added into a solution of 3-bromopropylamine hydrobromide 45 (4.0 g, 18.25 mmol, 
1.0eq) in H2O (15 mL). The colorless solution mixture was heated to 105°C for 18 
hours. The mixture was cooled to romm temperature and water was removed in 
vacuo until white crystals crashed out. Another 4mL of water was added into the 
mixture to re-dissolve the crystals and the resulting solution was mixed with diethyl 
ether (50 mL). Potassium hydroxide (4.0 g, 71.3 mmol) was added into the biphasic 
mixture at 0°C. After separating the ether phase, the aqueous phase was further 
extracted with diethyl ether twice (2 × 30 mL). The combined organic phase was 
dried over MgSO4, filtered and concentrated in vacuo, giving a colorless crude oil 
46 (1.2 mL, 95%). The product was stored under Argon at -20°C. 1H NMR (400Hz, 
CDCl3) δ 3.34(t, J = 7.0 Hz, 2H), 2.80(t, J = 7.0 Hz, 2H), 1.73 (quintet, J = 7.0 Hz, 
2H) 13C NMR (100Hz, CDCl3) δ 49.0, 39.0, 32.2; IR ν 3303, 2108 cm-1, The 
spectroscopic data are consistent with those reported in the literature.217,350 
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6-chloro-5-oxo-5H-benzo[a]phenoxazine-11-carboxylic acid (47) 220 This 
chemical was made in collaboration with Rouven Becker, a project student worked 
in our lab before. 
2,3-dichloro-1,4-naphthoquinone (0.42 g, 1.60 mmol), 3-amino-4-hydroxy 
anthranilic acid (250 mg, 1.60 mmol) and potassium acetate (310 mg, 3.20 mmol) 
were dissolved in MeOH (20 mL) and then heated to reflux for 12 hours. The 
reaction mixture was cooled to 0 °C and filtered. The solid precipitate was collected 
and washed with water and ice cold methanol. After drying over P2O5, the product 
47 was recovered by recrystalisation from MeOH and chloroform as a red 
crystalline solid (446 mg, 77%). 1H NMR (400Hz, DMSO-d6) δ 8.58 (d, 1H, J = 
8.0 Hz), 8.23 (d, 1H, J = 7.5 Hz), 7.97 (t, 1H, J = 7.5 Hz), 7.90 (t, 1H, J = 7.5 Hz), 
7.73 – 7.64 (m, 3H). IR: ν 2916, 1729, 1643, 1601, 1586, 1561, 1479, 1458, 1441, 
1364, 1331, 1300, 1282, 1264, 1183, 1137 cm-1 ; Melting Point: 274-276°C. The 
spectroscopic data are consistent with that reported in the literature.220 
 
N-(3-azidopropyl)-6-chloro-5-oxo-5H-benzo[a]phenoxazine-11-carboxamide 
(48)220 
Pre-dried starting material 47 (0.50 g, 1.535 mmol) was suspended in anhydrous 
chloroform (30 mL) under argon and cooled to 0°C. 1-chloro-N, N-2-trimethyl-1-
propenyl amine (Ghosez’s reagent, 800 μL, 4.605 mmol) was added dropwise into 
the system with syringe. After the suspended material fully dissolved in the 
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chloroform, triethylamine (2.1 mL, 15.4 mmol) was added, followed by azide 
linker 46 (420 μL, 4.2 mmol). After stirring overnight, a red precipitate crashed out 
and additional 30mL of DCM was added to the reaction mixture. The resulting red 
organic phase was washed with water three times (2 × 40 mL) and the aqueous 
phase was extracted with DCM three times (3 × 15 mL). The organic phase was 
dried over MgSO4 and the solvent evaporated. Column chromatography(eluent: 
DCM: methanol = 9:1) gave 48 (0.613 g, 97.2% yield) as an orange solid. 1H NMR 
(CDCl3, 400MHz) δH ppm= 9.53 (bs, 1H), 8.42(td, 2H, J1= 7.0 Hz, J2= 1.5 Hz), 
8.34 (dd, 1H, J1= 7.5 Hz, J2= 2.0 Hz), 7.90(m, 2H, J1= 7.5 Hz, J2= 2.0 Hz), 7.66(t, 
1H, J = 6.5 Hz), 7.60(dd, 1H, J1=8.0 Hz, J2=1.5 Hz), 3.76(dd, 2H, J1= 6.5 Hz, J2= 
6.0 Hz), 3.52(t, 2H, J = 6.5 Hz), 2.10(m, 2H); 13C NMR & 13C-DEPT (CDCl3, 
100MHz) δC ppm 177.0(C), 164.5 (C), 146.5(C), 146.2 (C), 143.6(C), 133.2 (C), 
133.0 (CH), 131.7 (CH), 131.6 (CH), 130.5 (C), 129.6(C), 129.3 (C), 128.6(CH), 
127.3(CH), 124.3 (CH), 119.4 (CH), 115.4 (C), 49.1(C), 37.3 (C), 28.8 (C); IR: ν 
3326, 2929, 2873, 2107, 1633, 1597, 1585, 1560, 1547, 1458, 1349, 1301, 1242, 
1137, 1016, 1028, 1016 cm-1; HRMS (ESI): calculated for C20H14ClN5O3H 
([M+H]+): 408.0858. Found: 408.0864; Melting point: 239-243°C 
6.3.4 Copper-catalysed alkyene-azide cycloaddition (CuAAC) & Boc group 
deprotection 
General procedures for CUAAC (GP 1) 
CuAAC reactions were carried out mainly via CuSO4·H2O with sodium ascorbate. 
100 mg around Boc-protected amino calix[4]arene platform was dissolved in 5 mL 
DMF (5 mL). After added 1-azidomethylpyrene, CuSO4·5H2O (20 mg, 0.8 mmol) 
and sodium ascorbate (120 mg, 0.61 mmol), or CuI (16.7 mg, 0.10 mmol) was also 
added into the reaction mixture. Then the reaction heated in a pre-heated oil bath 
(90°C), for 3 hours. The reaction was monitored with thin layer chromatography 
and later quenched by withdrawing the heat. After cooling to 50°C, icy cold water 
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was added to precipitate the crude product. The mixture was filtered and washed 
with water (50 mL). The precipitate was dissolved in DCM (30 mL) and after being 
washed with water (2 × 15 mL) and brine (15 mL), the organic phase was dried 
over MgSO4, evaporated under reduced pressure. The crude product was purified 
by column chromatography (eluent: DCM/acetone) to yield the pure product. 
General procedures for Boc deprotection (GP 2) 
Then the Boc-protected product was dissolved and stirring in 10 mL DCM. The 
DCM solution was bubbled with HCl gas. 15 minutes later, methanol was added 
into the reaction flask to dissolve the resulting precipitate. After 3 hours, the solvent 
was evaporated under reduced pressure to obtain the crude product which was 
purified via semi-prep HPLC purification or recrystallization in diethyl ether and 
methanol.  
 
Mono-pyrene substituted calixarene (28) 197 
Using GP 1, 33 (102.3 mg, 0.097mmol), azido-pyrene 44 (34.4 mg, 0.133mmol), 
CuSO4 5H2O (20 mg, 0.8 mmol). Brown-colored Boc-protected calixarene 
conjugate 49 (61.6 mg) was recovered from column chromatography (eluent: DCM: 
acetone = 80:20). After deprotecting the Boc group (GP 2), 35.2 mg product 28 was 
recovered as a brown colored salt from preparative RP-HPLC (gradient: starting 
from Solvent A : Solvent B = 30 : 70 to 90% Solvent B over 15 min; Rt = 3.1 min; 
35.2 mg, 33% over two steps) 1H NMR (400MHz, CD3OD) δ 8.40-8.08 (m, 9H, 
ArHpyrene), 7.79 (s, 1H, ArHtriazole), 6.75-6.55 (m, 8H, ArH), 6.38 (s, 2H, 
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ArtriazoleCH2Arpyrene), 5.07 (s, 2H, OCH2Artriazole), 4.37 (d, J = 13.5 Hz, 2H, 
ArCH2Ar), 4.12 (d, J = 13.5 Hz, 2H, ArCH2Ar), 3.81 (t, J = 7.5 Hz, 2H, 
OCH2CH2CH3), 3.49 (m, 4H, OCH2CH2CH3), 3.20 (d, J = 13.5 Hz, 2H, ArCH2Ar), 
2.93 (d, J = 13.5 Hz, 2H, ArCH2Ar), 1.83 (sext, J = 7.5 Hz, 2H, OCH2CH2CH3), 
1.48 (sext, J = 7.5 Hz, 2H, OCH2CH2CH3), 0.94 (t, J = 7.5 Hz, 3H, OCH2CH2CH3 ), 
0.52 (t, J = 7.5 Hz, 6H, OCH2CH2CH3) 13C NMR (400Hz, CD3OD), 157.77, 157.59, 
155.66, 144.79, 138.0749, 137.67, 137.63, 137.5146, 133.5073, 132.59, 131.89, 
130.44, 129.95, 129.32, 129.08, 129.04, 128.31, 127.57, 127.46, 127.02, 127.00, 
126.75, 126.55, 126.53, 126.20, 126.14,125.73, 125.59, 123.71, 123.62, 123.56, 
123.25, 78.37, 78.08, 67.00, 53.08, 31.84, 31.44, 24.20, 23.76, 10.51, 10.13 HRMS 
(ESI) m/z: [M+H]+ Calcd for C57H60N7O4 906.4701 ; Found 906.4700. Melting 
point: 242-244 °C (decomposed) IR ν 2931, 2631, 2101, 1702, 1667, 1556, 1471, 
1418, 1386, 1311, 1261, 1200, 1131, 1062, 1038 cm-1. The spectroscopic data are 
consistent with that reported in the literature.197 
 
1,3-dipyrene substituted calixarene (54) 
Using GP 1, Boc-protected calix[4]arene 37 (104.1 mg, 0.10 mmol), azido-pyrene 
44 (59.6mg, 0.23 mmol) CuSO4•5H2O (27 mg, 1.08 mmol) and sodium ascorbate 
(128 mg, 0.65 mmol) were used. After the CuAAC and purification via column 
chromatography (eluent: DCM:acetone = 9:1), the product 50 was recovered as a 
brown-colored solid (92 mg). After being deprotected with HCl gas (GP 2), the 
final compound 54 was purified via precipitation from ice-cold methanol and 
diethyl ether (56 mg, 43% over two steps).  1H NMR (400MHz, CD3OD) δ 8.40-
8.00 (m, 18H, ArHpyrene), 7.83 (s, 2H, ArHtraizole), 6.75 (s, 4H, ArH), 6.51 (s, 4H, 
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ArH), 6.24 (s, 4H, ArtriazoleCH2Arpyrene), 5.05 (s, 4H, OCH2Artriazole), 4.00 (d, J = 
13.5 Hz, 4H, ArCH2Ar), 3.10 (t, d, J = 7.5 Hz, 4H, OCH2CH2CH3) , 2.87 (d, J = 
13.5 Hz, 4H, ArCH2Ar), 1.08 (sext, J = 7.5 Hz, 4H, OCH2CH2CH3), 0.17 (t, J = 7.5 
Hz, 6H, OCH2CH2CH3); 13C NMR (400MHz, CD3OD) 157.43, 156.25, 144.84, 
138.41, 136.87, 134.68, 133.40, 132.56, 131.88, 130.38, 129.87, 129.28, 129.11, 
129.06, 128.34, 127.56, 127.00, 126.77, 126.72, 126.14, 126.11, 125.96, 125.58, 
124.30, 123.75, 123.34, 77.82 ,67.01, 52.74, 31.55, 23.31, 9.87 HRMS (ESI) m/z: 
[M+H]+ Calcd for C74H67N10O4 1159.5347; Found: 1159.5342 Melting point: 221-
223 °C (decomposed) IR ν 3376, 2869, 2592, 1982, 1696, 1588, 1525, 1470, 
1388, 1309, 1281, 1147, 1130, 1049 cm-1 
 
1,2-dipyrene substituted calixarene (55) 
Using GP 1, Boc-protected calix[4]arene 41 (103 mg, 0.098 mmol), azide-
functionalised pyrene 44 (59 mg, 0.23 mmol), CuSO4·5H2O (15 mg, 0.6 mmol) and 
sodium ascorbate (123 mg, 0.63 mmol) were used. After the reaction, the boc-
protected product 51 was recovered as a brown-colored solid (95 mg) via column 
chromatography (eluent: DCM: acetone = 85:15). After Boc deprotection (GP 2), 
the final product 55 as a brown-colored solid was obtained with preparative RP-
HPLC. (gradient: starting from Solvent A: Solvent B = 15: 85 to 90% MeOH over 
15 min, Rt = 4.2 min, 14 mg, 11 % over two steps) 1H NMR (400MHz, CD3OD) δ 
8.10-7.92 (m, 9H, ArHpyrene), 7.91 (m, 9H, ArHpyrene), 7.62 (s, 2H, ArHtriazole), 6.56 
(d, J = 2.5 Hz, 2H, ArH), 6.51 (m, 4H, ArH), 6.37 (d, J = 2.5 Hz, 2H, ArH), 6.06 
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(m, J = 15 Hz, 4H, ArpyreneCH2Artriazole), 4.50 (q, J = 15 Hz, 4H, OCH2Artriazole), 
4.23 (d, J = 13.5 Hz, 1H, ArCH2Ar), 4.08 (d, J = 13.5 Hz, 2H, ArCH2Ar), 3.57 (d, 
J = 13.5 Hz, 1H, ArCH2Ar), 3.45 (t, J = 7.5 Hz, 4H, OCH2CH2CH3), 3.09 (d, J = 
13.5 Hz, 1H, ArCH2Ar), 2.90 (d, J = 13.5 Hz, 2H, ArCH2Ar), 2.41 (d, J = 13.5 Hz, 
1H, ArCH2Ar), 1.44 (sext, d, J = 7.5 Hz, 4H, ArCH2Ar), 0.45 (t, J = 7.5 Hz, 6H, 
ArCH2Ar) 13C NMR (100MHz, CD3OD) 157.60, 155.40, 144.50, 138.07, 137.51, 
133.20, 132.38, 131.68, 130.13, 129.64, 129.08, 129.06, 128.75, 128.10, 127.62, 
127.60, 127.40, 126.86, 126.69, 126.67, 126.61, 125.95, 125.92, 125.85, 125.35, 
123.65, 123.57, 123.52, 123.23, 123.11, 78.36, 66.61, 52.99, 32.01, 31.96, 31.43, 
24.10, 10.36  HRMS (ESI) m/z: [M+H]+ Calcd for C74H67N10O4 1159. 5347; 
Found: 1159.53 Melting point: 134-136°C (decomposed). IR ν 2923, 1701, 1673, 
1652, 1650, 1506, 1470, 1363, 1201, 1130 cm-1. 
 
Mono-NRD substituted calixarene (56) 
Using GP 1, Boc-protected calix[4]arene 33 (101.7 mg, 0.096 mmol), azide-
functionlised NRD 48 (46.2 mg, 0.113 mmol), CuSO4·5H2O (27 mg, 1.08 mmol), 
sodium ascorbate (131.2 mg, 0.672 mmol) were used in the reaction. The boc 
protected product 52 (56 mg) was purified via column chromatography (eluent: 
DCM: Acetone = 95:5 to 93:7). After de-protection via HCl gas (GP 2), the final 
product 56 was recovered as a red-colored solid by precipitation from ice-cold 
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methanol and diethyl ether (13.1 mg, 11% over two steps). 1H NMR (400MHz, 
D2O) δ 8.20 (s, ArHNRD, 1H), 8.00- 7.25 (m, ArHNRD+ ArHtriazole, 7H), 6.93 (s, ArH, 
2H), 6.90 (s, ArH, 2H), 6.52 (s, ArH, 2H), 6.43 (s, ArH, 2H), 4.88(s, 
OCH2ArHtriazole, 2H), 4.69 (br s, ArtriazoleCH2CH2CH3NHCO, 2H), 4.26 (d, J = 13.5 
Hz, ArCH2Ar, 2H), 4.13 (d, J = 13.5 Hz, ArCH2Ar, 2H), 3.70-3.50 (m, 
OCH2CH2CH3+ ArtriazoleCH2CH2CH3NH CO, 8H), 3.31 (d, J = 13.5 Hz, ArCH2Ar, 
2H), 3.10 (d, J = 13.5 Hz, ArCH2Ar, 2H), 2.41 (br s, CH2CH2NHCO, 2H), 1.52 (m, 
OCH2CH2CH3, 6H), 0.56 (m, OCH2CH2CH3, 9H) 13C NMR  (100MHz, DMSO-
d6) 177.10, 165.71, 156.31, 155.76, 154.38, 147.48, 146.45, 143.57, 143.03, 
136.27, 136.17, 135.68, 135.42, 133.48, 133.16, 132.33, 131.34, 130.21, 129.78, 
126.50, 126.28, 126.16, 126.14, 126.01, 125.99, 125.96, 125.50, 125.17, 123.26, 
123.00 122.93, 118.32, 113.23, 76.44, 76.32, 66.17, 47.02, 36.27, 30.16, 29.78, 
22.56, 22.21, 10.06, 9.64 HRMS (ESI) m/z: Calcd for C60H63ClN7O9 [M+H]+ 
1056.4539; Found : 1056.4536 Melting point: 227-229 °C (decomposed) IR ν 
3381, 3872, 2600, 1644, 1587, 1561, 1464, 1386, 1301, 1262, 1218, 1140, 1044, 
1028, 1000 cm-1.  
 
1,3-diNRD substituted calixarene (57) 
Using GP 1, Boc-protected calix[4]arene 37 (100.0 mg, 0.096 mmol), azide-
functionalised NRD 48 (93.34 mg, 0.23 mmol), CuSO4·5H2O (12.5 mg, 0.5 mmol) 
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and sodium ascorbate (120 mg, 0.61 mmol) were used. The boc-protected product 
53 (51 mg) was obtained via column chromatography (eluent: DCM:Acetone = 9:1 
to 5:1). After deprotection and purification via precipitation from ice-cold methanol 
and diethyl ether, 14.5 mg product 57 was recovered as a red crystalline solid (9.4% 
yield over two steps). 1H NMR (400MHz, CD3OD) δ 8.37 (s, ArHtriazole, 2H), 8.20 
(d, J = 8Hz, ArHNRD, 2H), 7.88 (d, J = 8Hz, ArHNRD, 2H), 7.80 (dd, J1 = 8Hz, J2 = 
1.5 Hz, ArHNRD, 2H), 7.75 (td, J1 = 8Hz, J2 = 1.5 Hz, ArHNRD, 2H), 7.58 (m, 
ArHNRD, 4H), 7.44 (dd, J1 = 8Hz, J2 = 1.5 Hz, ArHNRD, 2H), 7.01 (s, ArH, 4H), 6.70 
(s, ArH, 4H), 5.34 (s, OCH2Artriazole, 4H), 4.63 (t, J = 7 Hz, 
ArtriazoleCH2CH2CH2NHCO, 4H), 4.48 (d, J = 13.5 Hz, ArCH2Ar, 4H), 3.78 (t, J = 
7.5 Hz, OCH2CH2CH3, 4H), 3.51 (t, J = 7 Hz, ArtriazoleCH2CH2CH2NHCO, 4H), 
3.32 (d, J = 13.5 Hz, ArCH2Ar, 4H), 2.32 (quin, J = 7 Hz, 
ArtriazoleCH2CH2CH2NHCO, 4H), 1.75 (sext, OCH2CH2CH3, 4H), 0.88 (t, J = 7.5 
Hz, OCH2CH2CH3, 6H) 13C NMR (100MHz, DMSO-d6) 176.39, 165.00, 155.77, 
154.20, 146.67, 145.72, 142.94, 142.80, 136.07, 135.49, 134.39, 132.92, 132.65, 
131.81, 130.70, 129.46, 129.15, 125.93, 124.90, 124.84, 122.56, 122.52, 122.48, 
122.44, 117.94, 122.87, 76.40, 66.22, 47.02, 36.27, 30.11, 30.21, 22.04, 9.63. 
HRMS (ESI) m/z: Calcd for C80H73Cl2N14O10 [M+H]+ 1459.5011; Found : 
1459.5006 Melting point: 178 °C (decomposed) IR ν 3390, 2875, 1652, 1645, 
1634, 1586, 1557, 1471, 1435, 1301.51, 1262, 1214, 1140, 1018 cm-1.  
6.3.5 FRET titration  
In a typical FRET titration, the specified FRET labelled oligonucleotide (200 μL, 
100 nM) in the corresponding buffer were made and used without annealing. The 
FAM fluorophore was excited at 490 nm and emission was measured from 500 nm 
to 650 nm. The scanning speed was set to 500 nm per minute and slit width was 
adjusted according to the relative fluorescence for the control sample. Small 
aliquots of ligands were prepared in buffer and titrated into the cuvette via pipette. 
The sample was mixed, and after an incubation time of 5 minutes, the fluorescent 
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spectra of the sample was measured. For each aliquot, the sample was scanned 3 
times and the spectra were the average of the scans.  
6.3.6 Other biophysical tests  
Other biophysical tests, including FRET melting, circular dichroism and 
fluorescent intercalator displacement on i-motifs were performed as described in 
Section 6.2.  
6.4  Experimental for Chapter 4 
6.4.1 Synthesis of Fmoc-Ser(OPrp)-OH 
The synthesis of propargylated Fmoc-Ser-OH was following the procedure 
published previously.321,322  
 
Boc-Ser(OPrp)-OH (85) 293,294 
Boc-protected serine 84 (600 mg, 2.90 mmol) was stirred with sodium hydride (246 
mg, 10.0 mmol) in DMF (5 mL) before the addition propargyl bromide (350 μL, 
80% w/w toluene solution, 3.1 mmol) at 0°C. The resulting mixture was stirred at 
room temperature for another 3 hours before being quenched with addition of 5 mL 
water. The resulting solution was dried in vacuo to give a brown-colored solid. The 
solid was dissolved in water and EtOAc (1:1); the organic layer was separated and 
the aqueous layer acidified with 2 M HCl solution at 0°C. When the pH value of 
the aqueous layer was 2, the aqueous layer was extracted with EtOAc (3 × 20 mL). 
The combined organic phases was then dried over Na2SO4 and the solvent was 
removed in vacuo to afford a viscous dark-brown oil as a crude product. The crude 
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product was then purified via column chromatography (eluent Hexane: EtOAc: 
Acetic acid = 27:23:0.5) to afford Boc-Ser(OPrp)-OH as a yellow-colored viscous 
oil (279 mg, 43% yield). The product (85) contained a small amount of acetic acid 
(≤ 5%) and was used in the next step without further purification. 1H NMR (400 
MHz, CDCl3) δ 5.38 (d, 1H, J = 8.0 Hz), 4.53 – 4.44 (m, 1H), 4.18 (t, 1H, J = 2.5 
Hz), 3.99 (dd, 1H, J1 = 9.0, J2 = 2.5 Hz), 3.81 (dd, 1H, J1 = 9.0, J2 = 2.5 Hz), 2.47 
(t, 1H, J = 2.5 Hz), 1.46 (s, 5H). The 1H NMR spectroscopic data are consistent 
with that reported in the literature.321,322 
 
Fmoc-Ser(OPrp)-OH (86) 293,294 
Boc-Ser(OPrp)-OH 85 (279 mg, 1.15 mmol) was dissolved in DCM (5 mL), 
stirring at room temperature. Then TFA (5 mL) was added into the reaction, 
followed by water (100 mL). After being stirred for two hours, the solvent and TFA 
in the reaction mixture was evaporated in vacuo to afford the de-protected amino 
acid as a crystalline TFA salt. The salt was then re-dissolved in a mixture of water 
and acetone (2.5 mL of acetone and 2.5 mL of water). Then sodium carbonate (300 
mg, 2.83 mmol) and Fmoc-N-hydroxysuccinimide ester (470 mg, 1.40 mmol) was 
added into the mixture and stirred for 4 hours. The solvent was removed in vacuo 
and the resulting solid residue dissolved in 1 M HCl solution with the pH adjusted 
(pH = 3). The mixture was then washed and extracted with EtOAc (3 × 20 mL) and 
the organic layer was dried over MgSO4. After the solvent was removed in vacuo 
the resulintg crude product was purified via column chromatography (eluent: 
hexane:EtOAc = 40:60) to afford Fmoc-Ser(OPrp)-OH (86) as a white colored 
solid (258 mg, 61%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.65-
7.58 (m, 2H), 7.40 (t, , 2H, J = 7.5 Hz), 7.32 (t, 2H, J = 7.5 Hz), 5.64 (d, 1H, J = 
Chapter 6 Experimental 
230 
 
8.5 Hz), 4.62-4.56 (m, 1H), 4.49 – 4.36 (m, 2H), 4.28-4.17 (m, 2H), 4.06 (dd, 1H, 
J = 9.0, 3.0 Hz), 3.84 (dd, 1H, J = 9.0, 3.0 Hz), 2.46 (t, J = 2.5 Hz, 1H); IR ν 3403, 
3259, 3201, 2981, 2387, 2376, 1759, 1720, 1704, 1678, 1651, 1522, 1449, 1438, 
1398, 1378, 1355, 1318, 1296, 1261, 1226, 1192, 1170, 1107 cm-1; Melting point: 
126-128 °C. The spectroscopic data are consistent with that reported in the 
literature. 321,322 
6.4.2 Solid Phase peptide Synthesis (SPPS) 
The synthesis of the linear RGD peptide analogue was performed following the 
procedure by Liu et. al. and Kessler et. al.324-326 The preparation of the linear 
peptide started with incorporating Fmoc-Gly-OH onto 2-chlorotitryl chloride resin. 
The loading of Fmoc-Gly-OH on the resin was monitored via UV spectroscopy. 
Then other amino acid residues were added on the peptide chain in standard SPPS 
coupling methods. Each deprotection and coupling was monitored using the Kaiser 
test. The final cleavage was conducted via treating the peptide-bearing resin with a 
mixture of trifluoroethanol and acetic acid. 
Coupling Fmoc-Gly-OH onto 2-chlorotitryl chloride resin 
2-chlorotitryl chloride resin (400 mg) in a peptide synthesis column was sealed 
under anhydrous conditions. Anhydrous DCM (5 mL) was added into the column 
via syringe and the resin was shaken in anhydrous DCM for 1.5 hours. Fmoc-Gly-
OH (400 mg) and DIPEA (350 μL) were added into the column to react with the 
resin. The column was shaken for 2.5 hours and then the solution was filtered. Then 
methanol (5 mL) and DIPEA (350 μL) were added into the column to cap unreacted 
binding sites on the resin. After being shaken for another 2.5 hours, the solution 
was filtered and the resin on the column was washed with DMF three times, DCM 
two times and diethyl ether two times. The resin was dried under vaccum for 
evaluation of Fmoc-Gly-OH loading. 
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Evaluation of level of the first attachment 
Loaded resin (3 × 1 mg) were each weighted into 3 × 10 mm matched silica UV 
cuvettes. Freshly prepared 20% piperidine in DMF (3 mL) was dispensed into each 
of the cells. After 1.5 hours, the absorbance at 290 nm was recorded on a UV 
spectrometer, using 20% piperidine in DMF as a control which was subtracted off 
the samples. The average loading of amino acid was calculated (Equation 5.3) as 
the mean value of three samples.326 
Equation 5.3   𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (𝑚𝑚𝑜𝑙 ∙ 𝑔−1) =
(𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒)
(𝑚𝑔 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒×1.75)
 
The average loading was 0.687 ± 0.1 mmol/g resin, this equates to 0.275 ± 0.04 
mmol Fmoc-Glycin loaded on the resin.  
Kaiser test 
‘Kaiser Solution A’ was prepared by dissolving phenol (8 g) in absolute ethanol (2 
mL) and then mixing it with KCN solution in pyridine (100μL, 0.0004 mM). 
‘Kaiser solution B’ was prepared using ninhydrin dye (1 g) in absolute ethanol (20 
mL). In a typical Kaiser test, small amount of resin (≤1 mg) was mixed with a few 
drops of Kaiser ‘A’ and ‘B’ solutions in a small vial. Then the vial was heated on a 
heating block for 2 min. The presence of free amino group on the peptide was 
indicated as a change in the solution color from yellow to dark blue. If the color of 
the solution did not change, this indicated the absence of free amino group on the 
peptide. 
Peptide synthesis  
The Fmoc-protecting group was removed by shaking with 20% piperidine in DMF 
three times. Then the resin was washed with DMF (5 × 20 mL) and DCM (2 × 20 
mL). Then Kaiser test was applied to qualitatively assess the presence of free amine 
group on the peptide chain. The resin was then shaken in a coupling cocktail 
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containing Fmoc-Arg(Pbf)-OH acid (454 mg, 0.7 mmol, 2.5 eq), HOBt (94.6 mg, 
0.7 mmol, 2.5 eq), HBTU (256.47 mg, 0.7 mmol, 2.5 eq) and DIPEA (244 μL, 
180.94 mg, 1.40 mmol, 5 eq) in 5 mL DMF for 2 hours. At the end of the coupling, 
the resin was filtered and washed with DMF 5 times before performing the Kaiser 
test to verify removal of the Fmoc. Other amino acids were coupled to the peptide 
chain using analogous procedures. 
Linear precursor cleavage  
The resin with the deprotected amine was shaken in a cleavage cocktail composed 
of DCM, 2,2,2-trifluoroethanol and acetic acid (3:1:1) over 1 hour at room 
temperature. The resin was filtered and washed with the same cocktail twice (2 × 
10 mL). The combined cocktail washes were removed in vacuo to give a dark-
brown solid residue. The crude solid was re-dissolved in small amount of DCM and 
precipitated using cold diethyl ether. The crude product 87 was collected by 
centrifugation as pink-orange colored precipitate (210 mg). 
Prep-HPLC purification on linear RGD peptide.  
 
linear RGDfS(O-Prp) (87) 
87 was purified by prep-HPLC using the setting described in Table 5.3. The linear 
peptide 87 was obtained as a off-white TFA salt (110 mg, 38%, calculated from the 
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amount of Fmoc-Glycine loaded on the resin). 1H-NMR (400 MHz, MeOD) δ 7.52 
– 7.39 (m, 5H), 4.83 (t, J = 8.0 Hz, 1H), 4.67 (dd, J1 = 9.5 Hz, J2 = 5.0 Hz, 1H), 
4.56 (t, J = 4.0 Hz, 1H), 4.43 – 4.38 (m, 1H), 4.30 – 4.19 (m, 2H), 4.15 – 4.04 (m, 
2H), 4.01 (dd, J1 = 9.5 Hz, J2 = 4.5 Hz, 1H), 3.63 (dd, J1 = 9.5 Hz, J2 = 4.0 Hz, 1H), 
3.43 – 3.32 (m, 2H), 3.26 (dd, J1 = 13.5, J2 = 8.0 Hz, 1H), 3.20-3.13 (m, 3H), 3.04 
(t, J = 2.5 Hz, 1H), 2.93 – 2.89 (m, 2H), 2.75 (s, 3H), 2.69 (s, 3H), 2.26 (s, 3H), 
2.15-2.06 (m, 1H), 2.01 – 1.88 (m, 1H), 1.88 – 1.70 (m, 2H), 1.64 (s, 9H), 1.63 (s, 
6H). 13C NMR (100 MHz, MeOD) δ 172.8, 172.7, 170.2, 169.0, 168.5, 158.5, 
156.8, 138.0, 136.1, 132.8, 132.1, 128.9, 128.97, 128.2, 126.7, 124.6, 117.0, 86.3, 
82.5, 78.6, 75.3, 68.3, 57.9, 55.5, 53.9, 52.5, 52.4, 49.4, 42.6, 36.7, 36.7, 35.6, 28.7, 
28.7, 27.3, 26.9, 26.9, 18.2, 17.1, 11.1. IR ν 3309, 1660, 1650, 1539, 1369, 1201, 
1138, 1094 cm-1; HRMS (ESI): calculated for C44H63N8O12S1 ([M-TFA]+): 
927.4281. Found: 927.4288; Melting point: 133 °C. (decomposed); Optical 
rotation: [α]D25 = -7 (c = 0.5, MeOH) 
 
Time Percentage of water (%) Percentage of methanol (%) Flow ( mL/min) 
0 50 50 1 
15 40 60 1 
25 30 70 1 
30 5 95 1 
35 95 5 1 
40 50 50 1 
Table 5.2  Analytical HPLC methods for linear RGDfS(O-Prp) 87  
Rt = 23.802 min 
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Time Percentage of water (%) Percentage of methanol (%) Flow ( mL/min) 
0 50 50 20 
15 40 60 20 
25 30 70 20 
30 5 95 20 
35 95 5 20 
40 50 50 20 
Table 5.3  Preparative HPLC methods for linear RGDfS(O-Prp) 87 
Rt = 13.4 min 
Linear peptide cyclisation 
 
Cyclic RGDfS(O-Prp) (83) 
Linear peptide 87 (70 mg, 0.062 mmol) was stirred in acetonitrile (80 mL) with 
HBTU (150 mg, 0.4 mmol) and DIPEA (40 μL, 0.24 mmol) at room temperature 
for 5 days. ([87] ≤ 1 mmol/L.) Additional HBTU (150 mg, 0.4 mmol), was added 
into the reaction mixture two days after the start of the reaction. The solvent was 
removed in vacuo and the solid residue redissolved in EtOAc (10 mL). The organic 
phase was washed with 0.1 M HCl solution (2 × 15 mL) and then saturated NaHCO3 
solution (20 mL) and brine (20 mL). The organic phase was then dried over MgSO4 
and then the solvent was removed in vacuo to afford a yellow-colored solid as the 
crude product amd was purified with preparative RP-HPLC to afford the pure 
product 83 (39 mg, 64%). The preparative and analytical RP-HPLC methods are 
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detailed in Table 5.4 & Table 5.5.  
Time Percentage of water (%) Percentage of acetonitrile (%) Flow ( mL/min) 
0 100 0 20 
5 60 40 20 
20 30 70 20 
25 0 100 20 
30 100 0 20 
Table 5.4  Preparative HPLC method for cyclic RGDfS(O-Prp) 83 
Rt = 13.4 min 
Time Percentage of water (%) Percentage of acetonitrile (%) Flow ( mL/min) 
0 95 5 1 
25 5 95 1 
30 95 5 1 
Table 5.5  Analytical HPLC method for cyclic RGDfS(O-Prp) 83 
Rt = 15.9 min, Blank acetonitrile solvent trace substracted, Purity 98.9% 
 
Peak Number Rt [min] Peak width [min] Area [mAU×s] Area [%] 
1 7.528 0.3324 118.6 1.1207 
2 15.873 0.1416 10468.6 98.8793 
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IR ν 3375, 2868, 2591, 1588, 1525, 1470, 1387, 1309, 1281, 1220, 1147, 1129, 
1048 cm-1; HRMS (NSI) m/z: Calculated for C44H60N8O11SNa [M+Na]+ 931.3994; 
Found : 931.3983. Melting Point: 142 °C (decomposed); Optical rotation: [α]D25 
= -16.4 (c=0.5, MeCN). 
6.4.3 Synthesis of coumarin dye for click reaction 
The synthesis of clickable coumarin was performed using previously described 
procedures.336  
 
3-acetamido-7-acetoxy-chromen-2-one (90) 336  
N-acetyl glycine (2.34 g, 20.00 mmol), 4-Hydroxysalicylaldehyde (2.76 g, 20.0 
mmol), anhydrous sodium acetate (16.0 g 19.99 mmol) and acetic anhydride (50 
mL) were heated to 120°C for 5 hours. Then the reaction mixture were poured into 
icy cold water (250 mL). The mixture was then filtered and the precipitate air-dried 
to afford a yellow powder 90 (1.23, 23%) 1H-NMR (400MHz, CDCl3): δ 8.67 (s, 
1 H), 8.04 (s, 1 H), 8.51 (d, J = 8 Hz, 1 H), 7.12 (d, J = 2.3 Hz, 1 H), 7.07 (dd, J = 
8, 2.3 Hz, 1 H), 2.34 (s, 3 H), 2.25 (s, 3 H); IR 3340, 3088, 2754, 1757, 1718, 1679, 
1624, 1611, 1534, 1431, 1370, 1353, 1287, 1259., 1250, 1203, 1156, 1118 cm-1; 
Melting point 237 °C (decomposed). The spectroscopic data are consistent with 
that reported in the literature. 336  
 
3-Azido-7-hydroxy-chromen-2-one (91) 336 
3-acetamido-7-acetoxy-chromen-2-one 90 (770 mg, 2.95 mmol) was added in a 
solution of 37% HCl and ethanol (VHCl: Vethanol= 2:1, 8mL) and heated to reflux for 
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1 hour. Then icy cold (15 ml) water were added into the mixture to quench the 
reaction and then the mixture was stirred at -30°C for 30 minutes. The mixture was 
warmed to 0°C and sodium nitrite (1 g, 14.5 mmol) was added followed by the slow 
addition of sodium azide (1.4 g, 21.5 mmol). Then the crude, brown-colored 
product was filtered and purified by column chromatography (eluent: 
Hexane:EtOAC = 3:2) to afford 91 as red-coloured needles (486 mg, 82%). 1H-
NMR (400 MHz, DMSO-D) δ 10.52 (s, 1H), 7.59 (s, 1H), 7.48 (d, J = 8.5 Hz, 1H), 
6.81 (dd, J = 8.5, 2.0 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H) ; IR ν 3287, 2917, 2849, 
2101, 1681, 1623, 1592, 1556, 1514, 1504, 1454, 1371, 1340, 1316, 1257, 1219, 
1156, 1119 cm-1 Melting point: 98-100 °C. The spectroscopic data are consistent 
with that reported in the literature.336 
6.4.4 Synthesis of fluorophore-tagged calix[4]arene platform for click  
  reaction 
 
Mono-coumarin substituted calixarene (94)197 
Mono-propargylated calix[4]arene 33 (241 mg, 0.30 mmol) was stirred in DMF (15 
mL) at room temperature. Azide-functionalised coumarin 91 (80 mg, 0.40 mmol), 
CuSO4.5H2O (10 mg, 0.04 mmol) and sodium ascorbate (100 mg, 0.51 mmol) were 
added to the mixture and heated at 85°C for 20 hours. The DMF solvent was then 
removed in vacuo and the solid was redissolved in DCM (20 mL) and washed with 
water (2 × 20 mL) and brine (20 mL). The organic phase was dried in vacuo to 
afford a brown-colored crude product which was further purified using column 
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chromatography (eluent: DCM: methanol = 99:1) to afford a yellow-colored 
crystalline solid 94 (235mg, 81.3%). 1H-NMR (400 MHz, CDCl3): δ 8.51 (s, 1H, 
ArHTriazole), 8.49 (s, 1H, ArHCoumarin), 7.50 (d, J = 8 Hz, 1H, ArHCoumarin), 6.89-6.84 
(m, 2H, ArHCoumarin), 6.71 (s, 4H, ArH), 6.52 (s, 4H, ArH), 6.28 (s, 2H, NHBoc), 
6.21 (s, 2H, NHBoc), 6.13 (s, 4H, NH), 5.21 (s, 2H, OCH2C), 4.37 (d, J = 13 Hz, 
2H, ArCH2Ar), 4.25 (d, J = 13 Hz, 2H, ArCH2Ar), 3.85 (t, J = 8 Hz, 2H, 
OCH2CH2CH3), 3.67 (t, J = 7 Hz, 4H, OCH2CH2CH3), 3.07 (d, J = 13 Hz, 2H, 
ArCH2Ar), 3.02 (d, J = 13 Hz, 2H, ArCH2Ar), 1.90 (sextet, J = 8 Hz, 2H, 
OCH2CH2CH3), 1.81-1.70 (m, 4H, OCH2CH2CH3), 1.50 (s, 9H, C(CH3)3), 1.49 (s, 
9H, C(CH3)3), 1.47 (s, 18H, C(CH3)3), 0.96 (t, J = 7 Hz, 3H, OCH2CH2CH3), 0.86 
(t, J = 8 Hz, 6H, OCH2CH2CH3); 13C-NMR (100 MHz, CDCl3): δ 162.3, 156.4, 
154.8, 153.9, 153.7, 153.6, 153.1, 153.1, 151.3, 144.5, 136.1, 135.7, 135.1, 135.0, 
132.0, 131.8, 120.4, 120.4, 120.2, 120.0, 119.6, 110.9, 130.2, 130.0, 80.5, 80.4, 
80.4, 65.9, 36.6, 31.6, 31.6, 31.2, 28.6, 23.3, 23.2, 10.5, 10.4.; IR  ν 2962, 2919, 
2865, 1689, 1602, 1514, 1466, 1412, 1365, 1290, 1219, 1213, 1149 cm-1; HRMS 
(NSI): m/z calculated for C69H85N7O15 [M+H]+ 1269.6421; Found : 1269.6442; 
Melting point: 168-170 °C. The spectroscopic data is consistent with the exisiting 
data.197 
 
Calixarene-coumarin conjugate 92 337 
Calixarene 94 (200 mg, 0.11 mmol) was stirred in DCM (10 mL) at room 
temperature. HCl gas was bubbled through this solution for 10 minutes and 20 mL 
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MeOH was added to dissolve the precipitated salt. After a further 20 minutes, the 
solvent was removed in vacuo to give a yellow-colored crystalline solid, 95. After 
dissolving 95 in a solution of 10% HCl and methanol (10% HCl:methanol = 2:1, 
30mL), the mixture was stirred at 0°C for 20 minutes, followed by the addition of 
sodium nitrite (150 mg, 2.2 mmol) and, after waiting for a further 30 minutes, 
sodium azide (390 mg, 6.0 mmol) was slowly added into the reaction mixture. After 
1.5 hours, the reaction mixture was extracted with DCM (3 × 20mL) and EtOAc (3 
× 20mL). The organic phases were combined, washed with brine and dried over 
anhydrous MgSO4. The solvent was then removed in vacuo to affored the brown-
colored solid as the crude product which was purified via column chromatography 
(eluent DCM:methanol = 100:1), 92 was recovered as a yellow-colored crystalline 
solid (111 mg, 73%). 1H-NMR (400 MHz, CDCl3): δ 8.65 (s, 1H, ArHTriazole), 8.57 
(s, 1H, ArHCoumarin), 7.57 (d, J = 7.5 Hz, 1H, ArHCoumarin), 6.96-6.94 (m, 2H, 
ArHCoumarin), 6.42 (s, 2H, ArHcalixarene), 6.34 (s, 2H, ArHcalixarene), 6.19 (d, J = 3.0 Hz, 
2H, ArHcalixarene), 6.15 (d, J = 3.0 Hz, 2H, ArHcalixarene), 5.21 (s, 2H, OCH2C), 4.42 
(d, J = 14 Hz, 2H, ArCH2Ar), 4.28 (d, J = 14 Hz, 2H, ArCH2Ar), 3.91 (t, J = 7.5 
Hz, 2H, OCH2CH2CH3), 3.75 (t, J = 7.5 Hz, 4H, OCH2CH2CH3), 3.11 (d, J = 14 
Hz, 2H, ArCH2Ar), 3.04 (d, J = 14 Hz, 2H, ArCH2Ar), 1.93 (sextet, J = 7.5 Hz, 2H, 
OCH2CH2CH3), 1.84-1.77 (m, 4H, OCH2CH2CH3), 1.01 (t, J = 7.5 Hz, 3H, 
OCH2CH2CH3), 0.94 (t, J = 7.5 Hz, 6H, OCH2CH2CH3); 13C NMR (100 MHz, 
CDCl3) δ 161.6, 156.3, 154.8, 154.2, 153.73, 152.0, 144.0, 137.0, 136.7, 135.8, 
135.7, 134.5, 134.4, 133.7, 130.5, 124.8, 119.6, 118.9, 118.8, 118.5, 118.3, 115.0, 
111.1, 103.3, 77.1, 65.6, 31.4, 31.2, 23.2, 23.2, 10.3; IR ν 2963, 2913, 2874, 2106, 
1732, 1607, 1464, 1384, 1311, 1234, 1114 cm-1; HRMS (NSI): m/z calculated for 
C49H45N15O7Na [M+Na]+ 978.3515; Found: 978.3519; Melting point: 127-129 °C. 
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6-azido-hexanoic acid (97) 351 
6-bromohexanoic acid 96 (914 mg, 4.68 mmol) and sodium azide (1.2 g, 18.5 mmol) 
were mixed in DMF (4 mL) and stirred at 50 °C. Then the mixture was cooled to 
room temperature and DCM (30 mL) was added. The organic phase was then 
washed with saturated lithium chloride solution (5 × 30 mL) and brine (2 × 30 mL). 
The organic phase was then dried over anhydrous MgSO4 and the solvent was 
removed in vacuo to afford the product 97 as a colorless oil (210 mg, 29%). 1H-
NMR (400 MHz, CDCl3): δ 3.28(t, J = 7.0 Hz, 2H), 2.37 (t, J = 7.0 Hz, 2H), 1.68-
1.60 (m, 4H), 1.45-1.43 (m, 2H); 13C-NMR(100 MHz, CDCl3) 178.14, , 50.79, 
33.44, 28.12, 25.77, 23.86 ppm; IR ν 2936, 2867, 2092, 1708, 1646, 1415, 1387, 
1253, 1153 cm-1. The spectroscoptic data was in consistent with the literature.351  
 
Calixarene-coumarin conjugate 93  
Calixarene 94 (180 mg, 0.1 mmol) was stirred in DCM (10 mL) at room 
temperature. HCl gas was bubbled through this solution for 10 minutes and MeOH 
(20 mL) was added to dissolve the precipitated salt. After a further 20 minutes, the 
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solvent was evaporated to give a yellow-colored crystalline solid, 95. This was 
dissolved in DMF (5 mL) with 6-azido-hexanoic acid (230 mg, 1.46 mmol), HBTU 
(500 mg, 1.31 mmol) and DIPEA (600 μL, 3.44 mmol) and stirred overnight at 
room temperature. The solvent was removed in vacuo to afford a brown-colored oil. 
After dissolving the residue oil in EtOAc (20 mL), the organic phase was washed 
with 1M HCl (1 × 10 mL) and brine (2 × 30 mL), then dried over anhydrous Na2SO4 
and the organic solvent was removed in vacuo to afford a crude oil. Purification 
with column chromatography (eluent: EtOAc:Hexane = 5:6 to 2:8) gave the final 
product, 93, was recovered as a yellow-colored crystalline solid (52 mg, 25%). 1H-
NMR (400 MHz, MeOH): δ 8.53 (s, 1H), 8.50(s, 1H), 7.64(d, 1H, J = 9Hz), 6.93-
6.88 (m, 9H), 6.82 (d, 1H, J = 2 Hz), 5.23 (s, 2H), 4.45 (d, 2H, J = 13 Hz), 4.37 (d, 
2H, J = 13 Hz), 3.87 (t, 2H, J = 7.5 Hz ), 3.80 (t, 4H, J = 7.5 Hz), 3.09 (d, 2H, J = 
13 Hz), 3.07 (d, 2H, J = 13 Hz), 2.26 (t, 9H, J = 7.5 Hz), 2.03-1.98 (m, 2H), 1.91-
1.85 (m, 4H), 1.66-1.61 (m, 16H), 1.45-1.38 (m, 8H), 1.05 (t, 3H, J = 7.5 Hz), 0.92 
(t, 6H, J = 7.5 Hz); 13C NMR (100 MHz, MeOD) δ 172.4, 172.4, 167.94 163.0, 
156.6, 155.1, 153.1, 152.9, 151.3, 144.0, 135.4, 135.4, 134.8, 134.7, 134.7, 132.9, 
132.2, 132.2, 132.1, 131.0, 130.5, 128.4, 125.1, 120.6, 120.5, 120.5, 120.4, 119.2, 
118.8, 114.2, 110.5, 102.0, 76.8, 76.7, 67.7, 65.8, 50.9, 38.7, 36.2, 31.5, 31.1, 30.7, 
30.2, 29.3, 29.3, 29.3, 29.3, 28.7, 28.2, 26.0, 24.9, 23.5, 23.1, 22.9, 22.6, 13.0, 10.0, 
9.5, 9.3; IR ν 2931, 2870, 2092, 1731, 1650, 1602, 1535, 1466, 1414, 1382, 1241, 
1126, 1041 cm-1; HRMS (NSI): m/z calculated for C146H176N38O22 [M-2H]2- 
1407.6942; Found : 1407.6936; Melting point: 128-130°C. 
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6.4.5 Synthesis of coumarin-tagged cRGD peptide 
 
cRGD-coumarin conjugate (99) 
Protected cRGDfS(O-Prp) 83 (31.2 mg, 0.034 mmol), clickable coumarin dye 91 
(10 mg, 0.049 mmol) and tetrakis(acetonitrile) copper (I) hexafluorophosphate (9.2 
mg, 0.024 mmol) were dissolved in 2 mL DMF which had previously been de-
gased with Argon. To this, DIPEA (50 μL, 0.34 mmol) was added. After stirring at 
room temperature overnight, the solvent was removed in vacuo. The brown-colored 
crude residue 98 was deprotected with a cocktail of TFA, H2O and TIS (95:2.5:2.5, 
3.2 mL). After stirring for 3 hours, the solvent in the reaction mixture were removed 
in vacuo to give a dark-brown-colored residue, which was purified via preparative 
HPLC using the method described in Table 5.4 to give the product, 99, as the TFA 
salt which had the appearance of a cream colored foam (10.9 mg, 40%). 1H-NMR 
(400 MHz,DMSO-D): δ 12.23 (s, 1H), 11.04 (s, 1H), 8.60 (s, 1H), 8.52 (s, 1H), 
8.21 (d, 1H, J = 7.0 Hz), 8.11 – 7.97 (m, 3H), 7.85 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 
8.5 Hz, , 1H), 7.55 (t, J = 5.0 Hz, 1H), 7.25-7.14 (m, 5H), 6.93 (d, J = 10.5 Hz, 1H), 
6.87 (d, J = 2.0 Hz, 1H), 4.74 – 4.49 (m, 4H), 4.43 – 4.30 (m, 1H), 4.22 (m,1H), 
4.14 (dd, J1 = 16 Hz, J2= 8.0 Hz, , 1H), 3.73 (dd, J1 = 9.5 Hz, J2= 5.5 Hz, 1H), 3.60 
(dd, J1 = 9.5 Hz, J2= 3.5 Hz, 1H), 3.27 (d, J = 13.0 Hz, 1H), 3.10 (d, J = 5.5 Hz, 
2H), 3.01 (dd, J1 = 13.0 Hz, J2= 7.0 Hz, 1H), 2.74 (dd, J1 = 13.5, J2= 7.0 Hz, 1H), 
2.65 (dd, J1 = 16.0, J2= 9.0 Hz, 1H), 2.30 (dd, J1 = 16.0, J2= 5.0 Hz, 1H), 1.85 (m, 
1H), 1.53 – 1.35 (m, 3H). 13C NMR (100 MHz, DMSO-d6) δ 171.7, 171.0, 170.7, 
Chapter 6 Experimental 
243 
 
170.0, 169.7, 169.2, 162.6, 156.70 156.4, 154.7, 143.5, 137.6, 136.3, 131.0, 129.2, 
128.0, 126.2, 125.1, 119.2, 114.4, 110.3, 102.2, 69.7, 63.3, 55.0, 53.7, 51.9, 48.8, 
43.0, 40.3, 37.0, 35.4, 27.9, 25.0. IR ν 3265.84, 1637, 1550, 1421, 1318, 1232, 
1186, 1128, 1038 cm-1; HRMS (NSI): m/z calculated for C36H41N11O11H [M+H]+ 
804.3060, Found : 804.3058; Melting point: 144-146 °C decomposed; Optical 
rotation: [α]D25 = -14.2 (c =0.5, DMSO). 
 
Time Percentage of water (%) Percentage of methanol (%) Flow ( mL/min) 
0 100 0 20 
5 60 40 20 
20 30 70 20 
25 0 100 20 
30 100 0 20 
Table 5.6  Preparaive HPLC methods for cRGD-coumarin conjugate 99 
Rt = 10.7 min  
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6.4.6 Synthesis of cRGD-tagged fluorescent calix[4]arene conjugate 
 
Cyclic RGD peptide-calixarene conjugate (101) 
Calixarene 93 (13 mg, 0.0092 mmol), peptide 83 (37 mg, 0.041 mmol) and 
tetrakis(acetonitrile) copper (I) hexafluorophosphate (3.5 mg, 0.0092 mmol) were 
dissolved DMF under Argon protection at room temperature. A small amout of 
DIPEA (50 μL, 0.34 mmol) was added into the reaction mixture and the reaction 
mixture was stirred overnight at room temperature. Then the solvent was removed 
in vacuo and a cleavage cocktail consisting of TFA, H2O and TIS (95:2.5:2.5, 2.0 
mL) was added into the reaction mixture and stirred for another hour at room 
temperature. After evapourating all the solvent in the reaction mixture, the crude 
product was purified via preparative HPLC as described in Table 5.7 to afford the 
pure product 101 as a TFA salt and a pink foam (4.9 mg, 15% yield). IR: ν 3280, 
3203, 3070, 2963, 2936, 2872, 2323, 2161,1982, 1739, 1654, 1649, 1643, 1530, 
1467, 1456, 1418, 1379, 1315, 1198, 1174, 1131, 1057, 1039, 1000 cm-1; Melting 
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point: 76-78 °C; HRMS (MALDI): m/z calculated for C181H232N51O43H [M+H]+ 
3811.8, Found: 3811.9 
Time 
Percentage of water 
(%) 
Percentage of methanol 
(%) 
Flow ( mL/min) 
0 100 0 20 
5 60 40 20 
15 30 70 20 
20 0 100 20 
Table 5.7  Preparative RP-HPLC methods for conjugate 101 
Rt = 8.2 min 
Time Percentage of water (%) Percentage of methanol (%) Flow ( mL/min) 
0 100 0 1 
25 0 100 1 
30 100 0 1 
 Table 5.8  Analytical HPLC methods for conjugate 101 
Rt = 25.401 min  Blank methanol solvent trace substracted, Purity 96.4% 
 
Peak Number Rt [min] Peak width [min] Area [mAU × s] Area [%] 
1 25.401 0.2649 2870.57104 96.4474 
2 26.175 0.1943 91.90798 3.0880 
3 29.711 0.0814 13.82742 0.4646 
min0 5 10 15 20 25
mAU
-150
-100
-50
0
50
100
*DAD1 A, Sig=214,8 Ref=360,100 (QIRAN\160804QA_PURITY CHECK_PREP HPLC_3_2016-10-23_00-52-23.D) - DAD1 A, Sig=214,8 Ref=
 2
5
.4
0
1
 2
6
.1
7
5
 2
9
.7
1
1
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